

CoVPN COVID-19 Vaccine Efficacy Trial Immunogenicity Report

January 15, 2021

Contents

Table 1. Responder rates	2
Table 1. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs)	47
Table 2. GMTRs or GMCRs between post-vaccinations vs. pre-vaccination	82
Table 3. Ratios of GMTs/GMCs between the vaccine arm vs. placebo arm, by baseline status	118
Table 4. Ratios of GMTs/GMCs between baseline positive participants vs. negative participants, among the vaccinees	120
Table 5. Ratios of GMTs/GMCs between demographic subgroups among the vaccine recipients	121
Table 6. Differences of responder rates between the vaccine arm and the placebo arm	127

Table 1. Responder rates

Table 1: Responder rates

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Total Total	Negative	D29	Anti-Spike IgG	1089	51.4% (49.4%, 53.3%)	51.4% (49.4%, 53.3%)	51.4% (49.4%, 53.3%)
			Anti-RBD IgG	1089	51.4% (49.4%, 53.3%)	51.4% (49.4%, 53.3%)	51.4% (49.4%, 53.3%)
			Pseudo nAb ID50	1089	41.6% (39.8%, 43.3%)	41.6% (39.8%, 43.3%)	35.3% (32.0%, 38.7%)
			Pseudo nAb ID80	1089	34.7% (31.4%, 38.0%)	34.7% (31.4%, 38.0%)	27.8% (23.9%, 31.7%)
			Live Virus nAb ID50	1089	41.8% (39.8%, 43.9%)	41.8% (39.8%, 43.9%)	33.8% (30.9%, 36.7%)
			Live Virus nAb ID80	1089	35.9% (33.8%, 38.0%)	35.9% (33.8%, 38.0%)	28.7% (25.5%, 31.9%)
		D57	Anti-Spike IgG	1089	51.4% (49.4%, 53.3%)	51.4% (49.4%, 53.3%)	51.4% (49.4%, 53.3%)
			Anti-RBD IgG	1089	51.4% (49.4%, 53.3%)	51.4% (49.4%, 53.3%)	51.4% (49.4%, 53.3%)
			Pseudo nAb ID50	1089	50.2% (48.0%, 52.4%)	50.2% (48.0%, 52.4%)	49.1% (47.2%, 51.1%)
			Pseudo nAb ID80	1089	48.6% (47.5%, 49.7%)	48.6% (47.5%, 49.7%)	46.1% (45.4%, 46.9%)
			Live Virus nAb ID50	1089	50.0% (48.4%, 51.7%)	50.0% (48.4%, 51.7%)	48.7% (46.2%, 51.1%)
			Live Virus nAb ID80	1089	48.6% (47.2%, 50.1%)	48.6% (47.2%, 50.1%)	46.0% (45.6%, 46.4%)
	Positive	D29	Anti-Spike IgG	523	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	523	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	523	78.7% (73.0%, 84.4%)	78.7% (73.0%, 84.4%)	67.4% (59.2%, 75.7%)
			Pseudo nAb ID80	523	64.7% (56.8%, 72.7%)	64.7% (56.8%, 72.7%)	49.2% (41.1%, 57.3%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age Age < 65	Negative	D57	Live Virus nAb ID50	523	76.8% (71.6%, 82.0%)	76.8% (71.6%, 82.0%)	65.9% (59.7%, 72.2%)
			Live Virus nAb ID80	523	70.1% (65.2%, 75.1%)	70.1% (65.2%, 75.1%)	55.1% (48.8%, 61.5%)
			Anti-Spike IgG	523	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	523	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	523	95.5% (93.7%, 97.2%)	95.5% (93.7%, 97.2%)	93.9% (92.3%, 95.5%)
			Pseudo nAb ID80	523	92.3% (90.1%, 94.6%)	92.3% (90.1%, 94.6%)	87.3% (83.8%, 90.7%)
			Live Virus nAb ID50	523	96.6% (95.4%, 97.9%)	96.6% (95.4%, 97.9%)	93.6% (91.8%, 95.5%)
			Live Virus nAb ID80	523	95.8% (92.9%, 98.7%)	95.8% (92.9%, 98.7%)	92.4% (88.7%, 96.0%)
		D29	Anti-Spike IgG	513	51.9% (50.6%, 53.1%)	51.9% (50.6%, 53.1%)	51.9% (50.6%, 53.1%)
			Anti-RBD IgG	513	51.9% (50.6%, 53.1%)	51.9% (50.6%, 53.1%)	51.9% (50.6%, 53.1%)
			Pseudo nAb ID50	513	40.9% (39.7%, 42.1%)	40.9% (39.7%, 42.1%)	34.0% (32.6%, 35.3%)
			Pseudo nAb ID80	513	33.4% (33.2%, 33.6%)	33.4% (33.2%, 33.6%)	26.3% (26.0%, 26.6%)
			Live Virus nAb ID50	513	41.4% (38.8%, 43.9%)	41.4% (38.8%, 43.9%)	32.6% (30.9%, 34.3%)
			Live Virus nAb ID80	513	35.1% (34.7%, 35.4%)	35.1% (34.7%, 35.4%)	27.4% (26.8%, 28.0%)
		D57	Anti-Spike IgG	513	51.9% (50.6%, 53.1%)	51.9% (50.6%, 53.1%)	51.9% (50.6%, 53.1%)
			Anti-RBD IgG	513	51.9% (50.6%, 53.1%)	51.9% (50.6%, 53.1%)	51.9% (50.6%, 53.1%)
			Pseudo nAb ID50	513	50.6% (48.7%, 52.6%)	50.6% (48.7%, 52.6%)	49.5% (47.7%, 51.2%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age >= 65	Positive	D29	Pseudo nAb ID80	513	48.8% (48.0%, 49.7%)	48.8% (48.0%, 49.7%)	46.1% (45.2%, 47.0%)
			Live Virus nAb ID50	513	50.5% (49.4%, 51.5%)	50.5% (49.4%, 51.5%)	49.0% (46.5%, 51.4%)
			Live Virus nAb ID80	513	48.9% (47.7%, 50.2%)	48.9% (47.7%, 50.2%)	46.1% (45.7%, 46.4%)
			Anti-Spike IgG	295	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	295	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	295	76.5% (75.4%, 77.6%)	76.5% (75.4%, 77.6%)	64.4% (64.2%, 64.6%)
			Pseudo nAb ID80	295	61.7% (60.9%, 62.5%)	61.7% (60.9%, 62.5%)	46.1% (45.3%, 46.9%)
			Live Virus nAb ID50	295	74.8% (73.9%, 75.7%)	74.8% (73.9%, 75.7%)	63.7% (58.6%, 68.8%)
			Live Virus nAb ID80	295	68.2% (66.2%, 70.2%)	68.2% (66.2%, 70.2%)	52.6% (49.6%, 55.7%)
		D57	Anti-Spike IgG	295	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	295	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	295	94.8% (94.6%, 95.1%)	94.8% (94.6%, 95.1%)	93.3% (92.7%, 93.8%)
			Pseudo nAb ID80	295	91.5% (91.3%, 91.7%)	91.5% (91.3%, 91.7%)	86.0% (83.4%, 88.5%)
			Live Virus nAb ID50	295	96.3% (95.6%, 97.0%)	96.3% (95.6%, 97.0%)	92.9% (91.7%, 94.2%)
			Live Virus nAb ID80	295	95.5% (92.0%, 99.0%)	95.5% (92.0%, 99.0%)	92.0% (87.6%, 96.4%)
	Negative	D29	Anti-Spike IgG	576	48.8% (48.8%, 48.8%)	48.8% (48.8%, 48.8%)	48.8% (48.8%, 48.8%)
			Anti-RBD IgG	576	48.8% (48.8%, 48.8%)	48.8% (48.8%, 48.8%)	48.8% (48.8%, 48.8%)
			Pseudo nAb ID50	576	45.1%	45.1%	42.4%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57		Pseudo nAb ID80	576	(45.1%, 45.1%)	(45.1%, 45.1%)	(42.4%, 42.4%)
					41.2%	41.2%	35.7%
			Live Virus nAb ID50	576	(41.2%, 41.2%)	(41.2%, 41.2%)	(35.7%, 35.7%)
					44.2%	44.2%	39.8%
			Live Virus nAb ID80	576	(44.2%, 44.2%)	(44.2%, 44.2%)	(39.8%, 39.8%)
					40.2%	40.2%	35.3%
			Anti-Spike IgG	576	(40.2%, 40.2%)	(40.2%, 40.2%)	(35.3%, 35.3%)
					48.8%	48.8%	48.8%
			Anti-RBD IgG	576	(48.8%, 48.8%)	(48.8%, 48.8%)	(48.8%, 48.8%)
					48.8%	48.8%	48.8%
			Pseudo nAb ID50	576	(48.8%, 48.8%)	(48.8%, 48.8%)	(48.8%, 48.8%)
					48.0%	48.0%	47.4%
			Pseudo nAb ID80	576	(48.0%, 48.0%)	(48.0%, 48.0%)	(47.4%, 47.4%)
					47.4%	47.4%	46.2%
			Live Virus nAb ID50	576	(47.4%, 47.4%)	(47.4%, 47.4%)	(46.2%, 46.2%)
					47.8%	47.8%	47.1%
			Live Virus nAb ID80	576	(47.8%, 47.8%)	(47.8%, 47.8%)	(47.1%, 47.1%)
					47.2%	47.2%	45.6%
	D29		Anti-Spike IgG	228	(47.2%, 47.2%)	(47.2%, 47.2%)	(45.6%, 45.6%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	228	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	228	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					93.2%	93.2%	87.5%
			Pseudo nAb ID80	228	(93.2%, 93.2%)	(93.2%, 93.2%)	(87.5%, 87.5%)
					84.5%	84.5%	69.5%
			Live Virus nAb ID50	228	(84.5%, 84.5%)	(84.5%, 84.5%)	(69.5%, 69.5%)
					90.0%	90.0%	80.7%
	D57		Live Virus nAb ID80	228	(90.0%, 90.0%)	(90.0%, 90.0%)	(80.7%, 80.7%)
					82.9%	82.9%	71.4%
			Anti-Spike IgG	228	(82.9%, 82.9%)	(82.9%, 82.9%)	(71.4%, 71.4%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	228	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
High Risk At-risk	Negative	D29	Pseudo nAb ID50	228	99.6% (99.6%, 99.6%)	99.6% (99.6%, 99.6%)	97.9% (97.9%, 97.9%)
			Pseudo nAb ID80	228	97.9% (97.9%, 97.9%)	97.9% (97.9%, 97.9%)	95.7% (95.7%, 95.7%)
			Live Virus nAb ID50	228	98.8% (98.8%, 98.8%)	98.8% (98.8%, 98.8%)	98.4% (98.4%, 98.4%)
			Live Virus nAb ID80	228	97.8% (97.8%, 97.8%)	97.8% (97.8%, 97.8%)	94.8% (94.8%, 94.8%)
			Anti-Spike IgG	568	50.7% (49.4%, 51.9%)	50.7% (49.4%, 51.9%)	50.7% (49.4%, 51.9%)
			Anti-RBD IgG	568	50.7% (49.4%, 51.9%)	50.7% (49.4%, 51.9%)	50.7% (49.4%, 51.9%)
			Pseudo nAb ID50	568	41.3% (36.2%, 46.4%)	41.3% (36.2%, 46.4%)	35.8% (27.2%, 44.3%)
			Pseudo nAb ID80	568	36.1% (29.3%, 42.9%)	36.1% (29.3%, 42.9%)	29.1% (21.5%, 36.7%)
			Live Virus nAb ID50	568	40.1% (34.7%, 45.5%)	40.1% (34.7%, 45.5%)	33.5% (25.9%, 41.0%)
			Live Virus nAb ID80	568	36.6% (31.8%, 41.4%)	36.6% (31.8%, 41.4%)	29.6% (22.6%, 36.6%)
	Positive	D29	Anti-Spike IgG	568	50.7% (49.4%, 51.9%)	50.7% (49.4%, 51.9%)	50.7% (49.4%, 51.9%)
			Anti-RBD IgG	568	50.7% (49.4%, 51.9%)	50.7% (49.4%, 51.9%)	50.7% (49.4%, 51.9%)
			Pseudo nAb ID50	568	48.7% (46.7%, 50.7%)	48.7% (46.7%, 50.7%)	47.7% (45.9%, 49.4%)
			Pseudo nAb ID80	568	48.2% (46.8%, 49.7%)	48.2% (46.8%, 49.7%)	45.8% (43.5%, 48.1%)
			Live Virus nAb ID50	568	49.4% (48.4%, 50.4%)	49.4% (48.4%, 50.4%)	46.6% (44.1%, 49.2%)
			Live Virus nAb ID80	568	47.8% (46.3%, 49.2%)	47.8% (46.3%, 49.2%)	46.2% (44.7%, 47.7%)
			Anti-Spike IgG	222	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Not at-risk	Negative	D57	Anti-RBD IgG	222	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	222	78.5% (68.8%, 88.1%)	78.5% (68.8%, 88.1%)	68.9% (57.4%, 80.4%)
			Pseudo nAb ID80	222	65.4% (52.2%, 78.7%)	65.4% (52.2%, 78.7%)	49.7% (36.7%, 62.7%)
			Live Virus nAb ID50	222	77.1% (67.4%, 86.8%)	77.1% (67.4%, 86.8%)	61.8% (47.4%, 76.2%)
			Live Virus nAb ID80	222	68.7% (59.6%, 77.7%)	68.7% (59.6%, 77.7%)	53.4% (39.7%, 67.1%)
			Anti-Spike IgG	222	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	222	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	222	96.2% (93.7%, 98.7%)	96.2% (93.7%, 98.7%)	93.7% (90.5%, 96.9%)
			Pseudo nAb ID80	222	92.6% (88.7%, 96.6%)	92.6% (88.7%, 96.6%)	85.0% (77.8%, 92.2%)
			Live Virus nAb ID50	222	97.5% (96.8%, 98.3%)	97.5% (96.8%, 98.3%)	92.4% (89.1%, 95.6%)
			Live Virus nAb ID80	222	91.8% (88.3%, 95.4%)	91.8% (88.3%, 95.4%)	87.5% (82.8%, 92.1%)
		D29	Anti-Spike IgG	521	51.6% (49.4%, 53.8%)	51.6% (49.4%, 53.8%)	51.6% (49.4%, 53.8%)
			Anti-RBD IgG	521	51.6% (49.4%, 53.8%)	51.6% (49.4%, 53.8%)	51.6% (49.4%, 53.8%)
			Pseudo nAb ID50	521	41.6% (40.7%, 42.6%)	41.6% (40.7%, 42.6%)	35.2% (33.0%, 37.4%)
			Pseudo nAb ID80	521	34.2% (32.0%, 36.4%)	34.2% (32.0%, 36.4%)	27.4% (24.4%, 30.3%)
			Live Virus nAb ID50	521	42.4% (42.1%, 42.7%)	42.4% (42.1%, 42.7%)	33.9% (31.9%, 35.8%)
			Live Virus nAb ID80	521	35.7% (34.3%, 37.1%)	35.7% (34.3%, 37.1%)	28.4% (26.1%, 30.7%)
		D57	Anti-Spike IgG	521	51.6%	51.6%	51.6%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive		D29	Anti-RBD IgG	521	(49.4%, 53.8%)	(49.4%, 53.8%)	(49.4%, 53.8%)
					51.6%	51.6%	51.6%
			Pseudo nAb ID50	521	(49.4%, 53.8%)	(49.4%, 53.8%)	(49.4%, 53.8%)
					50.7%	50.7%	49.6%
			Pseudo nAb ID80	521	(48.8%, 52.6%)	(48.8%, 52.6%)	(48.1%, 51.1%)
					48.7%	48.7%	46.2%
			Live Virus nAb ID50	521	(47.4%, 50.0%)	(47.4%, 50.0%)	(45.6%, 46.9%)
					50.2%	50.2%	49.3%
			Live Virus nAb ID80	521	(48.4%, 52.1%)	(48.4%, 52.1%)	(47.8%, 50.9%)
					48.9%	48.9%	45.9%
			Anti-Spike IgG	301	(47.6%, 50.3%)	(47.6%, 50.3%)	(45.1%, 46.8%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	301	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	301	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					78.8%	78.8%	67.0%
			Pseudo nAb ID80	301	(73.1%, 84.4%)	(73.1%, 84.4%)	(58.9%, 75.2%)
					64.5%	64.5%	49.0%
			Live Virus nAb ID50	301	(57.0%, 72.1%)	(57.0%, 72.1%)	(41.1%, 57.0%)
					76.7%	76.7%	67.1%
			Live Virus nAb ID80	301	(71.9%, 81.5%)	(71.9%, 81.5%)	(62.5%, 71.8%)
					70.5%	70.5%	55.6%
			Anti-Spike IgG	301	(65.7%, 75.4%)	(65.7%, 75.4%)	(50.1%, 61.2%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	301	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	301	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					95.3%	95.3%	93.9%
			Pseudo nAb ID80	301	(93.7%, 96.9%)	(93.7%, 96.9%)	(92.5%, 95.4%)
					92.2%	92.2%	87.9%
			Live Virus nAb ID50	301	(90.2%, 94.3%)	(90.2%, 94.3%)	(84.9%, 90.9%)
					96.3%	96.3%	94.0%
			Live Virus nAb ID80	301	(95.3%, 97.3%)	(95.3%, 97.3%)	(92.1%, 95.9%)
					96.9%	96.9%	93.8%
					(96.5%, 97.4%)	(96.5%, 97.4%)	(93.3%, 94.2%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age, Risk Age < 65 At-risk	Negative	D29	Anti-Spike IgG	259	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)
			Anti-RBD IgG	259	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)
			Pseudo nAb ID50	259	39.1% (39.1%, 39.1%)	39.1% (39.1%, 39.1%)	32.1% (32.1%, 32.1%)
			Pseudo nAb ID80	259	33.2% (33.2%, 33.2%)	33.2% (33.2%, 33.2%)	25.9% (25.9%, 25.9%)
			Live Virus nAb ID50	259	37.8% (37.8%, 37.8%)	37.8% (37.8%, 37.8%)	30.2% (30.2%, 30.2%)
			Live Virus nAb ID80	259	34.6% (34.6%, 34.6%)	34.6% (34.6%, 34.6%)	26.6% (26.6%, 26.6%)
		D57	Anti-Spike IgG	259	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)
			Anti-RBD IgG	259	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)	50.1% (50.1%, 50.1%)
			Pseudo nAb ID50	259	47.8% (47.8%, 47.8%)	47.8% (47.8%, 47.8%)	46.9% (46.9%, 46.9%)
			Pseudo nAb ID80	259	47.6% (47.6%, 47.6%)	47.6% (47.6%, 47.6%)	44.8% (44.8%, 44.8%)
			Live Virus nAb ID50	259	49.0% (49.0%, 49.0%)	49.0% (49.0%, 49.0%)	45.5% (45.5%, 45.5%)
			Live Virus nAb ID80	259	47.1% (47.1%, 47.1%)	47.1% (47.1%, 47.1%)	45.5% (45.5%, 45.5%)
	Positive	D29	Anti-Spike IgG	147	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	147	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	147	74.9% (74.9%, 74.9%)	74.9% (74.9%, 74.9%)	64.7% (64.7%, 64.7%)
			Pseudo nAb ID80	147	60.6% (60.6%, 60.6%)	60.6% (60.6%, 60.6%)	45.0% (45.0%, 45.0%)
			Live Virus nAb ID50	147	73.6% (73.6%, 73.6%)	73.6% (73.6%, 73.6%)	56.6% (56.6%, 56.6%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age < 65 Not at-risk	Negative	D57	Live Virus nAb ID80	147	65.4% (65.4%, 65.4%)	65.4% (65.4%, 65.4%)	48.4% (48.4%, 48.4%)
			Anti-Spike IgG	147	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	147	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	147	95.3% (95.3%, 95.3%)	95.3% (95.3%, 95.3%)	92.5% (92.5%, 92.5%)
			Pseudo nAb ID80	147	91.2% (91.2%, 91.2%)	91.2% (91.2%, 91.2%)	82.4% (82.4%, 82.4%)
			Live Virus nAb ID50	147	97.3% (97.3%, 97.3%)	97.3% (97.3%, 97.3%)	91.2% (91.2%, 91.2%)
		D29	Live Virus nAb ID80	147	90.5% (90.5%, 90.5%)	90.5% (90.5%, 90.5%)	85.8% (85.8%, 85.8%)
			Anti-Spike IgG	254	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)
			Anti-RBD IgG	254	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)
			Pseudo nAb ID50	254	41.3% (41.3%, 41.3%)	41.3% (41.3%, 41.3%)	34.5% (34.5%, 34.5%)
			Pseudo nAb ID80	254	33.5% (33.5%, 33.5%)	33.5% (33.5%, 33.5%)	26.4% (26.4%, 26.4%)
			Live Virus nAb ID50	254	42.3% (42.3%, 42.3%)	42.3% (42.3%, 42.3%)	33.2% (33.2%, 33.2%)
	Positive	D57	Live Virus nAb ID80	254	35.2% (35.2%, 35.2%)	35.2% (35.2%, 35.2%)	27.6% (27.6%, 27.6%)
			Anti-Spike IgG	254	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)
			Anti-RBD IgG	254	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)	52.3% (52.3%, 52.3%)
			Pseudo nAb ID50	254	51.3% (51.3%, 51.3%)	51.3% (51.3%, 51.3%)	50.1% (50.1%, 50.1%)
			Pseudo nAb ID80	254	49.1% (49.1%, 49.1%)	49.1% (49.1%, 49.1%)	46.5% (46.5%, 46.5%)
			Live Virus nAb ID50	254	50.9%	50.9%	49.9%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 At-risk	Positive	D29	Live Virus nAb ID80	254	(50.9%, 50.9%)	(50.9%, 50.9%)	(49.9%, 49.9%)
					49.4%	49.4%	46.2%
			Anti-Spike IgG	148	(49.4%, 49.4%)	(49.4%, 49.4%)	(46.2%, 46.2%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					76.9%	76.9%	64.3%
			Pseudo nAb ID80	148	(76.9%, 76.9%)	(76.9%, 76.9%)	(64.3%, 64.3%)
					62.0%	62.0%	46.4%
	D57		Live Virus nAb ID50	148	(62.0%, 62.0%)	(62.0%, 62.0%)	(46.4%, 46.4%)
					75.1%	75.1%	65.6%
			Live Virus nAb ID80	148	(75.1%, 75.1%)	(75.1%, 75.1%)	(65.6%, 65.6%)
					68.9%	68.9%	53.8%
			Anti-Spike IgG	148	(68.9%, 68.9%)	(68.9%, 68.9%)	(53.8%, 53.8%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					94.7%	94.7%	93.5%
			Pseudo nAb ID80	148	(94.7%, 94.7%)	(94.7%, 94.7%)	(93.5%, 93.5%)
					91.5%	91.5%	86.9%
Age >= 65 At-risk	Negative	D29	Live Virus nAb ID50	148	(91.5%, 91.5%)	(91.5%, 91.5%)	(86.9%, 86.9%)
					96.0%	96.0%	93.4%
			Live Virus nAb ID80	148	(96.0%, 96.0%)	(96.0%, 96.0%)	(93.4%, 93.4%)
					96.8%	96.8%	93.6%
			Anti-Spike IgG	309	(96.8%, 96.8%)	(96.8%, 96.8%)	(93.6%, 93.6%)
					51.8%	51.8%	51.8%
			Anti-RBD IgG	309	(51.8%, 51.8%)	(51.8%, 51.8%)	(51.8%, 51.8%)
					51.8%	51.8%	51.8%
			Pseudo nAb ID50	309	(51.8%, 51.8%)	(51.8%, 51.8%)	(51.8%, 51.8%)
					46.1%	46.1%	43.7%
			Pseudo nAb ID80	309	(46.1%, 46.1%)	(46.1%, 46.1%)	(43.7%, 43.7%)
					42.4%	42.4%	36.1%
					(42.4%, 42.4%)	(42.4%, 42.4%)	(36.1%, 36.1%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57		Live Virus nAb ID50	309	45.1% (45.1%, 45.1%)	45.1% (45.1%, 45.1%)	40.5% (40.5%, 40.5%)
			Live Virus nAb ID80	309	41.1% (41.1%, 41.1%)	41.1% (41.1%, 41.1%)	36.1% (36.1%, 36.1%)
			Anti-Spike IgG	309	51.8% (51.8%, 51.8%)	51.8% (51.8%, 51.8%)	51.8% (51.8%, 51.8%)
			Anti-RBD IgG	309	51.8% (51.8%, 51.8%)	51.8% (51.8%, 51.8%)	51.8% (51.8%, 51.8%)
			Pseudo nAb ID50	309	50.6% (50.6%, 50.6%)	50.6% (50.6%, 50.6%)	49.3% (49.3%, 49.3%)
			Pseudo nAb ID80	309	49.6% (49.6%, 49.6%)	49.6% (49.6%, 49.6%)	47.9% (47.9%, 47.9%)
			Live Virus nAb ID50	309	50.3% (50.3%, 50.3%)	50.3% (50.3%, 50.3%)	49.0% (49.0%, 49.0%)
			Live Virus nAb ID80	309	49.1% (49.1%, 49.1%)	49.1% (49.1%, 49.1%)	47.6% (47.6%, 47.6%)
		D29	Anti-Spike IgG	75	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	75	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	75	93.2% (93.2%, 93.2%)	93.2% (93.2%, 93.2%)	86.5% (86.5%, 86.5%)
			Pseudo nAb ID80	75	85.7% (85.7%, 85.7%)	85.7% (85.7%, 85.7%)	69.5% (69.5%, 69.5%)
			Live Virus nAb ID50	75	91.9% (91.9%, 91.9%)	91.9% (91.9%, 91.9%)	83.8% (83.8%, 83.8%)
			Live Virus nAb ID80	75	82.5% (82.5%, 82.5%)	82.5% (82.5%, 82.5%)	74.4% (74.4%, 74.4%)
		D57	Anti-Spike IgG	75	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	75	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	75	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	98.6% (98.6%, 98.6%)
			Pseudo nAb ID80	75	98.6% (98.6%, 98.6%)	98.6% (98.6%, 98.6%)	95.9% (95.9%, 95.9%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 Not at-risk	Negative	D29	Live Virus nAb ID50	75	(98.6%, 98.6%)	(98.6%, 98.6%)	(95.9%, 95.9%)
					98.6%	98.6%	97.3%
			Live Virus nAb ID80	75	(98.6%, 98.6%)	(98.6%, 98.6%)	(97.3%, 97.3%)
					97.3%	97.3%	94.6%
			Anti-Spike IgG	267	(97.3%, 97.3%)	(97.3%, 97.3%)	(94.6%, 94.6%)
					45.7%	45.7%	45.7%
			Anti-RBD IgG	267	(45.7%, 45.7%)	(45.7%, 45.7%)	(45.7%, 45.7%)
					45.7%	45.7%	45.7%
			Pseudo nAb ID50	267	(45.7%, 45.7%)	(45.7%, 45.7%)	(45.7%, 45.7%)
					44.1%	44.1%	41.1%
			Pseudo nAb ID80	267	(44.1%, 44.1%)	(44.1%, 44.1%)	(41.1%, 41.1%)
					40.1%	40.1%	35.2%
		D57	Live Virus nAb ID50	267	(40.1%, 40.1%)	(40.1%, 40.1%)	(35.2%, 35.2%)
					43.3%	43.3%	39.1%
			Live Virus nAb ID80	267	(43.3%, 43.3%)	(43.3%, 43.3%)	(39.1%, 39.1%)
					39.4%	39.4%	34.6%
			Anti-Spike IgG	267	(39.4%, 39.4%)	(39.4%, 39.4%)	(34.6%, 34.6%)
					45.7%	45.7%	45.7%
			Anti-RBD IgG	267	(45.7%, 45.7%)	(45.7%, 45.7%)	(45.7%, 45.7%)
					45.7%	45.7%	45.7%
			Pseudo nAb ID50	267	(45.7%, 45.7%)	(45.7%, 45.7%)	(45.7%, 45.7%)
					45.5%	45.5%	45.5%
			Pseudo nAb ID80	267	(45.5%, 45.5%)	(45.5%, 45.5%)	(45.5%, 45.5%)
					45.3%	45.3%	44.5%
			Live Virus nAb ID50	267	(45.3%, 45.3%)	(45.3%, 45.3%)	(44.5%, 44.5%)
					45.3%	45.3%	45.1%
			Live Virus nAb ID80	267	(45.3%, 45.3%)	(45.3%, 45.3%)	(45.1%, 45.1%)
					45.3%	45.3%	43.7%
	Positive	D29	Anti-Spike IgG	153	(45.3%, 45.3%)	(45.3%, 45.3%)	(43.7%, 43.7%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	153	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	153	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					93.2%	93.2%	87.9%
					(93.2%, 93.2%)	(93.2%, 93.2%)	(87.9%, 87.9%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Sex Female	Negative	D57	Pseudo nAb ID80	153	83.9% (83.9%, 83.9%)	83.9% (83.9%, 83.9%)	69.4% (69.4%, 69.4%)
			Live Virus nAb ID50	153	89.1% (89.1%, 89.1%)	89.1% (89.1%, 89.1%)	79.1% (79.1%, 79.1%)
			Live Virus nAb ID80	153	83.1% (83.1%, 83.1%)	83.1% (83.1%, 83.1%)	69.9% (69.9%, 69.9%)
			Anti-Spike IgG	153	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	153	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	153	99.3% (99.3%, 99.3%)	99.3% (99.3%, 99.3%)	97.6% (97.6%, 97.6%)
			Pseudo nAb ID80	153	97.6% (97.6%, 97.6%)	97.6% (97.6%, 97.6%)	95.6% (95.6%, 95.6%)
			Live Virus nAb ID50	153	98.9% (98.9%, 98.9%)	98.9% (98.9%, 98.9%)	98.9% (98.9%, 98.9%)
			Live Virus nAb ID80	153	98.0% (98.0%, 98.0%)	98.0% (98.0%, 98.0%)	95.0% (95.0%, 95.0%)
		D29	Anti-Spike IgG	595	52.2% (47.4%, 57.0%)	52.2% (47.4%, 57.0%)	52.2% (47.4%, 57.0%)
			Anti-RBD IgG	595	52.2% (47.4%, 57.0%)	52.2% (47.4%, 57.0%)	52.2% (47.4%, 57.0%)
			Pseudo nAb ID50	595	42.8% (39.9%, 45.7%)	42.8% (39.9%, 45.7%)	36.5% (34.7%, 38.3%)
			Pseudo nAb ID80	595	35.8% (34.5%, 37.0%)	35.8% (34.5%, 37.0%)	28.2% (26.3%, 30.0%)
			Live Virus nAb ID50	595	41.7% (39.1%, 44.2%)	41.7% (39.1%, 44.2%)	33.0% (30.7%, 35.3%)
			Live Virus nAb ID80	595	35.5% (34.5%, 36.6%)	35.5% (34.5%, 36.6%)	28.5% (25.9%, 31.0%)
			Anti-Spike IgG	595	52.2% (47.4%, 57.0%)	52.2% (47.4%, 57.0%)	52.2% (47.4%, 57.0%)
			Anti-RBD IgG	595	52.2% (47.4%, 57.0%)	52.2% (47.4%, 57.0%)	52.2% (47.4%, 57.0%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
		Positive	Pseudo nAb ID50	595	51.2% (45.5%, 56.8%)	51.2% (45.5%, 56.8%)	50.3% (44.9%, 55.8%)
			Pseudo nAb ID80	595	48.5% (45.6%, 51.5%)	48.5% (45.6%, 51.5%)	46.2% (43.5%, 49.0%)
			Live Virus nAb ID50	595	50.3% (46.2%, 54.4%)	50.3% (46.2%, 54.4%)	49.2% (44.3%, 54.1%)
			Live Virus nAb ID80	595	49.1% (45.5%, 52.7%)	49.1% (45.5%, 52.7%)	45.8% (43.6%, 47.9%)
			Anti-Spike IgG	294	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	294	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	294	77.6% (71.6%, 83.5%)	77.6% (71.6%, 83.5%)	63.7% (55.8%, 71.6%)
			Pseudo nAb ID80	294	60.4% (52.6%, 68.2%)	60.4% (52.6%, 68.2%)	46.0% (38.9%, 53.0%)
			Live Virus nAb ID50	294	78.6% (74.7%, 82.5%)	78.6% (74.7%, 82.5%)	63.8% (57.0%, 70.7%)
			Live Virus nAb ID80	294	71.3% (65.5%, 77.0%)	71.3% (65.5%, 77.0%)	54.0% (45.5%, 62.5%)
			Anti-Spike IgG	294	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	294	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	294	97.3% (95.7%, 98.8%)	97.3% (95.7%, 98.8%)	94.6% (92.1%, 97.2%)
			Pseudo nAb ID80	294	93.0% (91.2%, 94.8%)	93.0% (91.2%, 94.8%)	89.2% (83.5%, 94.8%)
			Live Virus nAb ID50	294	98.5% (97.5%, 99.5%)	98.5% (97.5%, 99.5%)	95.2% (91.0%, 99.4%)
			Live Virus nAb ID80	294	95.3% (91.6%, 99.0%)	95.3% (91.6%, 99.0%)	92.5% (87.3%, 97.7%)
			Anti-Spike IgG	494	50.4% (48.7%, 52.0%)	50.4% (48.7%, 52.0%)	50.4% (48.7%, 52.0%)
			Anti-RBD IgG	494	50.4%	50.4%	50.4%
Male	Negative	D29	Anti-Spike IgG	494	50.4% (48.7%, 52.0%)	50.4% (48.7%, 52.0%)	50.4% (48.7%, 52.0%)
			Anti-RBD IgG	494	50.4%	50.4%	50.4%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
		D57	Pseudo nAb ID50	494	(48.7%, 52.0%)	(48.7%, 52.0%)	(48.7%, 52.0%)
					40.1%	40.1%	34.0%
			Pseudo nAb ID80	494	(35.0%, 45.3%)	(35.0%, 45.3%)	(27.9%, 40.1%)
					33.5%	33.5%	27.4%
			Live Virus nAb ID50	494	(27.2%, 39.8%)	(27.2%, 39.8%)	(20.7%, 34.2%)
					42.0%	42.0%	34.7%
			Live Virus nAb ID80	494	(39.2%, 44.8%)	(39.2%, 44.8%)	(30.6%, 38.8%)
					36.3%	36.3%	29.0%
			Anti-Spike IgG	494	(32.8%, 39.9%)	(32.8%, 39.9%)	(24.6%, 33.3%)
					50.4%	50.4%	50.4%
			Anti-RBD IgG	494	(48.7%, 52.0%)	(48.7%, 52.0%)	(48.7%, 52.0%)
					50.4%	50.4%	50.4%
			Pseudo nAb ID50	494	(48.7%, 52.0%)	(48.7%, 52.0%)	(48.7%, 52.0%)
					49.1%	49.1%	47.7%
			Pseudo nAb ID80	494	(47.0%, 51.1%)	(47.0%, 51.1%)	(45.3%, 50.1%)
					48.6%	48.6%	46.0%
			Live Virus nAb ID50	494	(46.9%, 50.4%)	(46.9%, 50.4%)	(43.4%, 48.6%)
					49.7%	49.7%	48.0%
			Live Virus nAb ID80	494	(47.9%, 51.5%)	(47.9%, 51.5%)	(45.6%, 50.4%)
					48.1%	48.1%	46.3%
Positive	D29	Anti-Spike IgG	229	(46.3%, 50.0%)	(46.3%, 50.0%)	(44.2%, 48.4%)	
				100.0%	100.0%	100.0%	
		Anti-RBD IgG	229	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)	
				100.0%	100.0%	100.0%	
		Pseudo nAb ID50	229	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)	
				80.2%	80.2%	72.4%	
		Pseudo nAb ID80	229	(71.7%, 88.6%)	(71.7%, 88.6%)	(63.4%, 81.3%)	
				70.4%	70.4%	53.4%	
		Live Virus nAb ID50	229	(61.8%, 79.0%)	(61.8%, 79.0%)	(41.5%, 65.4%)	
				74.4%	74.4%	68.7%	
		Live Virus nAb ID80	229	(64.7%, 84.2%)	(64.7%, 84.2%)	(62.8%, 74.6%)	
				68.6%	68.6%	56.6%	
	D57	Anti-Spike IgG	229	(58.6%, 78.7%)	(58.6%, 78.7%)	(47.3%, 65.9%)	
				100.0%	100.0%	100.0%	
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age, Sex Age < 65 Female	Negative	D29	Anti-RBD IgG	229	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	229	93.1% (89.0%, 97.2%)	93.1% (89.0%, 97.2%)	92.9% (89.3%, 96.5%)
			Pseudo nAb ID80	229	91.4% (87.6%, 95.3%)	91.4% (87.6%, 95.3%)	84.7% (79.0%, 90.5%)
			Live Virus nAb ID50	229	94.2% (90.9%, 97.4%)	94.2% (90.9%, 97.4%)	91.6% (87.3%, 95.9%)
			Live Virus nAb ID80	229	96.4% (94.6%, 98.3%)	96.4% (94.6%, 98.3%)	92.2% (90.6%, 93.8%)
	Negative	D29	Anti-Spike IgG	285	53.8% (51.7%, 55.8%)	53.8% (51.7%, 55.8%)	53.8% (51.7%, 55.8%)
			Anti-RBD IgG	285	53.8% (51.7%, 55.8%)	53.8% (51.7%, 55.8%)	53.8% (51.7%, 55.8%)
			Pseudo nAb ID50	285	43.2% (40.3%, 46.1%)	43.2% (40.3%, 46.1%)	36.0% (33.9%, 38.1%)
			Pseudo nAb ID80	285	35.4% (34.0%, 36.7%)	35.4% (34.0%, 36.7%)	27.4% (26.0%, 28.9%)
			Live Virus nAb ID50	285	41.7% (38.7%, 44.8%)	41.7% (38.7%, 44.8%)	32.2% (29.9%, 34.5%)
			Live Virus nAb ID80	285	35.1% (34.3%, 35.9%)	35.1% (34.3%, 35.9%)	27.4% (26.0%, 28.9%)
		D57	Anti-Spike IgG	285	53.8% (51.7%, 55.8%)	53.8% (51.7%, 55.8%)	53.8% (51.7%, 55.8%)
			Anti-RBD IgG	285	53.8% (51.7%, 55.8%)	53.8% (51.7%, 55.8%)	53.8% (51.7%, 55.8%)
			Pseudo nAb ID50	285	52.7% (49.0%, 56.4%)	52.7% (49.0%, 56.4%)	51.8% (48.2%, 55.4%)
			Pseudo nAb ID80	285	49.6% (48.8%, 50.3%)	49.6% (48.8%, 50.3%)	47.1% (46.1%, 48.2%)
			Live Virus nAb ID50	285	51.8% (50.6%, 52.9%)	51.8% (50.6%, 52.9%)	50.6% (47.6%, 53.6%)
			Live Virus nAb ID80	285	50.2% (48.7%, 51.8%)	50.2% (48.7%, 51.8%)	46.6% (46.6%, 46.6%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age < 65 Male	Positive	D29	Anti-Spike IgG	177	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	177	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	177	75.5% (70.6%, 80.5%)	75.5% (70.6%, 80.5%)	60.7% (59.9%, 61.5%)
			Pseudo nAb ID80	177	57.4% (55.0%, 59.8%)	57.4% (55.0%, 59.8%)	43.4% (38.6%, 48.1%)
			Live Virus nAb ID50	177	77.5% (73.5%, 81.5%)	77.5% (73.5%, 81.5%)	61.7% (55.1%, 68.4%)
			Live Virus nAb ID80	177	70.2% (63.5%, 76.8%)	70.2% (63.5%, 76.8%)	51.6% (42.8%, 60.5%)
		D57	Anti-Spike IgG	177	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	177	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	177	96.9% (95.2%, 98.6%)	96.9% (95.2%, 98.6%)	94.2% (91.2%, 97.1%)
			Pseudo nAb ID80	177	92.4% (90.9%, 93.9%)	92.4% (90.9%, 93.9%)	88.2% (81.6%, 94.8%)
			Live Virus nAb ID50	177	98.3% (97.1%, 99.4%)	98.3% (97.1%, 99.4%)	94.5% (89.6%, 99.5%)
			Live Virus nAb ID80	177	94.9% (90.6%, 99.2%)	94.9% (90.6%, 99.2%)	91.9% (85.7%, 98.1%)
	Negative	D29	Anti-Spike IgG	228	49.7% (49.2%, 50.2%)	49.7% (49.2%, 50.2%)	49.7% (49.2%, 50.2%)
			Anti-RBD IgG	228	49.7% (49.2%, 50.2%)	49.7% (49.2%, 50.2%)	49.7% (49.2%, 50.2%)
			Pseudo nAb ID50	228	38.2% (37.7%, 38.7%)	38.2% (37.7%, 38.7%)	31.6% (30.9%, 32.3%)
			Pseudo nAb ID80	228	31.2% (30.2%, 32.1%)	31.2% (30.2%, 32.1%)	25.0% (24.1%, 25.9%)
			Live Virus nAb ID50	228	40.9% (38.9%, 42.9%)	40.9% (38.9%, 42.9%)	33.1% (32.1%, 34.0%)
			Live Virus nAb ID80	228	35.0%	35.0%	27.4%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive		D57	Anti-Spike IgG	228	(34.9%, 35.2%)	(34.9%, 35.2%)	(27.0%, 27.7%)
					49.7%	49.7%	49.7%
			Anti-RBD IgG	228	(49.2%, 50.2%)	(49.2%, 50.2%)	(49.2%, 50.2%)
					49.7%	49.7%	49.7%
			Pseudo nAb ID50	228	(49.2%, 50.2%)	(49.2%, 50.2%)	(49.2%, 50.2%)
					48.2%	48.2%	46.8%
		D29	Pseudo nAb ID80	228	(48.0%, 48.5%)	(48.0%, 48.5%)	(46.8%, 46.8%)
					47.9%	47.9%	44.9%
			Live Virus nAb ID50	228	(46.9%, 49.0%)	(46.9%, 49.0%)	(44.1%, 45.8%)
					49.0%	49.0%	47.1%
			Live Virus nAb ID80	228	(47.9%, 50.0%)	(47.9%, 50.0%)	(45.2%, 49.0%)
					47.4%	47.4%	45.5%
			Anti-Spike IgG	118	(46.4%, 48.5%)	(46.4%, 48.5%)	(44.6%, 46.3%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	118	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	118	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					77.7%	77.7%	69.4%
			Pseudo nAb ID80	118	(73.4%, 82.1%)	(73.4%, 82.1%)	(66.8%, 71.9%)
					67.6%	67.6%	49.8%
			Live Virus nAb ID50	118	(65.0%, 70.1%)	(65.0%, 70.1%)	(44.5%, 55.1%)
					71.2%	71.2%	66.3%
			Live Virus nAb ID80	118	(68.5%, 73.8%)	(68.5%, 73.8%)	(63.9%, 68.7%)
					65.5%	65.5%	54.0%
		D57	Anti-Spike IgG	118	(61.7%, 69.3%)	(61.7%, 69.3%)	(49.0%, 59.0%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	118	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	118	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					92.1%	92.1%	92.1%
			Pseudo nAb ID80	118	(89.5%, 94.6%)	(89.5%, 94.6%)	(89.5%, 94.6%)
					90.2%	90.2%	83.0%
			Live Virus nAb ID50	118	(88.8%, 91.6%)	(88.8%, 91.6%)	(80.6%, 85.3%)
					93.6%	93.6%	90.7%
					(90.8%, 96.3%)	(90.8%, 96.3%)	(87.4%, 94.1%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 Female	Negative	D29	Live Virus nAb ID80	118	96.3% (94.0%, 98.6%)	96.3% (94.0%, 98.6%)	92.1% (90.0%, 94.1%)
			Anti-Spike IgG	310	44.7% (44.7%, 44.7%)	44.7% (44.7%, 44.7%)	44.7% (44.7%, 44.7%)
			Anti-RBD IgG	310	44.7% (44.7%, 44.7%)	44.7% (44.7%, 44.7%)	44.7% (44.7%, 44.7%)
			Pseudo nAb ID50	310	40.9% (40.9%, 40.9%)	40.9% (40.9%, 40.9%)	38.7% (38.7%, 38.7%)
			Pseudo nAb ID80	310	37.6% (37.6%, 37.6%)	37.6% (37.6%, 37.6%)	31.6% (31.6%, 31.6%)
			Live Virus nAb ID50	310	41.3% (41.3%, 41.3%)	41.3% (41.3%, 41.3%)	36.8% (36.8%, 36.8%)
		D57	Live Virus nAb ID80	310	37.6% (37.6%, 37.6%)	37.6% (37.6%, 37.6%)	33.4% (33.4%, 33.4%)
			Anti-Spike IgG	310	44.7% (44.7%, 44.7%)	44.7% (44.7%, 44.7%)	44.7% (44.7%, 44.7%)
			Anti-RBD IgG	310	44.7% (44.7%, 44.7%)	44.7% (44.7%, 44.7%)	44.7% (44.7%, 44.7%)
			Pseudo nAb ID50	310	43.8% (43.8%, 43.8%)	43.8% (43.8%, 43.8%)	43.3% (43.3%, 43.3%)
			Pseudo nAb ID80	310	43.5% (43.5%, 43.5%)	43.5% (43.5%, 43.5%)	41.9% (41.9%, 41.9%)
			Live Virus nAb ID50	310	43.3% (43.3%, 43.3%)	43.3% (43.3%, 43.3%)	42.5% (42.5%, 42.5%)
	Positive	D29	Live Virus nAb ID80	310	43.4% (43.4%, 43.4%)	43.4% (43.4%, 43.4%)	41.6% (41.6%, 41.6%)
			Anti-Spike IgG	117	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	117	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	117	92.5% (92.5%, 92.5%)	92.5% (92.5%, 92.5%)	85.6% (85.6%, 85.6%)
			Pseudo nAb ID80	117	82.5% (82.5%, 82.5%)	82.5% (82.5%, 82.5%)	65.2% (65.2%, 65.2%)
			Live Virus nAb ID50	117	87.0%	87.0%	79.3%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 Male	Negative	D57	Live Virus nAb ID80	117	(87.0%, 87.0%)	(87.0%, 87.0%)	(79.3%, 79.3%)
					79.3%	79.3%	71.4%
			Anti-Spike IgG	117	(79.3%, 79.3%)	(79.3%, 79.3%)	(71.4%, 71.4%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	117	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
		D29	Pseudo nAb ID50	117	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	98.3%
			Pseudo nAb ID80	117	(100.0%, 100.0%)	(100.0%, 100.0%)	(98.3%, 98.3%)
					97.4%	97.4%	96.5%
			Live Virus nAb ID50	117	(97.4%, 97.4%)	(97.4%, 97.4%)	(96.5%, 96.5%)
					100.0%	100.0%	100.0%
		D57	Live Virus nAb ID80	117	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					98.3%	98.3%	96.6%
			Anti-Spike IgG	266	(98.3%, 98.3%)	(98.3%, 98.3%)	(96.6%, 96.6%)
					54.0%	54.0%	54.0%
			Anti-RBD IgG	266	(54.0%, 54.0%)	(54.0%, 54.0%)	(54.0%, 54.0%)
					54.0%	54.0%	54.0%
			Pseudo nAb ID50	266	(54.0%, 54.0%)	(54.0%, 54.0%)	(54.0%, 54.0%)
					50.6%	50.6%	47.2%
			Pseudo nAb ID80	266	(50.6%, 50.6%)	(50.6%, 50.6%)	(47.2%, 47.2%)
					46.0%	46.0%	41.0%
			Live Virus nAb ID50	266	(46.0%, 46.0%)	(46.0%, 46.0%)	(41.0%, 41.0%)
					48.0%	48.0%	43.6%
			Live Virus nAb ID80	266	(48.0%, 48.0%)	(48.0%, 48.0%)	(43.6%, 43.6%)
					43.7%	43.7%	37.8%
			Anti-Spike IgG	266	(43.7%, 43.7%)	(43.7%, 43.7%)	(37.8%, 37.8%)
					54.0%	54.0%	54.0%
			Anti-RBD IgG	266	(54.0%, 54.0%)	(54.0%, 54.0%)	(54.0%, 54.0%)
					54.0%	54.0%	54.0%
			Pseudo nAb ID50	266	(54.0%, 54.0%)	(54.0%, 54.0%)	(54.0%, 54.0%)
					53.6%	53.6%	52.8%
			Pseudo nAb ID80	266	(53.6%, 53.6%)	(53.6%, 53.6%)	(52.8%, 52.8%)
					52.6%	52.6%	51.8%
					(52.6%, 52.6%)	(52.6%, 52.6%)	(51.8%, 51.8%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Ethnicity Hispanic or Latino	Positive	D29	Live Virus nAb ID50	266	53.7% (53.7%, 53.7%)	53.7% (53.7%, 53.7%)	53.0% (53.0%, 53.0%)
			Live Virus nAb ID80	266	52.1% (52.1%, 52.1%)	52.1% (52.1%, 52.1%)	50.9% (50.9%, 50.9%)
			Anti-Spike IgG	111	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	111	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	111	94.0% (94.0%, 94.0%)	94.0% (94.0%, 94.0%)	89.4% (89.4%, 89.4%)
			Pseudo nAb ID80	111	86.7% (86.7%, 86.7%)	86.7% (86.7%, 86.7%)	74.0% (74.0%, 74.0%)
			Live Virus nAb ID50	111	93.1% (93.1%, 93.1%)	93.1% (93.1%, 93.1%)	82.1% (82.1%, 82.1%)
			Live Virus nAb ID80	111	86.7% (86.7%, 86.7%)	86.7% (86.7%, 86.7%)	71.3% (71.3%, 71.3%)
		D57	Anti-Spike IgG	111	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	111	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	111	99.1% (99.1%, 99.1%)	99.1% (99.1%, 99.1%)	97.6% (97.6%, 97.6%)
			Pseudo nAb ID80	111	98.5% (98.5%, 98.5%)	98.5% (98.5%, 98.5%)	94.8% (94.8%, 94.8%)
			Live Virus nAb ID50	111	97.6% (97.6%, 97.6%)	97.6% (97.6%, 97.6%)	96.7% (96.7%, 96.7%)
			Live Virus nAb ID80	111	97.3% (97.3%, 97.3%)	97.3% (97.3%, 97.3%)	93.0% (93.0%, 93.0%)
	Negative	D29	Anti-Spike IgG	139	48.8% (42.3%, 55.2%)	48.8% (42.3%, 55.2%)	48.8% (42.3%, 55.2%)
			Anti-RBD IgG	139	48.8% (42.3%, 55.2%)	48.8% (42.3%, 55.2%)	48.8% (42.3%, 55.2%)
			Pseudo nAb ID50	139	40.2% (32.9%, 47.4%)	40.2% (32.9%, 47.4%)	38.4% (31.3%, 45.6%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
		D57	Pseudo nAb ID80	139	38.1% (31.7%, 44.6%)	38.1% (31.7%, 44.6%)	29.2% (21.9%, 36.6%)
			Live Virus nAb ID50	139	43.7% (35.6%, 51.8%)	43.7% (35.6%, 51.8%)	35.1% (25.2%, 44.9%)
			Live Virus nAb ID80	139	39.2% (32.5%, 45.9%)	39.2% (32.5%, 45.9%)	34.3% (29.7%, 38.8%)
			Anti-Spike IgG	139	48.8% (42.3%, 55.2%)	48.8% (42.3%, 55.2%)	48.8% (42.3%, 55.2%)
			Anti-RBD IgG	139	48.8% (42.3%, 55.2%)	48.8% (42.3%, 55.2%)	48.8% (42.3%, 55.2%)
			Pseudo nAb ID50	139	47.0% (38.9%, 55.1%)	47.0% (38.9%, 55.1%)	47.0% (38.9%, 55.1%)
			Pseudo nAb ID80	139	46.8% (39.1%, 54.5%)	46.8% (39.1%, 54.5%)	45.2% (39.8%, 50.6%)
			Live Virus nAb ID50	139	48.1% (43.0%, 53.2%)	48.1% (43.0%, 53.2%)	47.3% (43.0%, 51.7%)
			Live Virus nAb ID80	139	45.7% (39.1%, 52.3%)	45.7% (39.1%, 52.3%)	43.4% (36.0%, 50.7%)
		Positive D29	Anti-Spike IgG	59	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	59	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	59	82.4% (75.3%, 89.5%)	82.4% (75.3%, 89.5%)	72.2% (63.8%, 80.7%)
			Pseudo nAb ID80	59	73.7% (67.0%, 80.4%)	73.7% (67.0%, 80.4%)	56.6% (48.9%, 64.4%)
			Live Virus nAb ID50	59	92.6% (86.2%, 98.9%)	92.6% (86.2%, 98.9%)	83.5% (68.2%, 98.8%)
			Live Virus nAb ID80	59	82.5% (66.2%, 98.8%)	82.5% (66.2%, 98.8%)	65.7% (45.3%, 86.1%)
		D57	Anti-Spike IgG	59	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	59	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	59	96.4%	96.4%	96.1%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Not Hispanic or Latino	Negative	D29	Pseudo nAb ID80	59	(93.5%, 99.3%)	(93.5%, 99.3%)	(93.7%, 98.4%)
					98.7%	98.7%	97.2%
			Live Virus nAb ID50	59	(95.6%, 101.7%)	(95.6%, 101.7%)	(90.8%, 103.5%)
					99.2%	99.2%	97.2%
			Live Virus nAb ID80	59	(97.0%, 101.4%)	(97.0%, 101.4%)	(90.8%, 103.5%)
					98.0%	98.0%	93.0%
			Anti-Spike IgG	837	(92.5%, 103.4%)	(92.5%, 103.4%)	(87.0%, 99.1%)
					53.6%	53.6%	53.6%
			Anti-RBD IgG	837	(48.8%, 58.4%)	(48.8%, 58.4%)	(48.8%, 58.4%)
					53.6%	53.6%	53.6%
			Pseudo nAb ID50	837	(48.8%, 58.4%)	(48.8%, 58.4%)	(48.8%, 58.4%)
					43.7%	43.7%	36.2%
			Pseudo nAb ID80	837	(40.3%, 47.2%)	(40.3%, 47.2%)	(32.8%, 39.6%)
					36.2%	36.2%	29.2%
			Live Virus nAb ID50	837	(33.5%, 39.0%)	(33.5%, 39.0%)	(25.9%, 32.5%)
					43.3%	43.3%	34.7%
			Live Virus nAb ID80	837	(38.5%, 48.1%)	(38.5%, 48.1%)	(31.3%, 38.2%)
					36.3%	36.3%	28.7%
		D57	Anti-Spike IgG	837	(34.2%, 38.5%)	(34.2%, 38.5%)	(25.3%, 32.2%)
					53.6%	53.6%	53.6%
			Anti-RBD IgG	837	(48.8%, 58.4%)	(48.8%, 58.4%)	(48.8%, 58.4%)
					53.6%	53.6%	53.6%
			Pseudo nAb ID50	837	(48.8%, 58.4%)	(48.8%, 58.4%)	(48.8%, 58.4%)
					52.3%	52.3%	51.2%
			Pseudo nAb ID80	837	(47.0%, 57.7%)	(47.0%, 57.7%)	(46.0%, 56.3%)
					50.6%	50.6%	48.1%
			Live Virus nAb ID50	837	(46.4%, 54.9%)	(46.4%, 54.9%)	(44.4%, 51.8%)
					52.1%	52.1%	50.7%
			Live Virus nAb ID80	837	(47.7%, 56.6%)	(47.7%, 56.6%)	(45.3%, 56.1%)
					51.0%	51.0%	48.1%
	Positive	D29	Anti-Spike IgG	418	(46.7%, 55.2%)	(46.7%, 55.2%)	(45.1%, 51.1%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	418	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
		D57	Pseudo nAb ID50	418	77.9% (71.8%, 84.1%)	77.9% (71.8%, 84.1%)	65.7% (56.5%, 74.9%)
			Pseudo nAb ID80	418	62.9% (54.6%, 71.2%)	62.9% (54.6%, 71.2%)	48.3% (39.4%, 57.1%)
			Live Virus nAb ID50	418	75.0% (69.0%, 81.0%)	75.0% (69.0%, 81.0%)	63.3% (57.0%, 69.6%)
			Live Virus nAb ID80	418	67.8% (61.1%, 74.6%)	67.8% (61.1%, 74.6%)	53.6% (45.8%, 61.5%)
			Anti-Spike IgG	418	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	418	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	418	95.6% (94.1%, 97.1%)	95.6% (94.1%, 97.1%)	93.7% (92.1%, 95.3%)
			Pseudo nAb ID80	418	92.2% (89.8%, 94.7%)	92.2% (89.8%, 94.7%)	86.3% (82.8%, 89.8%)
			Live Virus nAb ID50	418	96.5% (95.1%, 97.8%)	96.5% (95.1%, 97.8%)	93.1% (90.9%, 95.3%)
			Live Virus nAb ID80	418	96.3% (93.1%, 99.6%)	96.3% (93.1%, 99.6%)	93.3% (88.7%, 98.0%)
Race American Indian or Alaska Native	Negative	D29	Anti-Spike IgG	29	57.1% (1.1%, 113.2%)	57.1% (1.1%, 113.2%)	57.1% (1.1%, 113.2%)
			Anti-RBD IgG	29	57.1% (1.1%, 113.2%)	57.1% (1.1%, 113.2%)	57.1% (1.1%, 113.2%)
			Pseudo nAb ID50	29	41.6% (2.7%, 80.5%)	41.6% (2.7%, 80.5%)	33.8% (3.3%, 64.2%)
			Pseudo nAb ID80	29	32.2% (-0.4%, 64.8%)	32.2% (-0.4%, 64.8%)	31.4% (-2.2%, 65.0%)
			Live Virus nAb ID50	29	53.4% (-7.3%, 114.1%)	53.4% (-7.3%, 114.1%)	38.5% (-4.4%, 81.4%)
			Live Virus nAb ID80	29	44.9% (-8.4%, 98.1%)	44.9% (-8.4%, 98.1%)	44.9% (-8.4%, 98.1%)
		D57	Anti-Spike IgG	29	57.1% (1.1%, 113.2%)	57.1% (1.1%, 113.2%)	57.1% (1.1%, 113.2%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Asian	Positive	D29	Anti-RBD IgG	29	57.1% (1.1%, 113.2%)	57.1% (1.1%, 113.2%)	57.1% (1.1%, 113.2%)
			Pseudo nAb ID50	29	54.0% (-5.8%, 113.9%)	54.0% (-5.8%, 113.9%)	53.4% (-7.3%, 114.1%)
			Pseudo nAb ID80	29	50.2% (3.6%, 96.8%)	50.2% (3.6%, 96.8%)	49.5% (1.9%, 97.1%)
			Live Virus nAb ID50	29	55.6% (-2.3%, 113.4%)	55.6% (-2.3%, 113.4%)	53.4% (-7.3%, 114.1%)
			Live Virus nAb ID80	29	57.1% (1.1%, 113.2%)	57.1% (1.1%, 113.2%)	50.8% (5.2%, 96.5%)
			Anti-Spike IgG	8	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	8	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	8	83.5% (80.4%, 86.5%)	83.5% (80.4%, 86.5%)	67.0% (60.8%, 73.1%)
			Pseudo nAb ID80	8	67.0% (60.8%, 73.1%)	67.0% (60.8%, 73.1%)	67.0% (60.8%, 73.1%)
			Live Virus nAb ID50	8	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Live Virus nAb ID80	8	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	64.5% (56.3%, 72.8%)
		D57	Anti-Spike IgG	8	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	8	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	8	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID80	8	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Live Virus nAb ID50	8	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Live Virus nAb ID80	8	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-Spike IgG	73	44.0%	44.0%	44.0%
		D29	Anti-Spike IgG	73	44.0%	44.0%	44.0%
			Anti-Spike IgG	73	44.0%	44.0%	44.0%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57		Anti-RBD IgG	73	(40.6%, 47.5%)	(40.6%, 47.5%)	(40.6%, 47.5%)
					44.0%	44.0%	44.0%
			Pseudo nAb ID50	73	(40.6%, 47.5%)	(40.6%, 47.5%)	(40.6%, 47.5%)
					33.5%	33.5%	21.4%
			Pseudo nAb ID80	73	(31.0%, 36.1%)	(31.0%, 36.1%)	(9.9%, 32.9%)
					20.6%	20.6%	15.8%
			Live Virus nAb ID50	73	(10.4%, 30.8%)	(10.4%, 30.8%)	(0.9%, 30.7%)
					31.3%	31.3%	27.4%
			Live Virus nAb ID80	73	(28.9%, 33.8%)	(28.9%, 33.8%)	(23.2%, 31.5%)
					30.8%	30.8%	24.6%
			Anti-Spike IgG	73	(28.6%, 33.0%)	(28.6%, 33.0%)	(19.9%, 29.3%)
					44.0%	44.0%	44.0%
			Anti-RBD IgG	73	(40.6%, 47.5%)	(40.6%, 47.5%)	(40.6%, 47.5%)
					44.0%	44.0%	44.0%
			Pseudo nAb ID50	73	(40.6%, 47.5%)	(40.6%, 47.5%)	(40.6%, 47.5%)
					43.8%	43.8%	40.1%
			Pseudo nAb ID80	73	(39.8%, 47.8%)	(39.8%, 47.8%)	(37.4%, 42.9%)
					40.9%	40.9%	38.4%
			Live Virus nAb ID50	73	(38.5%, 43.4%)	(38.5%, 43.4%)	(35.3%, 41.5%)
					39.2%	39.2%	35.6%
			Live Virus nAb ID80	73	(34.8%, 43.6%)	(34.8%, 43.6%)	(32.0%, 39.2%)
					40.1%	40.1%	37.9%
	D29		Anti-Spike IgG	33	(37.4%, 42.9%)	(37.4%, 42.9%)	(36.0%, 39.7%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	33	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	33	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					78.9%	78.9%	60.9%
			Pseudo nAb ID80	33	(57.4%, 100.4%)	(57.4%, 100.4%)	(32.4%, 89.4%)
					54.9%	54.9%	34.2%
			Live Virus nAb ID50	33	(38.5%, 71.3%)	(38.5%, 71.3%)	(11.4%, 57.1%)
					74.1%	74.1%	63.0%
			Live Virus nAb ID80	33	(60.9%, 87.2%)	(60.9%, 87.2%)	(51.8%, 74.2%)
					75.1%	75.1%	49.0%
					(66.9%, 83.3%)	(66.9%, 83.3%)	(41.9%, 56.2%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Black or African American	Negative	D57	Anti-Spike IgG	33	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	33	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	33	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	93.0% (85.8%, 100.1%)
			Pseudo nAb ID80	33	85.0% (72.0%, 97.9%)	85.0% (72.0%, 97.9%)	83.0% (74.5%, 91.5%)
			Live Virus nAb ID50	33	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	98.0% (93.1%, 102.9%)
			Live Virus nAb ID80	33	93.0% (85.8%, 100.1%)	93.0% (85.8%, 100.1%)	93.0% (85.8%, 100.1%)
		D29	Anti-Spike IgG	242	61.1% (56.1%, 66.1%)	61.1% (56.1%, 66.1%)	61.1% (56.1%, 66.1%)
			Anti-RBD IgG	242	61.1% (56.1%, 66.1%)	61.1% (56.1%, 66.1%)	61.1% (56.1%, 66.1%)
			Pseudo nAb ID50	242	48.0% (45.4%, 50.6%)	48.0% (45.4%, 50.6%)	40.9% (36.0%, 45.8%)
			Pseudo nAb ID80	242	41.0% (35.9%, 46.1%)	41.0% (35.9%, 46.1%)	29.9% (21.7%, 38.1%)
			Live Virus nAb ID50	242	50.6% (45.8%, 55.3%)	50.6% (45.8%, 55.3%)	37.0% (31.3%, 42.7%)
			Live Virus nAb ID80	242	42.0% (39.0%, 44.9%)	42.0% (39.0%, 44.9%)	33.8% (30.6%, 37.1%)
		D57	Anti-Spike IgG	242	61.1% (56.1%, 66.1%)	61.1% (56.1%, 66.1%)	61.1% (56.1%, 66.1%)
			Anti-RBD IgG	242	61.1% (56.1%, 66.1%)	61.1% (56.1%, 66.1%)	61.1% (56.1%, 66.1%)
			Pseudo nAb ID50	242	59.4% (53.1%, 65.7%)	59.4% (53.1%, 65.7%)	57.6% (52.2%, 62.9%)
			Pseudo nAb ID80	242	58.2% (54.9%, 61.6%)	58.2% (54.9%, 61.6%)	54.6% (52.5%, 56.7%)
			Live Virus nAb ID50	242	61.0% (55.9%, 66.1%)	61.0% (55.9%, 66.1%)	57.6% (52.2%, 62.9%)
			Live Virus nAb ID80	242	57.0%	57.0%	53.8%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Multiracial	Positive	D29	Anti-Spike IgG	101	(53.2%, 60.7%)	(53.2%, 60.7%)	(51.0%, 56.7%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	101	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	101	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					69.4%	69.4%	66.1%
			Pseudo nAb ID80	101	(56.4%, 82.4%)	(56.4%, 82.4%)	(52.6%, 79.6%)
					59.9%	59.9%	52.7%
		D57	Live Virus nAb ID50	101	(42.8%, 77.0%)	(42.8%, 77.0%)	(42.3%, 63.1%)
					76.0%	76.0%	66.4%
			Live Virus nAb ID80	101	(68.8%, 83.1%)	(68.8%, 83.1%)	(58.3%, 74.5%)
					66.0%	66.0%	60.8%
			Anti-Spike IgG	101	(58.1%, 73.9%)	(58.1%, 73.9%)	(56.1%, 65.4%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	101	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	101	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					94.0%	94.0%	90.9%
			Pseudo nAb ID80	101	(91.3%, 96.7%)	(91.3%, 96.7%)	(86.9%, 95.0%)
					90.6%	90.6%	81.6%
			Live Virus nAb ID50	101	(87.4%, 93.9%)	(87.4%, 93.9%)	(75.6%, 87.6%)
					97.0%	97.0%	92.6%
			Live Virus nAb ID80	101	(95.6%, 98.3%)	(95.6%, 98.3%)	(89.3%, 95.9%)
					95.3%	95.3%	90.3%
Multiracial	Negative	D29	Anti-Spike IgG	64	(92.5%, 98.2%)	(92.5%, 98.2%)	(87.8%, 92.8%)
					37.8%	37.8%	37.8%
			Anti-RBD IgG	64	(19.5%, 56.0%)	(19.5%, 56.0%)	(19.5%, 56.0%)
					37.8%	37.8%	37.8%
			Pseudo nAb ID50	64	(19.5%, 56.0%)	(19.5%, 56.0%)	(19.5%, 56.0%)
					28.6%	28.6%	28.0%
			Pseudo nAb ID80	64	(13.5%, 43.8%)	(13.5%, 43.8%)	(13.7%, 42.3%)
					29.8%	29.8%	25.5%
			Live Virus nAb ID50	64	(19.5%, 40.1%)	(19.5%, 40.1%)	(16.9%, 34.2%)
					35.0%	35.0%	29.7%
					(21.6%, 48.4%)	(21.6%, 48.4%)	(18.5%, 40.9%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive		D57	Live Virus nAb ID80	64	31.6% (18.2%, 45.0%)	31.6% (18.2%, 45.0%)	22.6% (12.1%, 33.1%)
			Anti-Spike IgG	64	37.8% (19.5%, 56.0%)	37.8% (19.5%, 56.0%)	37.8% (19.5%, 56.0%)
			Anti-RBD IgG	64	37.8% (19.5%, 56.0%)	37.8% (19.5%, 56.0%)	37.8% (19.5%, 56.0%)
			Pseudo nAb ID50	64	36.9% (20.4%, 53.3%)	36.9% (20.4%, 53.3%)	36.2% (20.9%, 51.6%)
			Pseudo nAb ID80	64	36.9% (20.4%, 53.3%)	36.9% (20.4%, 53.3%)	35.1% (22.1%, 48.1%)
			Live Virus nAb ID50	64	35.5% (22.0%, 48.9%)	35.5% (22.0%, 48.9%)	35.5% (22.0%, 48.9%)
		D29	Live Virus nAb ID80	64	36.6% (20.8%, 52.5%)	36.6% (20.8%, 52.5%)	36.0% (21.3%, 50.7%)
			Anti-Spike IgG	31	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	31	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	31	76.0% (68.5%, 83.4%)	76.0% (68.5%, 83.4%)	73.8% (62.8%, 84.8%)
			Pseudo nAb ID80	31	71.6% (55.9%, 87.3%)	71.6% (55.9%, 87.3%)	68.5% (53.1%, 83.8%)
			Live Virus nAb ID50	31	88.0% (87.1%, 88.9%)	88.0% (87.1%, 88.9%)	84.8% (78.1%, 91.5%)
		D57	Live Virus nAb ID80	31	83.8% (78.1%, 89.6%)	83.8% (78.1%, 89.6%)	70.6% (60.7%, 80.6%)
			Anti-Spike IgG	31	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	31	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	31	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	99.0% (96.2%, 101.7%)
			Pseudo nAb ID80	31	92.2% (84.4%, 100.1%)	92.2% (84.4%, 100.1%)	92.2% (84.4%, 100.1%)
			Live Virus nAb ID50	31	100.0%	100.0%	97.8%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Native Hawaiian or Other Pacific Islander	Negative	D29	Live Virus nAb ID80	31	(100.0%, 100.0%)	(100.0%, 100.0%)	(92.3%, 103.3%)
					100.0%	100.0%	97.8%
			Anti-Spike IgG	11	(100.0%, 100.0%)	(100.0%, 100.0%)	(92.3%, 103.3%)
					31.4%	31.4%	31.4%
			Anti-RBD IgG	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
					31.4%	31.4%	31.4%
			Pseudo nAb ID50	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
					31.4%	31.4%	31.4%
			Pseudo nAb ID80	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
					31.4%	31.4%	28.0%
			Live Virus nAb ID50	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(1.4%, 54.7%)
					24.6%	24.6%	23.2%
			Live Virus nAb ID80	11	(4.8%, 44.4%)	(4.8%, 44.4%)	(7.5%, 38.8%)
					26.6%	26.6%	25.1%
		D57	Anti-Spike IgG	11	(3.5%, 49.7%)	(3.5%, 49.7%)	(5.3%, 45.0%)
					31.4%	31.4%	31.4%
			Anti-RBD IgG	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
					31.4%	31.4%	31.4%
			Pseudo nAb ID50	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
					31.4%	31.4%	31.4%
			Pseudo nAb ID80	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
					31.4%	31.4%	31.4%
			Live Virus nAb ID50	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
					31.4%	31.4%	31.4%
			Live Virus nAb ID80	11	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
					31.4%	31.4%	31.4%
	Positive	D29	Anti-Spike IgG	7	(-3.6%, 66.5%)	(-3.6%, 66.5%)	(-3.6%, 66.5%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	63.7%
			Pseudo nAb ID80	7	(100.0%, 100.0%)	(100.0%, 100.0%)	(30.2%, 97.2%)
					63.7%	63.7%	50.3%
					(30.2%, 97.2%)	(30.2%, 97.2%)	(43.0%, 57.6%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Not reported and unknown		D57	Live Virus nAb ID50	7	59.4% (32.3%, 86.5%)	59.4% (32.3%, 86.5%)	50.2% (43.0%, 57.4%)
			Live Virus nAb ID80	7	63.7% (30.2%, 97.2%)	63.7% (30.2%, 97.2%)	12.9% (-21.9%, 47.7%)
			Anti-Spike IgG	7	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	7	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	7	63.7% (30.2%, 97.2%)	63.7% (30.2%, 97.2%)	63.7% (30.2%, 97.2%)
			Pseudo nAb ID80	7	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Live Virus nAb ID50	7	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Live Virus nAb ID80	7	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
	Negative	D29	Anti-Spike IgG	115	43.8% (39.9%, 47.7%)	43.8% (39.9%, 47.7%)	43.8% (39.9%, 47.7%)
			Anti-RBD IgG	115	43.8% (39.9%, 47.7%)	43.8% (39.9%, 47.7%)	43.8% (39.9%, 47.7%)
			Pseudo nAb ID50	115	38.5% (35.0%, 41.9%)	38.5% (35.0%, 41.9%)	31.3% (29.3%, 33.3%)
			Pseudo nAb ID80	115	35.6% (32.7%, 38.5%)	35.6% (32.7%, 38.5%)	29.2% (25.8%, 32.5%)
			Live Virus nAb ID50	115	33.6% (31.1%, 36.1%)	33.6% (31.1%, 36.1%)	30.7% (29.3%, 32.0%)
			Live Virus nAb ID80	115	34.6% (30.7%, 38.6%)	34.6% (30.7%, 38.6%)	28.8% (25.6%, 32.0%)
		D57	Anti-Spike IgG	115	43.8% (39.9%, 47.7%)	43.8% (39.9%, 47.7%)	43.8% (39.9%, 47.7%)
			Anti-RBD IgG	115	43.8% (39.9%, 47.7%)	43.8% (39.9%, 47.7%)	43.8% (39.9%, 47.7%)
			Pseudo nAb ID50	115	42.5% (38.6%, 46.3%)	42.5% (38.6%, 46.3%)	42.3% (38.3%, 46.3%)
			Pseudo nAb ID80	115	43.8%	43.8%	39.7%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive		D29	Live Virus nAb ID50	115	(39.8%, 47.7%)	(39.8%, 47.7%)	(36.9%, 42.5%)
					43.7%	43.7%	43.0%
			Live Virus nAb ID80	115	(39.5%, 47.8%)	(39.5%, 47.8%)	(39.4%, 46.6%)
					43.5%	43.5%	39.1%
			Anti-Spike IgG	57	(40.0%, 46.9%)	(40.0%, 46.9%)	(35.1%, 43.0%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					82.3%	82.3%	70.4%
			Pseudo nAb ID80	57	(76.3%, 88.3%)	(76.3%, 88.3%)	(64.0%, 76.7%)
					64.2%	64.2%	43.3%
			Live Virus nAb ID50	57	(57.0%, 71.4%)	(57.0%, 71.4%)	(31.7%, 54.9%)
					75.4%	75.4%	64.1%
			Live Virus nAb ID80	57	(65.6%, 85.1%)	(65.6%, 85.1%)	(58.0%, 70.2%)
					63.6%	63.6%	57.5%
		D57	Anti-Spike IgG	57	(51.4%, 75.7%)	(51.4%, 75.7%)	(55.3%, 59.6%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	57	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					94.8%	94.8%	94.3%
			Pseudo nAb ID80	57	(92.7%, 97.0%)	(92.7%, 97.0%)	(93.5%, 95.0%)
					90.3%	90.3%	88.6%
Other		D29	Live Virus nAb ID50	57	(84.6%, 96.0%)	(84.6%, 96.0%)	(85.5%, 91.8%)
					98.9%	98.9%	94.3%
			Live Virus nAb ID80	57	(95.9%, 101.8%)	(95.9%, 101.8%)	(91.9%, 96.8%)
					94.8%	94.8%	93.7%
			Anti-Spike IgG	23	(92.7%, 97.0%)	(92.7%, 97.0%)	(90.1%, 97.3%)
					91.5%	91.5%	91.5%
			Anti-RBD IgG	23	(70.4%, 112.6%)	(70.4%, 112.6%)	(70.4%, 112.6%)
					91.5%	91.5%	91.5%
			Pseudo nAb ID50	23	(70.4%, 112.6%)	(70.4%, 112.6%)	(70.4%, 112.6%)
					80.4%	80.4%	77.6%
					(68.2%, 92.5%)	(68.2%, 92.5%)	(65.1%, 90.1%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57		Pseudo nAb ID80	23	75.3% (57.2%, 93.4%)	75.3% (57.2%, 93.4%)	61.5% (51.1%, 71.8%)
			Live Virus nAb ID50	23	77.6% (65.1%, 90.1%)	77.6% (65.1%, 90.1%)	77.6% (65.1%, 90.1%)
			Live Virus nAb ID80	23	76.5% (61.2%, 91.8%)	76.5% (61.2%, 91.8%)	71.5% (47.5%, 95.4%)
			Anti-Spike IgG	23	91.5% (70.4%, 112.6%)	91.5% (70.4%, 112.6%)	91.5% (70.4%, 112.6%)
			Anti-RBD IgG	23	91.5% (70.4%, 112.6%)	91.5% (70.4%, 112.6%)	91.5% (70.4%, 112.6%)
			Pseudo nAb ID50	23	80.4% (68.2%, 92.5%)	80.4% (68.2%, 92.5%)	80.4% (68.2%, 92.5%)
			Pseudo nAb ID80	23	79.2% (64.4%, 94.0%)	79.2% (64.4%, 94.0%)	78.1% (60.6%, 95.6%)
			Live Virus nAb ID50	23	91.5% (70.4%, 112.6%)	91.5% (70.4%, 112.6%)	91.5% (70.4%, 112.6%)
			Live Virus nAb ID80	23	77.6% (65.1%, 90.1%)	77.6% (65.1%, 90.1%)	77.6% (65.1%, 90.1%)
	D29		Anti-Spike IgG	14	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	14	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	14	84.2% (76.9%, 91.5%)	84.2% (76.9%, 91.5%)	59.7% (54.1%, 65.4%)
			Pseudo nAb ID80	14	50.1% (32.9%, 67.2%)	50.1% (32.9%, 67.2%)	29.1% (21.4%, 36.8%)
			Live Virus nAb ID50	14	81.0% (63.7%, 98.2%)	81.0% (63.7%, 98.2%)	79.4% (59.8%, 99.0%)
			Live Virus nAb ID80	14	84.2% (76.9%, 91.5%)	84.2% (76.9%, 91.5%)	58.2% (56.5%, 59.9%)
	D57		Anti-Spike IgG	14	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	14	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	14	100.0%	100.0%	99.0%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
White	Negative	D29	Pseudo nAb ID80	14	(100.0%, 100.0%)	(100.0%, 100.0%)	(96.0%, 102.0%)
					81.0%	81.0%	81.0%
					(63.7%, 98.2%)	(63.7%, 98.2%)	(63.7%, 98.2%)
			Live Virus nAb ID50	14	99.0%	99.0%	87.5%
					(96.0%, 102.0%)	(96.0%, 102.0%)	(84.8%, 90.1%)
					85.2%	85.2%	72.7%
			Live Virus nAb ID80	14	(78.5%, 91.9%)	(78.5%, 91.9%)	(68.3%, 77.1%)
					51.6%	51.6%	51.6%
					(46.3%, 57.0%)	(46.3%, 57.0%)	(46.3%, 57.0%)
			Anti-RBD IgG	55	51.6%	51.6%	51.6%
					(46.3%, 57.0%)	(46.3%, 57.0%)	(46.3%, 57.0%)
					40.3%	40.3%	38.8%
			Pseudo nAb ID50	55	(30.2%, 50.5%)	(30.2%, 50.5%)	(31.6%, 46.0%)
					29.5%	29.5%	21.4%
					(11.0%, 48.0%)	(11.0%, 48.0%)	(9.2%, 33.7%)
			Live Virus nAb ID50	55	39.6%	39.6%	34.3%
					(30.3%, 49.0%)	(30.3%, 49.0%)	(25.4%, 43.2%)
					41.2%	41.2%	33.6%
			Live Virus nAb ID80	55	(33.5%, 48.9%)	(33.5%, 48.9%)	(25.2%, 42.0%)
					51.6%	51.6%	51.6%
					(46.3%, 57.0%)	(46.3%, 57.0%)	(46.3%, 57.0%)
		D57	Anti-RBD IgG	55	51.6%	51.6%	51.6%
					(46.3%, 57.0%)	(46.3%, 57.0%)	(46.3%, 57.0%)
					51.3%	51.3%	51.3%
			Pseudo nAb ID50	55	(45.6%, 57.0%)	(45.6%, 57.0%)	(45.6%, 57.0%)
					47.9%	47.9%	44.2%
					(40.9%, 54.9%)	(40.9%, 54.9%)	(35.1%, 53.3%)
			Live Virus nAb ID50	55	48.3%	48.3%	47.9%
					(41.2%, 55.4%)	(41.2%, 55.4%)	(40.9%, 54.9%)
					47.2%	47.2%	46.9%
			Live Virus nAb ID80	55	(40.0%, 54.4%)	(40.0%, 54.4%)	(39.5%, 54.3%)
					100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
		Positive	D29	29	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
White Non-Hispanic	D57		Pseudo nAb ID50	29	86.0% (77.4%, 94.5%)	86.0% (77.4%, 94.5%)	86.0% (77.4%, 94.5%)
			Pseudo nAb ID80	29	75.1% (67.8%, 82.3%)	75.1% (67.8%, 82.3%)	48.8% (37.9%, 59.7%)
			Live Virus nAb ID50	29	76.1% (65.9%, 86.3%)	76.1% (65.9%, 86.3%)	69.8% (63.0%, 76.6%)
			Live Virus nAb ID80	29	82.4% (74.7%, 90.0%)	82.4% (74.7%, 90.0%)	54.6% (40.7%, 68.5%)
			Anti-Spike IgG	29	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	29	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	29	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID80	29	91.1% (81.8%, 100.3%)	91.1% (81.8%, 100.3%)	91.1% (81.8%, 100.3%)
			Live Virus nAb ID50	29	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Live Virus nAb ID80	29	91.1% (81.8%, 100.3%)	91.1% (81.8%, 100.3%)	82.1% (63.6%, 100.6%)
			Anti-Spike IgG	437	52.2% (47.7%, 56.6%)	52.2% (47.7%, 56.6%)	52.2% (47.7%, 56.6%)
			Anti-RBD IgG	437	52.2% (47.7%, 56.6%)	52.2% (47.7%, 56.6%)	52.2% (47.7%, 56.6%)
			Pseudo nAb ID50	437	42.9% (38.3%, 47.5%)	42.9% (38.3%, 47.5%)	36.4% (31.7%, 41.2%)
			Pseudo nAb ID80	437	34.7% (31.7%, 37.7%)	34.7% (31.7%, 37.7%)	28.9% (25.2%, 32.7%)
	Negative	D29	Anti-Spike IgG	437	52.2% (47.7%, 56.6%)	52.2% (47.7%, 56.6%)	52.2% (47.7%, 56.6%)
			Anti-RBD IgG	437	52.2% (47.7%, 56.6%)	52.2% (47.7%, 56.6%)	52.2% (47.7%, 56.6%)
			Pseudo nAb ID50	437	42.9% (38.3%, 47.5%)	42.9% (38.3%, 47.5%)	36.4% (31.7%, 41.2%)
			Pseudo nAb ID80	437	34.7% (31.7%, 37.7%)	34.7% (31.7%, 37.7%)	28.9% (25.2%, 32.7%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
			Live Virus nAb ID50	437	(31.7%, 37.7%)	(31.7%, 37.7%)	(25.2%, 32.7%)
					42.2%	42.2%	34.1%
					(38.0%, 46.4%)	(38.0%, 46.4%)	(30.1%, 38.1%)
					42.2%	42.2%	34.1%
					(38.0%, 46.4%)	(38.0%, 46.4%)	(30.1%, 38.1%)
			Live Virus nAb ID80	437	33.2%	33.2%	25.6%
					(29.2%, 37.2%)	(29.2%, 37.2%)	(20.2%, 31.0%)
					33.2%	33.2%	25.6%
					(29.2%, 37.2%)	(29.2%, 37.2%)	(20.2%, 31.0%)
			Anti-Spike IgG	437	52.2%	52.2%	52.2%
					(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
					52.2%	52.2%	52.2%
					(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
			Anti-RBD IgG	437	52.2%	52.2%	52.2%
					(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
					52.2%	52.2%	52.2%
					(47.7%, 56.6%)	(47.7%, 56.6%)	(47.7%, 56.6%)
			Pseudo nAb ID50	437	51.4%	51.4%	50.5%
					(46.4%, 56.3%)	(46.4%, 56.3%)	(46.1%, 54.8%)
					51.4%	51.4%	50.5%
					(46.4%, 56.3%)	(46.4%, 56.3%)	(46.1%, 54.8%)
			Pseudo nAb ID80	437	48.9%	48.9%	47.2%
					(44.6%, 53.2%)	(44.6%, 53.2%)	(42.8%, 51.6%)
					48.9%	48.9%	47.2%
					(44.6%, 53.2%)	(44.6%, 53.2%)	(42.8%, 51.6%)
			Live Virus nAb ID50	437	50.7%	50.7%	50.1%
					(46.8%, 54.6%)	(46.8%, 54.6%)	(44.8%, 55.4%)
					50.7%	50.7%	50.1%
					(46.8%, 54.6%)	(46.8%, 54.6%)	(44.8%, 55.4%)
			Live Virus nAb ID80	437	49.5%	49.5%	46.9%
					(45.5%, 53.6%)	(45.5%, 53.6%)	(43.5%, 50.4%)
					49.5%	49.5%	46.9%
					(45.5%, 53.6%)	(45.5%, 53.6%)	(43.5%, 50.4%)
Minority	Positive	D29	Anti-Spike IgG	230	100.0%	100.0%	100.0%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					79.3%	79.3%	65.5%
					(73.9%, 84.7%)	(73.9%, 84.7%)	(56.8%, 74.2%)
					79.3%	79.3%	65.5%
			Pseudo nAb ID80	230	(73.9%, 84.7%)	(73.9%, 84.7%)	(56.8%, 74.2%)
					66.4%	66.4%	48.9%
					(58.1%, 74.7%)	(58.1%, 74.7%)	(38.8%, 59.1%)
					66.4%	66.4%	48.9%
			Live Virus nAb ID50	230	(58.1%, 74.7%)	(58.1%, 74.7%)	(38.8%, 59.1%)
					74.5%	74.5%	61.2%
					(68.2%, 80.7%)	(68.2%, 80.7%)	(53.1%, 69.2%)
					74.5%	74.5%	61.2%
			Live Virus nAb ID80	230	(68.2%, 80.7%)	(68.2%, 80.7%)	(53.1%, 69.2%)
					66.2%	66.2%	50.9%
					(58.9%, 73.5%)	(58.9%, 73.5%)	(40.7%, 61.0%)
					66.2%	66.2%	50.9%
					(58.9%, 73.5%)	(58.9%, 73.5%)	(40.7%, 61.0%)
		D57	Anti-Spike IgG	230	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	230	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					94.6%	94.6%	93.6%
					(92.8%, 96.4%)	(92.8%, 96.4%)	(91.1%, 96.2%)
					94.6%	94.6%	93.6%
					(92.8%, 96.4%)	(92.8%, 96.4%)	(91.1%, 96.2%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Communities of Color	Negative	D29	Pseudo nAb ID80	230	94.7% (91.7%, 97.6%) 94.7% (91.7%, 97.6%)	94.7% (91.7%, 97.6%) 94.7% (91.7%, 97.6%)	88.0% (84.5%, 91.5%) 88.0% (84.5%, 91.5%)
			Live Virus nAb ID50	230	94.1% (90.7%, 97.5%) 94.1% (90.7%, 97.5%)	94.1% (90.7%, 97.5%) 94.1% (90.7%, 97.5%)	91.8% (89.3%, 94.4%) 91.8% (89.3%, 94.4%)
			Live Virus nAb ID80	230	97.2% (91.0%, 103.5%) 97.2% (91.0%, 103.5%)	97.2% (91.0%, 103.5%) 97.2% (91.0%, 103.5%)	94.1% (84.5%, 103.8%) 94.1% (84.5%, 103.8%)
			Anti-Spike IgG	557	51.6% (49.5%, 53.7%)	51.6% (49.5%, 53.7%)	51.6% (49.5%, 53.7%)
			Anti-RBD IgG	557	51.6% (49.5%, 53.7%)	51.6% (49.5%, 53.7%)	51.6% (49.5%, 53.7%)
			Pseudo nAb ID50	557	41.5% (40.1%, 42.9%)	41.5% (40.1%, 42.9%)	34.7% (30.9%, 38.6%)
			Pseudo nAb ID80	557	35.8% (33.3%, 38.3%)	35.8% (33.3%, 38.3%)	28.1% (23.9%, 32.3%)
			Live Virus nAb ID50	557	42.2% (40.0%, 44.3%)	42.2% (40.0%, 44.3%)	34.2% (31.1%, 37.2%)
			Live Virus nAb ID80	557	38.1% (37.1%, 39.2%)	38.1% (37.1%, 39.2%)	31.4% (30.2%, 32.5%)
		D57	Anti-Spike IgG	557	51.6% (49.5%, 53.7%)	51.6% (49.5%, 53.7%)	51.6% (49.5%, 53.7%)
			Anti-RBD IgG	557	51.6% (49.5%, 53.7%)	51.6% (49.5%, 53.7%)	51.6% (49.5%, 53.7%)
			Pseudo nAb ID50	557	50.0% (47.9%, 52.1%)	50.0% (47.9%, 52.1%)	48.6% (46.7%, 50.6%)
			Pseudo nAb ID80	557	49.2% (47.9%, 50.6%)	49.2% (47.9%, 50.6%)	46.2% (45.6%, 46.8%)
			Live Virus nAb ID50	557	50.5% (48.2%, 52.9%)	50.5% (48.2%, 52.9%)	48.4% (46.0%, 50.8%)
			Live Virus nAb ID80	557	48.8%	48.8%	45.8%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age, Minority Age < 65 Communities of Color	Positive	D29	Anti-Spike IgG	251	(47.2%, 50.4%)	(47.2%, 50.4%)	(45.4%, 46.3%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	251	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	251	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					77.0%	77.0%	66.8%
		D57	Pseudo nAb ID80	251	(69.6%, 84.4%)	(69.6%, 84.4%)	(56.3%, 77.2%)
					61.3%	61.3%	49.1%
			Live Virus nAb ID50	251	(50.1%, 72.5%)	(50.1%, 72.5%)	(40.2%, 58.0%)
					78.3%	78.3%	70.1%
			Live Virus nAb ID80	251	(74.1%, 82.6%)	(74.1%, 82.6%)	(64.3%, 75.9%)
					72.0%	72.0%	58.4%
		D57	Anti-Spike IgG	251	(68.2%, 75.8%)	(68.2%, 75.8%)	(54.2%, 62.7%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	251	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	251	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					95.6%	95.6%	93.3%
		D57	Pseudo nAb ID80	251	(93.7%, 97.5%)	(93.7%, 97.5%)	(91.0%, 95.5%)
					90.1%	90.1%	86.1%
			Live Virus nAb ID50	251	(86.4%, 93.8%)	(86.4%, 93.8%)	(82.6%, 89.6%)
					98.5%	98.5%	94.5%
			Live Virus nAb ID80	251	(97.9%, 99.2%)	(97.9%, 99.2%)	(92.2%, 96.8%)
					95.1%	95.1%	91.7%
					(93.6%, 96.5%)	(93.6%, 96.5%)	(89.7%, 93.8%)
	Negative	D29	Anti-Spike IgG	259	52.4%	52.4%	52.4%
					(52.0%, 52.8%)	(52.0%, 52.8%)	(52.0%, 52.8%)
			Anti-RBD IgG	259	52.4%	52.4%	52.4%
					(52.0%, 52.8%)	(52.0%, 52.8%)	(52.0%, 52.8%)
			Pseudo nAb ID50	259	41.0%	41.0%	33.3%
					(40.6%, 41.4%)	(40.6%, 41.4%)	(32.7%, 33.8%)
		D57	Pseudo nAb ID80	259	34.7%	34.7%	26.6%
					(34.0%, 35.5%)	(34.0%, 35.5%)	(25.7%, 27.6%)
		D57	Live Virus nAb ID50	259	41.8%	41.8%	32.9%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57		Live Virus nAb ID80	259	(39.1%, 44.5%)	(39.1%, 44.5%)	(31.2%, 34.7%)
					37.9%	37.9%	30.9%
			Anti-Spike IgG	259	(36.6%, 39.3%)	(36.6%, 39.3%)	(30.2%, 31.6%)
					52.4%	52.4%	52.4%
			Anti-RBD IgG	259	(52.0%, 52.8%)	(52.0%, 52.8%)	(52.0%, 52.8%)
					52.4%	52.4%	52.4%
			Pseudo nAb ID50	259	(52.0%, 52.8%)	(52.0%, 52.8%)	(52.0%, 52.8%)
					50.6%	50.6%	49.0%
			Pseudo nAb ID80	259	(49.2%, 52.0%)	(49.2%, 52.0%)	(47.4%, 50.6%)
					49.8%	49.8%	46.4%
			Live Virus nAb ID50	259	(49.4%, 50.2%)	(49.4%, 50.2%)	(45.9%, 46.9%)
					51.3%	51.3%	48.8%
	D29		Live Virus nAb ID80	259	(50.7%, 52.0%)	(50.7%, 52.0%)	(46.7%, 51.0%)
					49.3%	49.3%	45.9%
			Anti-Spike IgG	148	(48.5%, 50.2%)	(48.5%, 50.2%)	(45.4%, 46.5%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					74.7%	74.7%	64.1%
			Pseudo nAb ID80	148	(72.0%, 77.4%)	(72.0%, 77.4%)	(57.7%, 70.5%)
					58.2%	58.2%	46.6%
			Live Virus nAb ID50	148	(52.4%, 64.0%)	(52.4%, 64.0%)	(42.1%, 51.0%)
					76.8%	76.8%	68.8%
	D57		Live Virus nAb ID80	148	(76.6%, 77.0%)	(76.6%, 77.0%)	(62.2%, 75.4%)
					70.6%	70.6%	56.8%
			Anti-Spike IgG	148	(69.4%, 71.7%)	(69.4%, 71.7%)	(53.9%, 59.7%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	148	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					95.0%	95.0%	92.7%
			Pseudo nAb ID80	148	(94.3%, 95.7%)	(94.3%, 95.7%)	(91.3%, 94.1%)
					89.1%	89.1%	84.8%
					(87.1%, 91.1%)	(87.1%, 91.1%)	(82.2%, 87.4%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age < 65 White Non-Hispanic	Negative	D29	Live Virus nAb ID50	148	98.4% (97.6%, 99.2%)	98.4% (97.6%, 99.2%)	93.9% (91.5%, 96.2%)
			Live Virus nAb ID80	148	94.5% (93.6%, 95.5%)	94.5% (93.6%, 95.5%)	91.0% (90.7%, 91.2%)
			Anti-Spike IgG	216	52.7% (48.1%, 57.2%)	52.7% (48.1%, 57.2%)	52.7% (48.1%, 57.2%)
			Anti-RBD IgG	216	52.7% (48.1%, 57.2%)	52.7% (48.1%, 57.2%)	52.7% (48.1%, 57.2%)
			Pseudo nAb ID50	216	42.3% (36.6%, 48.0%)	42.3% (36.6%, 48.0%)	35.3% (29.7%, 40.9%)
			Pseudo nAb ID80	216	33.6% (31.1%, 36.0%)	33.6% (31.1%, 36.0%)	27.8% (23.8%, 31.7%)
			Live Virus nAb ID50	216	41.9% (36.8%, 47.0%)	41.9% (36.8%, 47.0%)	33.3% (28.4%, 38.1%)
			Live Virus nAb ID80	216	31.6% (30.3%, 33.0%)	31.6% (30.3%, 33.0%)	23.4% (20.4%, 26.4%)
		D57	Anti-Spike IgG	216	52.7% (48.1%, 57.2%)	52.7% (48.1%, 57.2%)	52.7% (48.1%, 57.2%)
			Anti-RBD IgG	216	52.7% (48.1%, 57.2%)	52.7% (48.1%, 57.2%)	52.7% (48.1%, 57.2%)
			Pseudo nAb ID50	216	51.9% (46.7%, 57.0%)	51.9% (46.7%, 57.0%)	51.0% (46.5%, 55.4%)
			Pseudo nAb ID80	216	49.0% (44.1%, 54.0%)	49.0% (44.1%, 54.0%)	47.2% (42.0%, 52.3%)
			Live Virus nAb ID50	216	51.1% (46.9%, 55.2%)	51.1% (46.9%, 55.2%)	50.5% (44.8%, 56.2%)
			Live Virus nAb ID80	216	49.8% (45.4%, 54.2%)	49.8% (45.4%, 54.2%)	47.1% (43.2%, 51.0%)
		Positive	Anti-Spike IgG	128	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	128	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	128	77.3% (73.3%, 81.3%)	77.3% (73.3%, 81.3%)	62.1% (57.6%, 66.6%)
			Pseudo nAb ID80	128	63.6%	63.6%	45.3%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 Communities of Color	Negative	D57	Live Virus nAb ID50	128	(55.8%, 71.4%)	(55.8%, 71.4%)	(37.0%, 53.6%)
					72.0%	72.0%	58.0%
			Live Virus nAb ID80	128	(69.5%, 74.6%)	(69.5%, 74.6%)	(55.3%, 60.8%)
					63.4%	63.4%	47.0%
			Anti-Spike IgG	128	(62.4%, 64.4%)	(62.4%, 64.4%)	(46.4%, 47.6%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	128	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	128	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					93.9%	93.9%	93.0%
			Pseudo nAb ID80	128	(93.8%, 94.1%)	(93.8%, 94.1%)	(90.1%, 95.8%)
					94.1%	94.1%	86.8%
	Negative	D29	Live Virus nAb ID50	128	(90.5%, 97.7%)	(90.5%, 97.7%)	(83.9%, 89.7%)
					93.3%	93.3%	90.9%
			Live Virus nAb ID80	128	(90.8%, 95.8%)	(90.8%, 95.8%)	(90.6%, 91.1%)
					97.4%	97.4%	94.6%
			Anti-Spike IgG	298	(90.4%, 104.4%)	(90.4%, 104.4%)	(84.0%, 105.2%)
					47.9%	47.9%	47.9%
			Anti-RBD IgG	298	(47.9%, 47.9%)	(47.9%, 47.9%)	(47.9%, 47.9%)
					47.9%	47.9%	47.9%
			Pseudo nAb ID50	298	(47.9%, 47.9%)	(47.9%, 47.9%)	(47.9%, 47.9%)
					43.8%	43.8%	41.7%
			Pseudo nAb ID80	298	(43.8%, 43.8%)	(43.8%, 43.8%)	(41.7%, 41.7%)
					40.7%	40.7%	35.4%
	Negative	D57	Live Virus nAb ID50	298	(40.7%, 40.7%)	(40.7%, 40.7%)	(35.4%, 35.4%)
					44.0%	44.0%	40.1%
			Live Virus nAb ID80	298	(44.0%, 44.0%)	(44.0%, 44.0%)	(40.1%, 40.1%)
					39.1%	39.1%	33.7%
			Anti-Spike IgG	298	(39.1%, 39.1%)	(39.1%, 39.1%)	(33.7%, 33.7%)
					47.9%	47.9%	47.9%
			Anti-RBD IgG	298	(47.9%, 47.9%)	(47.9%, 47.9%)	(47.9%, 47.9%)
					47.9%	47.9%	47.9%
			Pseudo nAb ID50	298	(47.9%, 47.9%)	(47.9%, 47.9%)	(47.9%, 47.9%)
					47.3%	47.3%	46.8%
					(47.3%, 47.3%)	(47.3%, 47.3%)	(46.8%, 46.8%)

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age >= 65 White Non-Hispanic	Positive	D29	Pseudo nAb ID80	298	46.6% (46.6%, 46.6%)	46.6% (46.6%, 46.6%)	45.1% (45.1%, 45.1%)
			Live Virus nAb ID50	298	46.6% (46.6%, 46.6%)	46.6% (46.6%, 46.6%)	46.1% (46.1%, 46.1%)
			Live Virus nAb ID80	298	46.5% (46.5%, 46.5%)	46.5% (46.5%, 46.5%)	45.4% (45.4%, 45.4%)
			Anti-Spike IgG	103	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	103	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	103	93.9% (93.9%, 93.9%)	93.9% (93.9%, 93.9%)	86.0% (86.0%, 86.0%)
			Pseudo nAb ID80	103	84.0% (84.0%, 84.0%)	84.0% (84.0%, 84.0%)	67.3% (67.3%, 67.3%)
			Live Virus nAb ID50	103	89.6% (89.6%, 89.6%)	89.6% (89.6%, 89.6%)	79.7% (79.7%, 79.7%)
			Live Virus nAb ID80	103	82.7% (82.7%, 82.7%)	82.7% (82.7%, 82.7%)	69.9% (69.9%, 69.9%)
			Anti-Spike IgG	103	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
		D57	Anti-RBD IgG	103	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	103	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	97.4% (97.4%, 97.4%)
			Pseudo nAb ID80	103	97.4% (97.4%, 97.4%)	97.4% (97.4%, 97.4%)	95.4% (95.4%, 95.4%)
			Live Virus nAb ID50	103	99.4% (99.4%, 99.4%)	99.4% (99.4%, 99.4%)	99.4% (99.4%, 99.4%)
			Live Virus nAb ID80	103	99.0% (99.0%, 99.0%)	99.0% (99.0%, 99.0%)	97.4% (97.4%, 97.4%)
		D29	Anti-Spike IgG	221	49.3% (49.3%, 49.3%)	49.3% (49.3%, 49.3%)	49.3% (49.3%, 49.3%)
			Anti-RBD IgG	221	49.3% (49.3%, 49.3%)	49.3% (49.3%, 49.3%)	49.3% (49.3%, 49.3%)
			Pseudo nAb ID50	221	46.4%	46.4%	42.7%

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Positive	D57		Pseudo nAb ID80	221	(46.4%, 46.4%)	(46.4%, 46.4%)	(42.7%, 42.7%)
					41.1%	41.1%	35.6%
			Live Virus nAb ID50	221	(41.1%, 41.1%)	(41.1%, 41.1%)	(35.6%, 35.6%)
					43.7%	43.7%	38.8%
			Live Virus nAb ID80	221	(43.7%, 43.7%)	(43.7%, 43.7%)	(38.8%, 38.8%)
					42.4%	42.4%	37.8%
			Anti-Spike IgG	221	(42.4%, 42.4%)	(42.4%, 42.4%)	(37.8%, 37.8%)
					49.3%	49.3%	49.3%
			Anti-RBD IgG	221	(49.3%, 49.3%)	(49.3%, 49.3%)	(49.3%, 49.3%)
					49.3%	49.3%	49.3%
			Pseudo nAb ID50	221	(49.3%, 49.3%)	(49.3%, 49.3%)	(49.3%, 49.3%)
					48.5%	48.5%	47.6%
			Pseudo nAb ID80	221	(48.5%, 48.5%)	(48.5%, 48.5%)	(47.6%, 47.6%)
					48.1%	48.1%	47.3%
			Live Virus nAb ID50	221	(48.1%, 48.1%)	(48.1%, 48.1%)	(47.3%, 47.3%)
					48.7%	48.7%	47.6%
			Live Virus nAb ID80	221	(48.7%, 48.7%)	(48.7%, 48.7%)	(47.6%, 47.6%)
					47.9%	47.9%	46.2%
	D29		Anti-Spike IgG	102	(47.9%, 47.9%)	(47.9%, 47.9%)	(46.2%, 46.2%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	102	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	102	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					92.0%	92.0%	87.2%
			Pseudo nAb ID80	102	(92.0%, 92.0%)	(92.0%, 92.0%)	(87.2%, 87.2%)
					84.1%	84.1%	72.3%
			Live Virus nAb ID50	102	(84.1%, 84.1%)	(84.1%, 84.1%)	(72.3%, 72.3%)
					90.1%	90.1%	81.3%
			Live Virus nAb ID80	102	(90.1%, 90.1%)	(90.1%, 90.1%)	(81.3%, 81.3%)
					84.2%	84.2%	75.4%
D57		Anti-Spike IgG	102	(84.2%, 84.2%)	(84.2%, 84.2%)	(75.4%, 75.4%)	
				100.0%	100.0%	100.0%	
		Anti-RBD IgG	102	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)	
				100.0%	100.0%	100.0%	
				(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)	

Table 1: Responder rates (*continued*)

Group	Baseline	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
			Pseudo nAb ID50	102	99.0% (99.0%, 99.0%)	99.0% (99.0%, 99.0%)	98.0% (98.0%, 98.0%)
			Pseudo nAb ID80	102	98.0% (98.0%, 98.0%)	98.0% (98.0%, 98.0%)	96.0% (96.0%, 96.0%)
			Live Virus nAb ID50	102	99.0% (99.0%, 99.0%)	99.0% (99.0%, 99.0%)	98.0% (98.0%, 98.0%)
			Live Virus nAb ID80	102	96.0% (96.0%, 96.0%)	96.0% (96.0%, 96.0%)	91.1% (91.1%, 91.1%)

Neutralization Responders are defined as participants who had baseline values below the lower limit of quantification (LLOQ) with detectable ID50 neutralization titer above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in ID50.

Binding Antibody Responders are defined as participants who had baseline values below the LLOQ with detectable antibody concentration above the assay LLOQ, or as participants with baseline values above the LLOQ with a 4-fold increase in antibody concentration.

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 1. Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Total						
Total	Negative	D1	Anti-Spike IgG	1089	17	(17, 17)
			Anti-RBD IgG	1089	17	(17, 17)
			Pseudo nAb ID50	1089	24	(24, 24)
			Pseudo nAb ID80	1089	22	(22, 22)
			Live Virus nAb ID50	1089	24	(24, 24)
			Live Virus nAb ID80	1089	22	(22, 22)
		D29	Anti-Spike IgG	1089	957	(815, 1125)
			Anti-RBD IgG	1089	707	(592, 845)
			Pseudo nAb ID50	1089	79	(64, 98)
			Pseudo nAb ID80	1089	50	(41, 62)
			Live Virus nAb ID50	1089	78	(69, 88)
			Live Virus nAb ID80	1089	54	(46, 62)
		D57	Anti-Spike IgG	1089	7399	(6478, 8451)
			Anti-RBD IgG	1089	5101	(4474, 5816)
			Pseudo nAb ID50	1089	327	(273, 393)
			Pseudo nAb ID80	1089	217	(180, 262)
			Live Virus nAb ID50	1089	291	(256, 329)
			Live Virus nAb ID80	1089	203	(175, 235)
	Positive	D1	Anti-Spike IgG	523	17	(17, 17)
			Anti-RBD IgG	523	17	(17, 17)
			Pseudo nAb ID50	523	24	(24, 24)
			Pseudo nAb ID80	523	22	(22, 22)
			Live Virus nAb ID50	523	24	(24, 24)
			Live Virus nAb ID80	523	22	(22, 22)
		D29	Anti-Spike IgG	523	38159	(22997, 63318)
			Anti-RBD IgG	523	20277	(12080, 34034)
			Pseudo nAb ID50	523	246	(157, 385)
			Pseudo nAb ID80	523	111	(74, 165)
			Live Virus nAb ID50	523	237	(172, 326)
			Live Virus nAb ID80	523	140	(107, 183)
		D57	Anti-Spike IgG	523	2047688	(1298529, 3229060)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age Age < 65	Negative	D1	Anti-RBD IgG	523	1178653	(767915, 1809084)
			Pseudo nAb ID50	523	4252	(2601, 6952)
			Pseudo nAb ID80	523	1635	(975, 2740)
			Live Virus nAb ID50	523	3501	(2411, 5084)
			Live Virus nAb ID80	523	1922	(1374, 2689)
		D29	Anti-Spike IgG	513	17	(17, 17)
			Anti-RBD IgG	513	17	(17, 17)
			Pseudo nAb ID50	513	24	(24, 24)
			Pseudo nAb ID80	513	22	(22, 22)
			Live Virus nAb ID50	513	24	(24, 24)
		D57	Live Virus nAb ID80	513	22	(22, 22)
			Anti-Spike IgG	513	897	(834, 964)
			Anti-RBD IgG	513	659	(591, 734)
			Pseudo nAb ID50	513	73	(73, 74)
			Pseudo nAb ID80	513	47	(46, 47)
			Live Virus nAb ID50	513	74	(70, 79)
			Live Virus nAb ID80	513	51	(51, 51)
Age Age ≥ 65	Positive	D1	Anti-Spike IgG	295	17	(17, 17)
			Anti-RBD IgG	295	17	(17, 17)
			Pseudo nAb ID50	295	24	(24, 24)
			Pseudo nAb ID80	295	22	(22, 22)
			Live Virus nAb ID50	295	24	(24, 24)
			Live Virus nAb ID80	295	22	(22, 22)
		D29	Anti-Spike IgG	295	31296	(26523, 36929)
			Anti-RBD IgG	295	16593	(14964, 18400)
			Pseudo nAb ID50	295	206	(189, 225)
			Pseudo nAb ID80	295	95	(89, 101)
		D57	Anti-Spike IgG	295	17	(17, 17)
			Anti-RBD IgG	295	17	(17, 17)
			Pseudo nAb ID50	295	24	(24, 24)
			Pseudo nAb ID80	295	22	(22, 22)
			Live Virus nAb ID50	295	24	(24, 24)
			Live Virus nAb ID80	295	22	(22, 22)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age \geq 65	Negative	D57	Live Virus nAb ID50	295	209	(173, 253)
			Live Virus nAb ID80	295	127	(105, 154)
			Anti-Spike IgG	295	1713071	(1408080, 2084123)
			Anti-RBD IgG	295	997439	(893511, 1113455)
			Pseudo nAb ID50	295	3546	(2453, 5125)
			Pseudo nAb ID80	295	1335	(1119, 1593)
			Live Virus nAb ID50	295	3025	(2599, 3521)
			Live Virus nAb ID80	295	1697	(1325, 2174)
		D1	Anti-Spike IgG	576	17	(17, 17)
			Anti-RBD IgG	576	17	(17, 17)
			Pseudo nAb ID50	576	25	(24, 25)
			Pseudo nAb ID80	576	22	(22, 22)
			Live Virus nAb ID50	576	25	(24, 25)
			Live Virus nAb ID80	576	22	(22, 22)
		D29	Anti-Spike IgG	576	1338	(1338, 1338)
			Anti-RBD IgG	576	1018	(1018, 1018)
			Pseudo nAb ID50	576	120	(120, 120)
			Pseudo nAb ID80	576	74	(74, 74)
			Live Virus nAb ID50	576	101	(101, 101)
			Live Virus nAb ID80	576	71	(71, 71)
		D57	Anti-Spike IgG	576	8330	(8330, 8330)
			Anti-RBD IgG	576	6241	(6241, 6241)
			Pseudo nAb ID50	576	478	(478, 478)
			Pseudo nAb ID80	576	320	(320, 320)
			Live Virus nAb ID50	576	376	(376, 376)
			Live Virus nAb ID80	576	269	(269, 269)
	Positive	D1	Anti-Spike IgG	228	17	(17, 17)
			Anti-RBD IgG	228	17	(17, 17)
			Pseudo nAb ID50	228	24	(24, 24)
			Pseudo nAb ID80	228	21	(21, 22)
			Live Virus nAb ID50	228	24	(24, 24)
			Live Virus nAb ID80	228	21	(21, 22)
		D29	Anti-Spike IgG	228	140004	(140004, 140004)
			Anti-RBD IgG	228	75484	(75484, 75484)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
High Risk At-risk		D57	Pseudo nAb ID50	228	769	(769, 769)
			Pseudo nAb ID80	228	304	(304, 304)
			Live Virus nAb ID50	228	530	(530, 530)
			Live Virus nAb ID80	228	271	(271, 271)
			Anti-Spike IgG	228	6596632	(6596632, 6596632)
			Anti-RBD IgG	228	3521571	(3521571, 3521571)
			Pseudo nAb ID50	228	13988	(13988, 13988)
			Pseudo nAb ID80	228	6158	(6158, 6158)
			Live Virus nAb ID50	228	9132	(9132, 9132)
			Live Virus nAb ID80	228	4349	(4349, 4349)
	Negative	D1	Anti-Spike IgG	568	17	(17, 17)
			Anti-RBD IgG	568	17	(17, 17)
			Pseudo nAb ID50	568	24	(24, 24)
			Pseudo nAb ID80	568	21	(21, 22)
			Live Virus nAb ID50	568	24	(24, 24)
			Live Virus nAb ID80	568	21	(21, 22)
		D29	Anti-Spike IgG	568	1003	(610, 1650)
			Anti-RBD IgG	568	715	(415, 1232)
			Pseudo nAb ID50	568	86	(58, 128)
			Pseudo nAb ID80	568	55	(39, 78)
			Live Virus nAb ID50	568	78	(58, 104)
			Live Virus nAb ID80	568	56	(44, 72)
		D57	Anti-Spike IgG	568	6843	(4493, 10421)
			Anti-RBD IgG	568	4914	(3039, 7945)
			Pseudo nAb ID50	568	325	(211, 500)
			Pseudo nAb ID80	568	225	(149, 341)
			Live Virus nAb ID50	568	302	(229, 398)
			Live Virus nAb ID80	568	224	(167, 302)
	Positive	D1	Anti-Spike IgG	222	17	(17, 17)
			Anti-RBD IgG	222	17	(17, 17)
			Pseudo nAb ID50	222	24	(24, 24)
			Pseudo nAb ID80	222	21	(21, 22)
			Live Virus nAb ID50	222	24	(24, 24)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Not at-risk	Negative	D29	Live Virus nAb ID80	222	21	(21, 22)
			Anti-Spike IgG	222	35049	(13597, 90344)
			Anti-RBD IgG	222	20339	(7825, 52867)
			Pseudo nAb ID50	222	247	(107, 568)
			Pseudo nAb ID80	222	113	(55, 234)
			Live Virus nAb ID50	222	204	(105, 398)
		D57	Live Virus nAb ID80	222	119	(68, 208)
			Anti-Spike IgG	222	1788765	(747425, 4280939)
			Anti-RBD IgG	222	1166347	(497582, 2733955)
			Pseudo nAb ID50	222	3059	(1112, 8416)
			Pseudo nAb ID80	222	1558	(518, 4683)
			Live Virus nAb ID50	222	3129	(1591, 6154)
		D1	Live Virus nAb ID80	222	1550	(766, 3135)
			Anti-Spike IgG	521	17	(17, 17)
			Anti-RBD IgG	521	17	(17, 17)
			Pseudo nAb ID50	521	24	(24, 24)
			Pseudo nAb ID80	521	22	(22, 22)
			Live Virus nAb ID50	521	24	(24, 24)
		D29	Live Virus nAb ID80	521	22	(22, 22)
			Anti-Spike IgG	521	942	(880, 1009)
			Anti-RBD IgG	521	705	(649, 765)
			Pseudo nAb ID50	521	77	(66, 90)
			Pseudo nAb ID80	521	49	(42, 57)
			Live Virus nAb ID50	521	78	(72, 86)
		D57	Live Virus nAb ID80	521	53	(47, 59)
			Anti-Spike IgG	521	7599	(7327, 7882)
			Anti-RBD IgG	521	5167	(5142, 5192)
			Pseudo nAb ID50	521	328	(286, 376)
			Pseudo nAb ID80	521	215	(187, 246)
			Live Virus nAb ID50	521	287	(263, 313)
		D1	Live Virus nAb ID80	521	196	(180, 213)
			Anti-Spike IgG	301	17	(17, 17)
			Anti-RBD IgG	301	17	(17, 17)
			Pseudo nAb ID50	301	25	(24, 25)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Risk Age < 65 At-risk	Negative	D29	Pseudo nAb ID80	301	22	(22, 22)
			Live Virus nAb ID50	301	25	(24, 25)
			Live Virus nAb ID80	301	22	(22, 22)
			Anti-Spike IgG	301	39116	(24087, 63522)
			Anti-RBD IgG	301	20258	(12485, 32872)
			Pseudo nAb ID50	301	245	(161, 373)
			Pseudo nAb ID80	301	110	(76, 160)
			Live Virus nAb ID50	301	247	(186, 328)
			Live Virus nAb ID80	301	147	(117, 185)
		D57	Anti-Spike IgG	301	2129922	(1378740, 3290374)
			Anti-RBD IgG	301	1182262	(802359, 1742043)
			Pseudo nAb ID50	301	4680	(3070, 7133)
			Pseudo nAb ID80	301	1658	(1054, 2606)
			Live Virus nAb ID50	301	3618	(2504, 5226)
			Live Virus nAb ID80	301	2046	(1538, 2722)
		D1	Anti-Spike IgG	259	17	(17, 17)
			Anti-RBD IgG	259	17	(17, 17)
			Pseudo nAb ID50	259	24	(24, 25)
			Pseudo nAb ID80	259	21	(21, 22)
			Live Virus nAb ID50	259	24	(24, 25)
			Live Virus nAb ID80	259	21	(21, 22)
	D29		Anti-Spike IgG	259	809	(809, 809)
			Anti-RBD IgG	259	565	(565, 565)
			Pseudo nAb ID50	259	72	(72, 72)
			Pseudo nAb ID80	259	47	(47, 47)
			Live Virus nAb ID50	259	68	(68, 68)
			Live Virus nAb ID80	259	51	(51, 51)
	D57		Anti-Spike IgG	259	5706	(5706, 5706)
			Anti-RBD IgG	259	3992	(3992, 3992)
			Pseudo nAb ID50	259	270	(270, 270)
			Pseudo nAb ID80	259	189	(189, 189)
			Live Virus nAb ID50	259	268	(268, 268)
			Live Virus nAb ID80	259	197	(197, 197)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age < 65 Not at-risk	Positive	D1	Anti-Spike IgG	147	17	(17, 17)
			Anti-RBD IgG	147	17	(17, 17)
			Pseudo nAb ID50	147	25	(24, 25)
			Pseudo nAb ID80	147	22	(22, 22)
			Live Virus nAb ID50	147	25	(24, 25)
			Live Virus nAb ID80	147	22	(22, 22)
		D29	Anti-Spike IgG	147	24807	(24807, 24807)
			Anti-RBD IgG	147	14352	(14352, 14352)
			Pseudo nAb ID50	147	182	(182, 182)
			Pseudo nAb ID80	147	87	(87, 87)
			Live Virus nAb ID50	147	160	(160, 160)
			Live Virus nAb ID80	147	97	(97, 97)
		D57	Anti-Spike IgG	147	1300844	(1300844, 1300844)
			Anti-RBD IgG	147	854659	(854659, 854659)
			Pseudo nAb ID50	147	2114	(2114, 2114)
			Pseudo nAb ID80	147	1042	(1042, 1042)
			Live Virus nAb ID50	147	2444	(2444, 2444)
			Live Virus nAb ID80	147	1199	(1199, 1199)
	Negative	D1	Anti-Spike IgG	254	17	(17, 17)
			Anti-RBD IgG	254	17	(17, 17)
			Pseudo nAb ID50	254	24	(24, 25)
			Pseudo nAb ID80	254	22	(22, 22)
			Live Virus nAb ID50	254	24	(24, 25)
			Live Virus nAb ID80	254	22	(22, 22)
		D29	Anti-Spike IgG	254	921	(921, 921)
			Anti-RBD IgG	254	686	(686, 686)
			Pseudo nAb ID50	254	73	(73, 73)
			Pseudo nAb ID80	254	47	(47, 47)
			Live Virus nAb ID50	254	76	(76, 76)
			Live Virus nAb ID80	254	51	(51, 51)
		D57	Anti-Spike IgG	254	7692	(7692, 7692)
			Anti-RBD IgG	254	5175	(5175, 5175)
			Pseudo nAb ID50	254	313	(313, 313)
			Pseudo nAb ID80	254	205	(205, 205)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age \geq 65 At-risk	Positive	D1	Live Virus nAb ID50	254	279	(279, 279)
			Live Virus nAb ID80	254	191	(191, 191)
			Anti-Spike IgG	148	17	(17, 17)
			Anti-RBD IgG	148	17	(17, 17)
			Pseudo nAb ID50	148	24	(24, 24)
			Pseudo nAb ID80	148	22	(22, 22)
		D29	Live Virus nAb ID50	148	24	(24, 24)
			Live Virus nAb ID80	148	22	(22, 22)
			Anti-Spike IgG	148	33288	(33288, 33288)
			Anti-RBD IgG	148	17245	(17245, 17245)
			Pseudo nAb ID50	148	213	(213, 213)
			Pseudo nAb ID80	148	97	(97, 97)
		D57	Live Virus nAb ID50	148	225	(225, 225)
			Live Virus nAb ID80	148	136	(136, 136)
			Anti-Spike IgG	148	1842965	(1842965, 1842965)
			Anti-RBD IgG	148	1039202	(1039202, 1039202)
			Pseudo nAb ID50	148	4068	(4068, 4068)
			Pseudo nAb ID80	148	1426	(1426, 1426)
	Negative	D1	Live Virus nAb ID50	148	3201	(3201, 3201)
			Live Virus nAb ID80	148	1861	(1861, 1861)
			Anti-Spike IgG	309	17	(17, 17)
			Anti-RBD IgG	309	17	(17, 17)
			Pseudo nAb ID50	309	24	(24, 24)
			Pseudo nAb ID80	309	22	(22, 22)
		D29	Live Virus nAb ID50	309	24	(24, 24)
			Live Virus nAb ID80	309	22	(22, 22)
			Anti-Spike IgG	309	1590	(1590, 1590)
			Anti-RBD IgG	309	1183	(1183, 1183)
			Pseudo nAb ID50	309	124	(124, 124)
			Pseudo nAb ID80	309	76	(76, 76)
		D57	Live Virus nAb ID50	309	101	(101, 101)
			Live Virus nAb ID80	309	70	(70, 70)
			Anti-Spike IgG	309	10101	(10101, 10101)
			Anti-RBD IgG	309	7667	(7667, 7667)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age \geq 65 Not at-risk	Positive	D1	Pseudo nAb ID50	309	485	(485, 485)
			Pseudo nAb ID80	309	330	(330, 330)
			Live Virus nAb ID50	309	390	(390, 390)
			Live Virus nAb ID80	309	295	(295, 295)
			Anti-Spike IgG	75	17	(17, 17)
			Anti-RBD IgG	75	17	(17, 17)
			Pseudo nAb ID50	75	24	(24, 24)
			Pseudo nAb ID80	75	21	(21, 22)
			Live Virus nAb ID50	75	24	(24, 24)
			Live Virus nAb ID80	75	21	(21, 22)
		D29	Anti-Spike IgG	75	148764	(148764, 148764)
			Anti-RBD IgG	75	87437	(87437, 87437)
			Pseudo nAb ID50	75	882	(882, 882)
			Pseudo nAb ID80	75	344	(344, 344)
			Live Virus nAb ID50	75	565	(565, 565)
			Live Virus nAb ID80	75	280	(280, 280)
		D57	Anti-Spike IgG	75	6778884	(6778884, 6778884)
			Anti-RBD IgG	75	4282114	(4282114, 4282114)
			Pseudo nAb ID50	75	14343	(14343, 14343)
			Pseudo nAb ID80	75	8363	(8363, 8363)
			Live Virus nAb ID50	75	8788	(8788, 8788)
			Live Virus nAb ID80	75	4543	(4543, 4543)
	Negative	D1	Anti-Spike IgG	267	17	(17, 17)
			Anti-RBD IgG	267	17	(17, 17)
			Pseudo nAb ID50	267	24	(24, 24)
			Pseudo nAb ID80	267	21	(21, 22)
			Live Virus nAb ID50	267	24	(24, 24)
			Live Virus nAb ID80	267	21	(21, 22)
		D29	Anti-Spike IgG	267	1130	(1130, 1130)
			Anti-RBD IgG	267	878	(878, 878)
			Pseudo nAb ID50	267	117	(117, 117)
			Pseudo nAb ID80	267	72	(72, 72)
			Live Virus nAb ID50	267	100	(100, 100)
			Live Virus nAb ID80	267	72	(72, 72)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Sex Female	Positive	D57	Anti-Spike IgG	267	6894	(6894, 6894)
			Anti-RBD IgG	267	5100	(5100, 5100)
			Pseudo nAb ID50	267	472	(472, 472)
			Pseudo nAb ID80	267	310	(310, 310)
			Live Virus nAb ID50	267	362	(362, 362)
			Live Virus nAb ID80	267	245	(245, 245)
		D1	Anti-Spike IgG	153	17	(17, 17)
			Anti-RBD IgG	153	17	(17, 17)
			Pseudo nAb ID50	153	24	(24, 24)
			Pseudo nAb ID80	153	22	(22, 22)
			Live Virus nAb ID50	153	24	(24, 24)
			Live Virus nAb ID80	153	22	(22, 22)
		D29	Anti-Spike IgG	153	135901	(135901, 135901)
			Anti-RBD IgG	153	70239	(70239, 70239)
			Pseudo nAb ID50	153	719	(719, 719)
			Pseudo nAb ID80	153	287	(287, 287)
			Live Virus nAb ID50	153	513	(513, 513)
			Live Virus nAb ID80	153	266	(266, 266)
		D57	Anti-Spike IgG	153	6509123	(6509123, 6509123)
			Anti-RBD IgG	153	3199803	(3199803, 3199803)
			Pseudo nAb ID50	153	13817	(13817, 13817)
			Pseudo nAb ID80	153	5301	(5301, 5301)
			Live Virus nAb ID50	153	9305	(9305, 9305)
			Live Virus nAb ID80	153	4257	(4257, 4257)
	Negative	D1	Anti-Spike IgG	595	17	(17, 17)
			Anti-RBD IgG	595	17	(17, 17)
			Pseudo nAb ID50	595	24	(24, 24)
			Pseudo nAb ID80	595	22	(22, 22)
			Live Virus nAb ID50	595	24	(24, 24)
			Live Virus nAb ID80	595	22	(22, 22)
		D29	Anti-Spike IgG	595	1005	(850, 1187)
			Anti-RBD IgG	595	739	(634, 861)
			Pseudo nAb ID50	595	84	(75, 93)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Male	Positive	D57	Pseudo nAb ID80	595	51	(46, 58)
			Live Virus nAb ID50	595	79	(71, 87)
			Live Virus nAb ID80	595	53	(48, 58)
			Anti-Spike IgG	595	8165	(5246, 12710)
			Anti-RBD IgG	595	5444	(3962, 7481)
			Pseudo nAb ID50	595	340	(286, 404)
			Pseudo nAb ID80	595	220	(199, 244)
			Live Virus nAb ID50	595	293	(266, 323)
		D1	Live Virus nAb ID80	595	206	(198, 215)
			Anti-Spike IgG	294	17	(17, 17)
			Anti-RBD IgG	294	17	(17, 17)
			Pseudo nAb ID50	294	24	(24, 24)
			Pseudo nAb ID80	294	22	(22, 22)
			Live Virus nAb ID50	294	24	(24, 24)
			Live Virus nAb ID80	294	22	(22, 22)
		D29	Anti-Spike IgG	294	35842	(22322, 57551)
			Anti-RBD IgG	294	18915	(11740, 30474)
			Pseudo nAb ID50	294	224	(149, 335)
			Pseudo nAb ID80	294	92	(64, 133)
			Live Virus nAb ID50	294	233	(169, 320)
			Live Virus nAb ID80	294	138	(99, 191)
		D57	Anti-Spike IgG	294	1815938	(1120167, 2943877)
			Anti-RBD IgG	294	1154615	(754361, 1767239)
			Pseudo nAb ID50	294	3874	(2220, 6763)
			Pseudo nAb ID80	294	1753	(1057, 2908)
			Live Virus nAb ID50	294	3444	(2324, 5105)
			Live Virus nAb ID80	294	1983	(1304, 3015)
	Negative	D1	Anti-Spike IgG	494	17	(17, 17)
			Anti-RBD IgG	494	17	(17, 17)
			Pseudo nAb ID50	494	24	(24, 24)
			Pseudo nAb ID80	494	22	(22, 22)
			Live Virus nAb ID50	494	24	(24, 24)
			Live Virus nAb ID80	494	22	(22, 22)
		D29	Anti-Spike IgG	494	905	(580, 1410)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Sex Age < 65 Female	Positive	D57	Anti-RBD IgG	494	672	(437, 1032)
			Pseudo nAb ID50	494	75	(53, 105)
			Pseudo nAb ID80	494	49	(37, 66)
			Live Virus nAb ID50	494	78	(64, 95)
			Live Virus nAb ID80	494	54	(44, 67)
			Anti-Spike IgG	494	6595	(4205, 10344)
			Anti-RBD IgG	494	4728	(3032, 7374)
			Pseudo nAb ID50	494	313	(207, 472)
			Pseudo nAb ID80	494	214	(145, 315)
			Live Virus nAb ID50	494	288	(204, 405)
		D1	Live Virus nAb ID80	494	200	(144, 277)
			Anti-Spike IgG	229	17	(17, 17)
			Anti-RBD IgG	229	17	(17, 17)
			Pseudo nAb ID50	229	24	(24, 24)
			Pseudo nAb ID80	229	21	(21, 22)
			Live Virus nAb ID50	229	24	(24, 24)
			Live Virus nAb ID80	229	21	(21, 22)
		D29	Anti-Spike IgG	229	41419	(22799, 75245)
			Anti-RBD IgG	229	22208	(11744, 41995)
			Pseudo nAb ID50	229	277	(163, 471)
			Pseudo nAb ID80	229	141	(91, 218)
			Live Virus nAb ID50	229	242	(170, 344)
			Live Virus nAb ID80	229	144	(107, 193)
		D57	Anti-Spike IgG	229	2396263	(1518286, 3781946)
			Anti-RBD IgG	229	1210873	(718001, 2042076)
			Pseudo nAb ID50	229	4802	(3111, 7412)
			Pseudo nAb ID80	229	1492	(795, 2798)
			Live Virus nAb ID50	229	3577	(2254, 5677)
			Live Virus nAb ID80	229	1845	(1253, 2717)
		D1	Anti-Spike IgG	285	17	(17, 17)
			Anti-RBD IgG	285	17	(17, 17)
			Pseudo nAb ID50	285	24	(24, 24)
			Pseudo nAb ID80	285	22	(22, 22)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age < 65 Male	Positive	D29	Live Virus nAb ID50	285	24	(24, 24)
			Live Virus nAb ID80	285	22	(22, 22)
			Anti-Spike IgG	285	1028	(870, 1216)
			Anti-RBD IgG	285	750	(635, 885)
			Pseudo nAb ID50	285	80	(75, 85)
			Pseudo nAb ID80	285	49	(48, 51)
			Live Virus nAb ID50	285	77	(68, 87)
			Live Virus nAb ID80	285	51	(49, 53)
			Anti-Spike IgG	285	9108	(6590, 12587)
			Anti-RBD IgG	285	5901	(4708, 7395)
			Pseudo nAb ID50	285	338	(272, 418)
			Pseudo nAb ID80	285	217	(191, 247)
	D57	D1	Live Virus nAb ID50	285	297	(268, 328)
			Live Virus nAb ID80	285	205	(194, 216)
			Anti-Spike IgG	177	17	(17, 17)
			Anti-RBD IgG	177	17	(17, 17)
			Pseudo nAb ID50	177	25	(24, 25)
			Pseudo nAb ID80	177	22	(22, 22)
			Live Virus nAb ID50	177	25	(24, 25)
			Live Virus nAb ID80	177	22	(22, 22)
		D29	Anti-Spike IgG	177	29998	(22550, 39905)
			Anti-RBD IgG	177	15775	(12195, 20406)
			Pseudo nAb ID50	177	191	(162, 226)
			Pseudo nAb ID80	177	80	(74, 86)
			Live Virus nAb ID50	177	208	(160, 272)
			Live Virus nAb ID80	177	125	(90, 175)
		D57	Anti-Spike IgG	177	1517697	(1108888, 2077220)
			Anti-RBD IgG	177	986223	(745070, 1305429)
			Pseudo nAb ID50	177	3222	(1968, 5273)
			Pseudo nAb ID80	177	1458	(1018, 2088)
			Live Virus nAb ID50	177	3010	(2166, 4183)
			Live Virus nAb ID80	177	1774	(1135, 2772)
	Negative	D1	Anti-Spike IgG	228	17	(17, 17)
			Anti-RBD IgG	228	17	(17, 17)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
			Pseudo nAb ID50	228	24	(24, 24)
			Pseudo nAb ID80	228	22	(22, 22)
			Live Virus nAb ID50	228	24	(24, 24)
			Live Virus nAb ID80	228	22	(22, 22)
		D29	Anti-Spike IgG	228	767	(749, 784)
			Anti-RBD IgG	228	568	(538, 600)
			Pseudo nAb ID50	228	66	(63, 69)
			Pseudo nAb ID80	228	44	(42, 47)
			Live Virus nAb ID50	228	72	(71, 73)
			Live Virus nAb ID80	228	50	(48, 53)
		D57	Anti-Spike IgG	228	5556	(5491, 5621)
			Anti-RBD IgG	228	3971	(3696, 4266)
			Pseudo nAb ID50	228	269	(255, 285)
			Pseudo nAb ID80	228	185	(178, 193)
			Live Virus nAb ID50	228	255	(239, 271)
			Live Virus nAb ID80	228	179	(163, 196)
	Positive	D1	Anti-Spike IgG	118	17	(17, 17)
			Anti-RBD IgG	118	17	(17, 17)
			Pseudo nAb ID50	118	24	(24, 24)
			Pseudo nAb ID80	118	21	(21, 22)
			Live Virus nAb ID50	118	24	(24, 24)
			Live Virus nAb ID80	118	21	(21, 22)
		D29	Anti-Spike IgG	118	33145	(32896, 33396)
			Anti-RBD IgG	118	17769	(15791, 19995)
			Pseudo nAb ID50	118	228	(220, 237)
			Pseudo nAb ID80	118	119	(119, 120)
			Live Virus nAb ID50	118	210	(193, 230)
			Live Virus nAb ID80	118	129	(129, 130)
		D57	Anti-Spike IgG	118	2018334	(2006320, 2030419)
			Anti-RBD IgG	118	1012831	(895123, 1146016)
			Pseudo nAb ID50	118	4037	(3386, 4813)
			Pseudo nAb ID80	118	1185	(1129, 1245)
			Live Virus nAb ID50	118	3045	(2784, 3330)
			Live Virus nAb ID80	118	1598	(1581, 1614)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age \geq 65 Female	Negative	D1	Anti-Spike IgG	310	17	(17, 17)
			Anti-RBD IgG	310	17	(17, 17)
			Pseudo nAb ID50	310	24	(24, 24)
			Pseudo nAb ID80	310	22	(22, 22)
			Live Virus nAb ID50	310	24	(24, 24)
			Live Virus nAb ID80	310	22	(22, 22)
		D29	Anti-Spike IgG	310	898	(898, 898)
			Anti-RBD IgG	310	689	(689, 689)
			Pseudo nAb ID50	310	103	(103, 103)
			Pseudo nAb ID80	310	65	(65, 65)
			Live Virus nAb ID50	310	89	(89, 89)
			Live Virus nAb ID80	310	64	(64, 64)
		D57	Anti-Spike IgG	310	4832	(4832, 4832)
			Anti-RBD IgG	310	3697	(3697, 3697)
			Pseudo nAb ID50	310	352	(352, 352)
			Pseudo nAb ID80	310	238	(238, 238)
			Live Virus nAb ID50	310	276	(276, 276)
			Live Virus nAb ID80	310	212	(212, 212)
	Positive	D1	Anti-Spike IgG	117	17	(17, 17)
			Anti-RBD IgG	117	17	(17, 17)
			Pseudo nAb ID50	117	24	(24, 24)
			Pseudo nAb ID80	117	21	(21, 22)
			Live Virus nAb ID50	117	24	(24, 24)
			Live Virus nAb ID80	117	21	(21, 22)
		D29	Anti-Spike IgG	117	132964	(132964, 132964)
			Anti-RBD IgG	117	72010	(72010, 72010)
			Pseudo nAb ID50	117	705	(705, 705)
			Pseudo nAb ID80	117	261	(261, 261)
			Live Virus nAb ID50	117	523	(523, 523)
			Live Virus nAb ID80	117	273	(273, 273)
		D57	Anti-Spike IgG	117	6806544	(6806544, 6806544)
			Anti-RBD IgG	117	3686701	(3686701, 3686701)
			Pseudo nAb ID50	117	15080	(15080, 15080)
			Pseudo nAb ID80	117	6812	(6812, 6812)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age \geq 65 Male	Negative	D1	Live Virus nAb ID50	117	9289	(9289, 9289)
			Live Virus nAb ID80	117	4501	(4501, 4501)
			Anti-Spike IgG	266	17	(17, 17)
			Anti-RBD IgG	266	17	(17, 17)
			Pseudo nAb ID50	266	24	(24, 24)
			Pseudo nAb ID80	266	22	(22, 22)
			Live Virus nAb ID50	266	24	(24, 24)
			Live Virus nAb ID80	266	22	(22, 22)
		D29	Anti-Spike IgG	266	2262	(2262, 2262)
			Anti-RBD IgG	266	1700	(1700, 1700)
			Pseudo nAb ID50	266	147	(147, 147)
			Pseudo nAb ID80	266	88	(88, 88)
			Live Virus nAb ID50	266	117	(117, 117)
			Live Virus nAb ID80	266	82	(82, 82)
		D57	Anti-Spike IgG	266	17057	(17057, 17057)
			Anti-RBD IgG	266	12429	(12429, 12429)
			Pseudo nAb ID50	266	714	(714, 714)
			Pseudo nAb ID80	266	471	(471, 471)
			Live Virus nAb ID50	266	563	(563, 563)
			Live Virus nAb ID80	266	368	(368, 368)
	Positive	D1	Anti-Spike IgG	111	17	(17, 17)
			Anti-RBD IgG	111	17	(17, 17)
			Pseudo nAb ID50	111	24	(24, 24)
			Pseudo nAb ID80	111	21	(21, 22)
			Live Virus nAb ID50	111	24	(24, 24)
			Live Virus nAb ID80	111	21	(21, 22)
		D29	Anti-Spike IgG	111	147794	(147794, 147794)
			Anti-RBD IgG	111	79311	(79311, 79311)
			Pseudo nAb ID50	111	842	(842, 842)
			Pseudo nAb ID80	111	357	(357, 357)
			Live Virus nAb ID50	111	536	(536, 536)
			Live Virus nAb ID80	111	268	(268, 268)
		D57	Anti-Spike IgG	111	6383261	(6383261, 6383261)
			Anti-RBD IgG	111	3356195	(3356195, 3356195)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI	
Ethnicity Hispanic or Latino	Negative		Pseudo nAb ID50	111	12927	(12927, 12927)	
			Pseudo nAb ID80	111	5539	(5539, 5539)	
			Live Virus nAb ID50	111	8970	(8970, 8970)	
			Live Virus nAb ID80	111	4195	(4195, 4195)	
		D1	Anti-Spike IgG	139	17	(17, 17)	
			Anti-RBD IgG	139	17	(17, 17)	
			Pseudo nAb ID50	139	24	(24, 24)	
			Pseudo nAb ID80	139	22	(22, 22)	
			Live Virus nAb ID50	139	24	(24, 24)	
			Live Virus nAb ID80	139	22	(22, 22)	
			D29	Anti-Spike IgG	139	797	(342, 1859)
				Anti-RBD IgG	139	652	(324, 1310)
				Pseudo nAb ID50	139	85	(61, 119)
				Pseudo nAb ID80	139	53	(39, 73)
				Live Virus nAb ID50	139	91	(70, 119)
				Live Virus nAb ID80	139	68	(56, 82)
			D57	Anti-Spike IgG	139	6381	(2626, 15501)
				Anti-RBD IgG	139	4523	(2007, 10193)
				Pseudo nAb ID50	139	370	(219, 627)
				Pseudo nAb ID80	139	214	(134, 343)
				Live Virus nAb ID50	139	293	(216, 398)
				Live Virus nAb ID80	139	199	(127, 312)
		Positive	D1	Anti-Spike IgG	59	17	(17, 17)
				Anti-RBD IgG	59	17	(17, 17)
				Pseudo nAb ID50	59	24	(24, 24)
				Pseudo nAb ID80	59	22	(22, 22)
				Live Virus nAb ID50	59	24	(24, 24)
				Live Virus nAb ID80	59	22	(22, 22)
			D29	Anti-Spike IgG	59	54043	(35496, 82281)
				Anti-RBD IgG	59	23396	(15585, 35122)
				Pseudo nAb ID50	59	336	(226, 501)
				Pseudo nAb ID80	59	138	(96, 198)
				Live Virus nAb ID50	59	449	(255, 790)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Not Hispanic or Latino	Negative	D57	Live Virus nAb ID80	59	203	(111, 372)
			Anti-Spike IgG	59	2865592	(1842286, 4457299)
			Anti-RBD IgG	59	2242537	(1228777, 4092663)
			Pseudo nAb ID50	59	8848	(3798, 20613)
			Pseudo nAb ID80	59	2181	(1240, 3838)
			Live Virus nAb ID50	59	4088	(2356, 7094)
		D1	Live Virus nAb ID80	59	2813	(1154, 6855)
			Anti-Spike IgG	837	17	(17, 17)
			Anti-RBD IgG	837	17	(17, 17)
			Pseudo nAb ID50	837	24	(24, 24)
			Pseudo nAb ID80	837	22	(22, 22)
			Live Virus nAb ID50	837	24	(24, 24)
			Live Virus nAb ID80	837	22	(22, 22)
		D29	Anti-Spike IgG	837	1136	(885, 1459)
			Anti-RBD IgG	837	826	(628, 1085)
			Pseudo nAb ID50	837	83	(69, 100)
			Pseudo nAb ID80	837	52	(44, 62)
			Live Virus nAb ID50	837	80	(70, 92)
			Live Virus nAb ID80	837	53	(46, 62)
		D57	Anti-Spike IgG	837	9406	(5972, 14816)
			Anti-RBD IgG	837	6379	(4313, 9435)
			Pseudo nAb ID50	837	354	(281, 446)
			Pseudo nAb ID80	837	232	(190, 283)
			Live Virus nAb ID50	837	317	(276, 363)
			Live Virus nAb ID80	837	220	(195, 249)
	Positive	D1	Anti-Spike IgG	418	17	(17, 17)
			Anti-RBD IgG	418	17	(17, 17)
			Pseudo nAb ID50	418	24	(24, 24)
			Pseudo nAb ID80	418	21	(21, 22)
			Live Virus nAb ID50	418	24	(24, 24)
			Live Virus nAb ID80	418	21	(21, 22)
		D29	Anti-Spike IgG	418	36030	(21191, 61260)
			Anti-RBD IgG	418	19917	(11928, 33260)
			Pseudo nAb ID50	418	234	(148, 371)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Race American Indian or Alaska Native	Negative	D57	Pseudo nAb ID80	418	108	(72, 162)
			Live Virus nAb ID50	418	218	(156, 306)
			Live Virus nAb ID80	418	134	(104, 173)
			Anti-Spike IgG	418	1984198	(1254429, 3138514)
			Anti-RBD IgG	418	1079713	(675920, 1724729)
			Pseudo nAb ID50	418	3814	(2402, 6055)
			Pseudo nAb ID80	418	1618	(993, 2638)
			Live Virus nAb ID50	418	3528	(2497, 4984)
			Live Virus nAb ID80	418	1856	(1352, 2548)
		D29	Anti-Spike IgG	29	17	(17, 17)
			Anti-RBD IgG	29	17	(17, 17)
			Pseudo nAb ID50	29	24	(24, 24)
			Pseudo nAb ID80	29	22	(22, 22)
			Live Virus nAb ID50	29	24	(24, 24)
			Live Virus nAb ID80	29	22	(22, 22)
			Anti-Spike IgG	29	1395	(24, 82225)
			Anti-RBD IgG	29	1130	(18, 69837)
		D57	Pseudo nAb ID50	29	70	(31, 160)
			Pseudo nAb ID80	29	49	(25, 96)
			Live Virus nAb ID50	29	86	(26, 281)
			Live Virus nAb ID80	29	66	(20, 213)
			Anti-Spike IgG	29	14995	(17, 13109763)
			Anti-RBD IgG	29	13295	(16, 10926221)
			Pseudo nAb ID50	29	399	(25, 6428)
			Pseudo nAb ID80	29	385	(19, 7644)
		Positive	Live Virus nAb ID50	29	373	(19, 7464)
			Live Virus nAb ID80	29	288	(22, 3705)
			Anti-Spike IgG	8	17	(17, 17)
			Anti-RBD IgG	8	17	(17, 17)
			Pseudo nAb ID50	8	25	(24, 25)
			Pseudo nAb ID80	8	22	(22, 22)
			Live Virus nAb ID50	8	25	(24, 25)
			Live Virus nAb ID80	8	22	(22, 22)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Asian		D29	Anti-Spike IgG	8	69682	(62813, 77301)
			Anti-RBD IgG	8	42921	(32224, 57171)
			Pseudo nAb ID50	8	415	(381, 453)
			Pseudo nAb ID80	8	179	(164, 196)
			Live Virus nAb ID50	8	634	(575, 700)
			Live Virus nAb ID80	8	267	(220, 324)
		D57	Anti-Spike IgG	8	3023902	(2733955, 3344599)
			Anti-RBD IgG	8	1804180	(1602365, 2031413)
			Pseudo nAb ID50	8	9013	(7415, 10955)
			Pseudo nAb ID80	8	4836	(3858, 6061)
			Live Virus nAb ID50	8	11946	(9631, 14819)
			Live Virus nAb ID80	8	2899	(2636, 3189)
	Negative	D1	Anti-Spike IgG	73	17	(17, 17)
			Anti-RBD IgG	73	17	(17, 17)
			Pseudo nAb ID50	73	24	(24, 24)
			Pseudo nAb ID80	73	22	(22, 22)
			Live Virus nAb ID50	73	24	(24, 24)
			Live Virus nAb ID80	73	22	(22, 22)
		D29	Anti-Spike IgG	73	489	(436, 549)
			Anti-RBD IgG	73	348	(287, 422)
			Pseudo nAb ID50	73	53	(34, 82)
			Pseudo nAb ID80	73	36	(23, 56)
			Live Virus nAb ID50	73	63	(51, 77)
			Live Virus nAb ID80	73	46	(38, 56)
		D57	Anti-Spike IgG	73	2837	(2472, 3256)
			Anti-RBD IgG	73	2118	(2006, 2236)
			Pseudo nAb ID50	73	200	(154, 259)
			Pseudo nAb ID80	73	116	(79, 170)
			Live Virus nAb ID50	73	144	(111, 188)
			Live Virus nAb ID80	73	127	(98, 165)
	Positive	D1	Anti-Spike IgG	33	17	(17, 17)
			Anti-RBD IgG	33	17	(17, 17)
			Pseudo nAb ID50	33	24	(24, 24)
			Pseudo nAb ID80	33	22	(22, 22)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Black or African American	Negative	D29	Live Virus nAb ID50	33	24	(24, 24)
			Live Virus nAb ID80	33	22	(22, 22)
			Anti-Spike IgG	33	39067	(16080, 94915)
			Anti-RBD IgG	33	23630	(10983, 50843)
			Pseudo nAb ID50	33	198	(54, 723)
			Pseudo nAb ID80	33	94	(34, 257)
			Live Virus nAb ID50	33	216	(80, 580)
			Live Virus nAb ID80	33	109	(64, 187)
		D57	Anti-Spike IgG	33	1809471	(813982, 4022433)
			Anti-RBD IgG	33	1770159	(941781, 3327168)
			Pseudo nAb ID50	33	4233	(1432, 12513)
			Pseudo nAb ID80	33	1372	(449, 4193)
			Live Virus nAb ID50	33	5227	(2286, 11950)
			Live Virus nAb ID80	33	1650	(569, 4782)
		D1	Anti-Spike IgG	242	17	(17, 17)
			Anti-RBD IgG	242	17	(17, 17)
			Pseudo nAb ID50	242	24	(24, 24)
			Pseudo nAb ID80	242	22	(22, 22)
			Live Virus nAb ID50	242	24	(24, 24)
			Live Virus nAb ID80	242	22	(22, 22)
		D29	Anti-Spike IgG	242	1773	(1274, 2466)
			Anti-RBD IgG	242	1320	(975, 1786)
			Pseudo nAb ID50	242	97	(71, 132)
			Pseudo nAb ID80	242	57	(41, 78)
			Live Virus nAb ID50	242	96	(80, 115)
			Live Virus nAb ID80	242	62	(51, 75)
		D57	Anti-Spike IgG	242	22954	(13933, 37815)
			Anti-RBD IgG	242	13533	(8887, 20609)
			Pseudo nAb ID50	242	511	(394, 662)
			Pseudo nAb ID80	242	332	(248, 445)
			Live Virus nAb ID50	242	446	(361, 550)
			Live Virus nAb ID80	242	270	(194, 377)
	Positive	D1	Anti-Spike IgG	101	17	(17, 17)
			Anti-RBD IgG	101	17	(17, 17)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Multiracial	Negative	D29	Pseudo nAb ID50	101	25	(24, 25)
			Pseudo nAb ID80	101	22	(22, 22)
			Live Virus nAb ID50	101	25	(24, 25)
			Live Virus nAb ID80	101	22	(22, 22)
			Anti-Spike IgG	101	33099	(22202, 49346)
			Anti-RBD IgG	101	17389	(10782, 28047)
			Pseudo nAb ID50	101	217	(147, 321)
			Pseudo nAb ID80	101	110	(87, 139)
			Live Virus nAb ID50	101	236	(168, 333)
			Live Virus nAb ID80	101	141	(114, 174)
		D57	Anti-Spike IgG	101	1706573	(1017248, 2863009)
			Anti-RBD IgG	101	1065956	(741989, 1531373)
			Pseudo nAb ID50	101	3084	(1956, 4862)
			Pseudo nAb ID80	101	1383	(830, 2303)
			Live Virus nAb ID50	101	3228	(2039, 5110)
			Live Virus nAb ID80	101	1530	(1001, 2340)
		D1	Anti-Spike IgG	64	17	(17, 17)
			Anti-RBD IgG	64	17	(17, 17)
			Pseudo nAb ID50	64	24	(24, 24)
			Pseudo nAb ID80	64	22	(22, 22)
			Live Virus nAb ID50	64	24	(24, 24)
			Live Virus nAb ID80	64	22	(22, 22)
		D29	Anti-Spike IgG	64	312	(58, 1692)
			Anti-RBD IgG	64	253	(61, 1037)
			Pseudo nAb ID50	64	63	(42, 93)
			Pseudo nAb ID80	64	45	(34, 59)
			Live Virus nAb ID50	64	71	(52, 97)
			Live Virus nAb ID80	64	47	(34, 65)
		D57	Anti-Spike IgG	64	1740	(211, 14352)
			Anti-RBD IgG	64	1224	(156, 9637)
			Pseudo nAb ID50	64	184	(68, 496)
			Pseudo nAb ID80	64	138	(69, 277)
			Live Virus nAb ID50	64	152	(75, 307)
			Live Virus nAb ID80	64	113	(52, 245)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Native Hawaiian or Other Pacific Islander	Positive	D1	Anti-Spike IgG	31	17	(17, 17)
			Anti-RBD IgG	31	17	(17, 17)
			Pseudo nAb ID50	31	24	(24, 24)
			Pseudo nAb ID80	31	22	(22, 22)
			Live Virus nAb ID50	31	24	(24, 24)
			Live Virus nAb ID80	31	22	(22, 22)
		D29	Anti-Spike IgG	31	61671	(31660, 120130)
			Anti-RBD IgG	31	25202	(13055, 48654)
			Pseudo nAb ID50	31	372	(198, 700)
			Pseudo nAb ID80	31	176	(101, 306)
			Live Virus nAb ID50	31	606	(377, 972)
			Live Virus nAb ID80	31	199	(158, 250)
		D57	Anti-Spike IgG	31	3629072	(1701152, 7741908)
			Anti-RBD IgG	31	1911840	(1162573, 3144002)
			Pseudo nAb ID50	31	8820	(2796, 27821)
			Pseudo nAb ID80	31	2413	(1212, 4804)
			Live Virus nAb ID50	31	4141	(2040, 8406)
			Live Virus nAb ID80	31	4773	(1678, 13579)
		D1	Anti-Spike IgG	11	17	(17, 17)
			Anti-RBD IgG	11	17	(17, 17)
			Pseudo nAb ID50	11	24	(24, 24)
			Pseudo nAb ID80	11	22	(22, 22)
			Live Virus nAb ID50	11	24	(24, 24)
			Live Virus nAb ID80	11	22	(22, 22)
		D29	Anti-Spike IgG	11	297	(15, 5859)
			Anti-RBD IgG	11	234	(13, 4147)
			Pseudo nAb ID50	11	86	(41, 182)
			Pseudo nAb ID80	11	55	(23, 128)
			Live Virus nAb ID50	11	65	(46, 91)
			Live Virus nAb ID80	11	47	(30, 74)
		D57	Anti-Spike IgG	11	1070	(15, 77760)
			Anti-RBD IgG	11	761	(12, 49173)
			Pseudo nAb ID50	11	149	(35, 627)
			Pseudo nAb ID80	11	114	(25, 521)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
		Positive	Live Virus nAb ID50	11	181	(36, 908)
			Live Virus nAb ID80	11	126	(27, 597)
			Anti-Spike IgG	7	17	(17, 17)
			Anti-RBD IgG	7	17	(17, 17)
			Pseudo nAb ID50	7	24	(24, 24)
			Pseudo nAb ID80	7	22	(22, 22)
			Live Virus nAb ID50	7	24	(24, 24)
			Live Virus nAb ID80	7	22	(22, 22)
			D29 Anti-Spike IgG	7	28121	(13016, 60757)
			Anti-RBD IgG	7	9761	(2303, 41365)
			Pseudo nAb ID50	7	157	(70, 354)
			Pseudo nAb ID80	7	89	(35, 230)
			Live Virus nAb ID50	7	88	(36, 212)
			Live Virus nAb ID80	7	64	(23, 179)
			D57 Anti-Spike IgG	7	2214732	(1317196, 3723848)
			Anti-RBD IgG	7	964639	(389361, 2389888)
			Pseudo nAb ID50	7	1482	(183, 11965)
			Pseudo nAb ID80	7	418	(131, 1336)
			Live Virus nAb ID50	7	1357	(630, 2924)
			Live Virus nAb ID80	7	495	(84, 2917)
	Not reported and unknown	Negative	D1 Anti-Spike IgG	115	17	(17, 17)
			Anti-RBD IgG	115	17	(17, 17)
			Pseudo nAb ID50	115	24	(24, 24)
			Pseudo nAb ID80	115	22	(22, 22)
			Live Virus nAb ID50	115	24	(24, 24)
			Live Virus nAb ID80	115	22	(22, 22)
			D29 Anti-Spike IgG	115	624	(506, 771)
			Anti-RBD IgG	115	487	(418, 567)
			Pseudo nAb ID50	115	72	(67, 77)
			Pseudo nAb ID80	115	54	(50, 58)
			Live Virus nAb ID50	115	69	(64, 75)
			Live Virus nAb ID80	115	54	(51, 57)
			D57 Anti-Spike IgG	115	3245	(2300, 4579)
			Anti-RBD IgG	115	2740	(1874, 4004)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Other	Positive	D1	Pseudo nAb ID50	115	279	(238, 327)
			Pseudo nAb ID80	115	178	(161, 196)
			Live Virus nAb ID50	115	233	(212, 257)
			Live Virus nAb ID80	115	198	(155, 253)
			Anti-Spike IgG	57	17	(17, 17)
			Anti-RBD IgG	57	17	(17, 17)
			Pseudo nAb ID50	57	24	(24, 24)
			Pseudo nAb ID80	57	21	(21, 22)
			Live Virus nAb ID50	57	24	(24, 24)
			Live Virus nAb ID80	57	21	(21, 22)
		D29	Anti-Spike IgG	57	41513	(24786, 69526)
			Anti-RBD IgG	57	21397	(11856, 38615)
			Pseudo nAb ID50	57	215	(136, 342)
			Pseudo nAb ID80	57	89	(54, 147)
			Live Virus nAb ID50	57	237	(180, 312)
			Live Virus nAb ID80	57	153	(130, 180)
		D57	Anti-Spike IgG	57	2354129	(1547568, 3581053)
			Anti-RBD IgG	57	1348247	(933001, 1948305)
			Pseudo nAb ID50	57	4595	(2635, 8012)
			Pseudo nAb ID80	57	2027	(1537, 2674)
			Live Virus nAb ID50	57	4368	(3172, 6017)
			Live Virus nAb ID80	57	2688	(2255, 3203)
	Negative	D1	Anti-Spike IgG	23	17	(17, 17)
			Anti-RBD IgG	23	17	(17, 17)
			Pseudo nAb ID50	23	24	(24, 24)
			Pseudo nAb ID80	23	21	(21, 22)
			Live Virus nAb ID50	23	24	(24, 24)
			Live Virus nAb ID80	23	21	(21, 22)
		D29	Anti-Spike IgG	23	23151	(7384, 72584)
			Anti-RBD IgG	23	11296	(4418, 28880)
			Pseudo nAb ID50	23	321	(269, 382)
			Pseudo nAb ID80	23	128	(122, 136)
			Live Virus nAb ID50	23	363	(168, 784)
			Live Virus nAb ID80	23	131	(97, 176)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
White	Positive	D57	Anti-Spike IgG	23	768534	(82667, 7144887)
			Anti-RBD IgG	23	530546	(62165, 4527910)
			Pseudo nAb ID50	23	2747	(1336, 5648)
			Pseudo nAb ID80	23	1260	(529, 3004)
			Live Virus nAb ID50	23	2618	(1080, 6346)
			Live Virus nAb ID80	23	1338	(798, 2243)
		D1	Anti-Spike IgG	14	17	(17, 17)
			Anti-RBD IgG	14	17	(17, 17)
			Pseudo nAb ID50	14	24	(24, 24)
			Pseudo nAb ID80	14	21	(21, 22)
			Live Virus nAb ID50	14	24	(24, 24)
			Live Virus nAb ID80	14	21	(21, 22)
		D29	Anti-Spike IgG	14	31016	(22150, 43432)
			Anti-RBD IgG	14	13558	(9536, 19276)
			Pseudo nAb ID50	14	153	(106, 222)
			Pseudo nAb ID80	14	48	(27, 86)
			Live Virus nAb ID50	14	230	(150, 352)
			Live Virus nAb ID80	14	137	(109, 171)
		D57	Anti-Spike IgG	14	1424369	(1010643, 2007461)
			Anti-RBD IgG	14	1006396	(779593, 1299182)
			Pseudo nAb ID50	14	3470	(1891, 6365)
			Pseudo nAb ID80	14	569	(246, 1316)
			Live Virus nAb ID50	14	1278	(733, 2230)
			Live Virus nAb ID80	14	420	(204, 864)
	Negative	D1	Anti-Spike IgG	55	17	(17, 17)
			Anti-RBD IgG	55	17	(17, 17)
			Pseudo nAb ID50	55	24	(24, 24)
			Pseudo nAb ID80	55	22	(22, 22)
			Live Virus nAb ID50	55	24	(24, 24)
			Live Virus nAb ID80	55	22	(22, 22)
		D29	Anti-Spike IgG	55	1156	(637, 2098)
			Anti-RBD IgG	55	961	(608, 1520)
			Pseudo nAb ID50	55	72	(45, 115)
			Pseudo nAb ID80	55	44	(26, 73)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
White Non-Hispanic	Positive	D57	Live Virus nAb ID50	55	69	(48, 98)
			Live Virus nAb ID80	55	56	(41, 77)
			Anti-Spike IgG	55	8408	(4155, 17015)
			Anti-RBD IgG	55	5867	(2557, 13459)
			Pseudo nAb ID50	55	368	(211, 644)
			Pseudo nAb ID80	55	233	(112, 484)
		D1	Live Virus nAb ID50	55	316	(185, 541)
			Live Virus nAb ID80	55	219	(148, 324)
			Anti-Spike IgG	29	17	(17, 17)
			Anti-RBD IgG	29	17	(17, 17)
			Pseudo nAb ID50	29	24	(24, 24)
			Pseudo nAb ID80	29	21	(21, 22)
		D29	Live Virus nAb ID50	29	24	(24, 24)
			Live Virus nAb ID80	29	21	(21, 22)
			Anti-Spike IgG	29	37164	(21777, 63424)
			Anti-RBD IgG	29	20304	(8359, 49323)
			Pseudo nAb ID50	29	263	(133, 519)
			Pseudo nAb ID80	29	102	(56, 186)
		D57	Live Virus nAb ID50	29	222	(139, 353)
			Live Virus nAb ID80	29	137	(79, 237)
			Anti-Spike IgG	29	1671870	(866997, 3223941)
			Anti-RBD IgG	29	1113942	(438949, 2826900)
			Pseudo nAb ID50	29	6423	(3676, 11221)
			Pseudo nAb ID80	29	1267	(461, 3478)
	Negative	D1	Live Virus nAb ID50	29	3159	(1737, 5745)
			Live Virus nAb ID80	29	1575	(593, 4184)
			Anti-Spike IgG	437	17	(17, 17)
					17	(17, 17)
			Anti-RBD IgG	437	17	(17, 17)
					17	(17, 17)
		D57	Pseudo nAb ID50	437	24	(24, 24)
					24	(24, 24)
			Pseudo nAb ID80	437	22	(22, 22)
					22	(22, 22)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
			Live Virus nAb ID50	437	24	(24, 24)
					24	(24, 24)
			Live Virus nAb ID80	437	22	(22, 22)
					22	(22, 22)
		D29	Anti-Spike IgG	437	1030	(775, 1367)
					1030	(775, 1367)
			Anti-RBD IgG	437	733	(537, 1000)
					733	(537, 1000)
			Pseudo nAb ID50	437	82	(67, 101)
					82	(67, 101)
			Pseudo nAb ID80	437	51	(42, 61)
					51	(42, 61)
		D57	Live Virus nAb ID50	437	76	(64, 90)
					76	(64, 90)
			Live Virus nAb ID80	437	51	(41, 62)
					51	(41, 62)
			Anti-Spike IgG	437	7809	(5118, 11916)
					7809	(5118, 11916)
			Anti-RBD IgG	437	5195	(3535, 7635)
					5195	(3535, 7635)
			Pseudo nAb ID50	437	318	(246, 410)
					318	(246, 410)
			Pseudo nAb ID80	437	214	(165, 279)
					214	(165, 279)
			Live Virus nAb ID50	437	301	(259, 349)
					301	(259, 349)
			Live Virus nAb ID80	437	204	(168, 248)
					204	(168, 248)
Minority	Positive	D1	Anti-Spike IgG	230	17	(17, 17)
					17	(17, 17)
			Anti-RBD IgG	230	17	(17, 17)
					17	(17, 17)
			Pseudo nAb ID50	230	24	(24, 24)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Communities of Color	Negative	D1	Pseudo nAb ID80	230	24	(24, 24)
					22	(22, 22)
			Live Virus nAb ID50	230	22	(22, 22)
					24	(24, 24)
			Live Virus nAb ID80	230	24	(24, 24)
					22	(22, 22)
			Anti-Spike IgG	230	22	(22, 22)
					22	(22, 22)
			Anti-RBD IgG	230	36564	(20217, 66129)
					36564	(20217, 66129)
			Pseudo nAb ID50	230	20597	(12022, 35291)
					20597	(12022, 35291)
			Pseudo nAb ID80	230	261	(165, 413)
					261	(165, 413)
			Live Virus nAb ID50	230	118	(78, 179)
					118	(78, 179)
			Live Virus nAb ID80	230	210	(141, 314)
					210	(141, 314)
			Anti-Spike IgG	230	131	(92, 188)
					131	(92, 188)
			Anti-RBD IgG	230	2062687	(1265341, 3362474)
					2062687	(1265341, 3362474)
			Pseudo nAb ID50	230	1024342	(621932, 1687126)
					1024342	(621932, 1687126)
			Pseudo nAb ID80	230	4036	(2257, 7218)
					4036	(2257, 7218)
			Live Virus nAb ID50	230	1784	(1025, 3106)
					1784	(1025, 3106)
			Live Virus nAb ID80	230	3291	(2274, 4762)
					3291	(2274, 4762)
			Anti-Spike IgG	557	2150	(1405, 3289)
					2150	(1405, 3289)
			Anti-RBD IgG	557	17	(17, 17)
					17	(17, 17)
			Pseudo nAb ID50	557	24	(24, 24)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age, Minority	Positive	D29	Pseudo nAb ID80	557	22	(22, 22)
			Live Virus nAb ID50	557	24	(24, 24)
			Live Virus nAb ID80	557	22	(22, 22)
			Anti-Spike IgG	557	947	(822, 1091)
			Anti-RBD IgG	557	711	(625, 809)
			Pseudo nAb ID50	557	80	(64, 99)
			Pseudo nAb ID80	557	52	(43, 62)
			Live Virus nAb ID50	557	82	(74, 91)
			Live Virus nAb ID80	557	57	(52, 62)
		D57	Anti-Spike IgG	557	7825	(7061, 8672)
			Anti-RBD IgG	557	5475	(5032, 5957)
			Pseudo nAb ID50	557	343	(296, 399)
			Pseudo nAb ID80	557	226	(195, 262)
			Live Virus nAb ID50	557	291	(260, 326)
			Live Virus nAb ID80	557	209	(177, 247)
		D1	Anti-Spike IgG	251	17	(17, 17)
			Anti-RBD IgG	251	17	(17, 17)
			Pseudo nAb ID50	251	24	(24, 24)
			Pseudo nAb ID80	251	21	(21, 22)
			Live Virus nAb ID50	251	24	(24, 24)
			Live Virus nAb ID80	251	21	(21, 22)
		D29	Anti-Spike IgG	251	39503	(25451, 61315)
			Anti-RBD IgG	251	20121	(12379, 32704)
			Pseudo nAb ID50	251	229	(142, 367)
			Pseudo nAb ID80	251	104	(68, 160)
			Live Virus nAb ID50	251	268	(211, 340)
			Live Virus nAb ID80	251	147	(124, 174)
		D57	Anti-Spike IgG	251	2067190	(1370989, 3116926)
			Anti-RBD IgG	251	1310542	(931458, 1843906)
			Pseudo nAb ID50	251	4166	(2761, 6286)
			Pseudo nAb ID80	251	1560	(991, 2457)
			Live Virus nAb ID50	251	3711	(2549, 5402)
			Live Virus nAb ID80	251	1816	(1418, 2326)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age < 65 Communities of Color	Negative	D1	Anti-Spike IgG	259	17	(17, 17)
			Anti-RBD IgG	259	17	(17, 17)
			Pseudo nAb ID50	259	24	(24, 24)
			Pseudo nAb ID80	259	22	(22, 22)
			Live Virus nAb ID50	259	24	(24, 24)
			Live Virus nAb ID80	259	22	(22, 22)
		D29	Anti-Spike IgG	259	896	(888, 904)
			Anti-RBD IgG	259	674	(647, 703)
			Pseudo nAb ID50	259	74	(70, 78)
			Pseudo nAb ID80	259	48	(46, 51)
			Live Virus nAb ID50	259	79	(76, 82)
			Live Virus nAb ID80	259	55	(54, 56)
		D57	Anti-Spike IgG	259	7861	(6981, 8851)
			Anti-RBD IgG	259	5466	(4930, 6061)
			Pseudo nAb ID50	259	323	(299, 349)
			Pseudo nAb ID80	259	213	(211, 215)
			Live Virus nAb ID50	259	278	(264, 292)
			Live Virus nAb ID80	259	199	(181, 219)
	Positive	D1	Anti-Spike IgG	148	17	(17, 17)
			Anti-RBD IgG	148	17	(17, 17)
			Pseudo nAb ID50	148	24	(24, 24)
			Pseudo nAb ID80	148	21	(21, 22)
			Live Virus nAb ID50	148	24	(24, 24)
			Live Virus nAb ID80	148	21	(21, 22)
		D29	Anti-Spike IgG	148	33412	(30921, 36103)
			Anti-RBD IgG	148	16832	(16794, 16869)
			Pseudo nAb ID50	148	195	(177, 214)
			Pseudo nAb ID80	148	90	(82, 100)
			Live Virus nAb ID50	148	245	(217, 276)
			Live Virus nAb ID80	148	137	(124, 152)
		D57	Anti-Spike IgG	148	1765431	(1596082, 1952749)
			Anti-RBD IgG	148	1148387	(1011777, 1303441)
			Pseudo nAb ID50	148	3557	(2882, 4390)
			Pseudo nAb ID80	148	1309	(1089, 1574)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age < 65 White Non-Hispanic	Negative	D1	Live Virus nAb ID50	148	3210	(2860, 3602)
			Live Virus nAb ID80	148	1652	(1445, 1888)
			Anti-Spike IgG	216	17	(17, 17)
			Anti-RBD IgG	216	17	(17, 17)
			Pseudo nAb ID50	216	24	(24, 24)
			Pseudo nAb ID80	216	22	(22, 22)
			Live Virus nAb ID50	216	24	(24, 24)
			Live Virus nAb ID80	216	22	(22, 22)
		D29	Anti-Spike IgG	216	969	(690, 1362)
			Anti-RBD IgG	216	678	(473, 972)
			Pseudo nAb ID50	216	76	(65, 89)
			Pseudo nAb ID80	216	47	(43, 52)
			Live Virus nAb ID50	216	72	(61, 86)
			Live Virus nAb ID80	216	47	(43, 51)
		D57	Anti-Spike IgG	216	7625	(4559, 12752)
			Anti-RBD IgG	216	4910	(3053, 7895)
			Pseudo nAb ID50	216	293	(226, 379)
			Pseudo nAb ID80	216	196	(152, 254)
			Live Virus nAb ID50	216	286	(247, 330)
			Live Virus nAb ID80	216	191	(159, 229)
	Positive	D1	Anti-Spike IgG	128	17	(17, 17)
			Anti-RBD IgG	128	17	(17, 17)
			Pseudo nAb ID50	128	25	(24, 25)
			Pseudo nAb ID80	128	22	(22, 22)
			Live Virus nAb ID50	128	25	(24, 25)
			Live Virus nAb ID80	128	22	(22, 22)
		D29	Anti-Spike IgG	128	28984	(21712, 38692)
			Anti-RBD IgG	128	16693	(12510, 22275)
			Pseudo nAb ID50	128	219	(162, 297)
			Pseudo nAb ID80	128	100	(78, 130)
			Live Virus nAb ID50	128	180	(141, 231)
			Live Virus nAb ID80	128	115	(90, 147)
		D57	Anti-Spike IgG	128	1711797	(1237969, 2366982)
			Anti-RBD IgG	128	842504	(732240, 969373)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age \geq 65 Communities of Color	Negative	D1	Pseudo nAb ID50	128	3287	(1991, 5424)
			Pseudo nAb ID80	128	1435	(1130, 1822)
			Live Virus nAb ID50	128	2846	(2392, 3387)
			Live Virus nAb ID80	128	1873	(1236, 2837)
			Anti-Spike IgG	298	17	(17, 17)
			Anti-RBD IgG	298	17	(17, 17)
			Pseudo nAb ID50	298	25	(24, 25)
			Pseudo nAb ID80	298	22	(21, 22)
			Live Virus nAb ID50	298	25	(24, 25)
			Live Virus nAb ID80	298	22	(21, 22)
		D29	Anti-Spike IgG	298	1240	(1240, 1240)
			Anti-RBD IgG	298	918	(918, 918)
			Pseudo nAb ID50	298	115	(115, 115)
			Pseudo nAb ID80	298	72	(72, 72)
			Live Virus nAb ID50	298	101	(101, 101)
			Live Virus nAb ID80	298	66	(66, 66)
		D57	Anti-Spike IgG	298	7656	(7656, 7656)
			Anti-RBD IgG	298	5519	(5519, 5519)
			Pseudo nAb ID50	298	462	(462, 462)
			Pseudo nAb ID80	298	299	(299, 299)
			Live Virus nAb ID50	298	365	(365, 365)
			Live Virus nAb ID80	298	264	(264, 264)
	Positive	D1	Anti-Spike IgG	103	17	(17, 17)
			Anti-RBD IgG	103	17	(17, 17)
			Pseudo nAb ID50	103	24	(24, 24)
			Pseudo nAb ID80	103	21	(21, 22)
			Live Virus nAb ID50	103	24	(24, 24)
			Live Virus nAb ID80	103	21	(21, 22)
		D29	Anti-Spike IgG	103	133776	(133776, 133776)
			Anti-RBD IgG	103	73816	(73816, 73816)
			Pseudo nAb ID50	103	742	(742, 742)
			Pseudo nAb ID80	103	298	(298, 298)
			Live Virus nAb ID50	103	522	(522, 522)
			Live Virus nAb ID80	103	235	(235, 235)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
Age >= 65 White Non-Hispanic	Negative	D57	Anti-Spike IgG	103	6523569	(6523569, 6523569)
			Anti-RBD IgG	103	3429481	(3429481, 3429481)
			Pseudo nAb ID50	103	13171	(13171, 13171)
			Pseudo nAb ID80	103	5608	(5608, 5608)
			Live Virus nAb ID50	103	10671	(10671, 10671)
			Live Virus nAb ID80	103	3622	(3622, 3622)
		D1	Anti-Spike IgG	221	17	(17, 17)
			Anti-RBD IgG	221	17	(17, 17)
			Pseudo nAb ID50	221	24	(24, 24)
			Pseudo nAb ID80	221	22	(22, 22)
			Live Virus nAb ID50	221	24	(24, 24)
			Live Virus nAb ID80	221	22	(22, 22)
		D29	Anti-Spike IgG	221	1458	(1458, 1458)
			Anti-RBD IgG	221	1146	(1146, 1146)
			Pseudo nAb ID50	221	129	(129, 129)
			Pseudo nAb ID80	221	78	(78, 78)
			Live Virus nAb ID50	221	102	(102, 102)
			Live Virus nAb ID80	221	81	(81, 81)
		D57	Anti-Spike IgG	221	8956	(8956, 8956)
			Anti-RBD IgG	221	7189	(7189, 7189)
			Pseudo nAb ID50	221	507	(507, 507)
			Pseudo nAb ID80	221	355	(355, 355)
			Live Virus nAb ID50	221	400	(400, 400)
			Live Virus nAb ID80	221	300	(300, 300)
	Positive	D1	Anti-Spike IgG	102	17	(17, 17)
			Anti-RBD IgG	102	17	(17, 17)
			Pseudo nAb ID50	102	24	(24, 24)
			Pseudo nAb ID80	102	21	(21, 22)
			Live Virus nAb ID50	102	24	(24, 24)
			Live Virus nAb ID80	102	21	(21, 22)
		D29	Anti-Spike IgG	102	161036	(161036, 161036)
			Anti-RBD IgG	102	78748	(78748, 78748)
			Pseudo nAb ID50	102	795	(795, 795)
			Pseudo nAb ID80	102	328	(328, 328)

Table 2: Geometric mean titers (GMTs) or geometric mean value of concentrations (GMCs) (*continued*)

Group	Baseline	Visit	Endpoint	N	GMT/GMC	95% CI
			Live Virus nAb ID50	102	563	(563, 563)
			Live Virus nAb ID80	102	311	(311, 311)
		D57	Anti-Spike IgG	102	6779392	(6779392, 6779392)
			Anti-RBD IgG	102	3564826	(3564826, 3564826)
			Pseudo nAb ID50	102	14967	(14967, 14967)
			Pseudo nAb ID80	102	7169	(7169, 7169)
			Live Virus nAb ID50	102	8306	(8306, 8306)
			Live Virus nAb ID80	102	5191	(5191, 5191)

bAb LLOQ = 34; nAb ID50 LLOQ = 49; nAb ID80 LLOQ = 43

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 2. GMTRs or GMCRs between post-vaccinations vs. pre-vaccination

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Total						
Total	Negative	Anti-Spike IgG	D29 vs. Baseline	1089	267.32	(211.32, 338.17)
		Anti-RBD IgG		1089	164.37	(126.35, 213.83)
		Pseudo nAb ID50		1089	14.34	(10.81, 19.04)
		Pseudo nAb ID80		1089	9.68	(7.31, 12.83)
		Live Virus nAb ID50		1089	15.43	(12.85, 18.52)
		Live Virus nAb ID80		1089	11.95	(9.96, 14.34)
		Anti-Spike IgG	D57 vs. Baseline	1089	1975.38	(1500.31, 2600.89)
		Anti-RBD IgG		1089	1251.28	(1001.98, 1562.62)
		Pseudo nAb ID50		1089	59.22	(44.94, 78.02)
		Pseudo nAb ID80		1089	44.79	(33.18, 60.47)
		Live Virus nAb ID50		1089	61.89	(50.01, 76.59)
		Live Virus nAb ID80		1089	46.84	(39.25, 55.90)
		Anti-Spike IgG	D57 vs. D29	1089	7.39	(6.34, 8.61)
		Anti-RBD IgG		1089	7.61	(6.75, 8.59)
		Pseudo nAb ID50		1089	4.13	(3.82, 4.46)
		Pseudo nAb ID80		1089	4.63	(4.31, 4.97)
		Live Virus nAb ID50		1089	4.01	(3.69, 4.36)
		Live Virus nAb ID80		1089	3.92	(3.84, 4.00)
	Positive	Anti-Spike IgG	D29 vs. Baseline	523	39909.50	(24196.71, 65825.81)
		Anti-RBD IgG		523	20080.73	(11960.52, 33713.89)
		Pseudo nAb ID50		523	220.40	(133.77, 363.13)
		Pseudo nAb ID80		523	92.34	(57.35, 148.68)
		Live Virus nAb ID50		523	217.30	(155.23, 304.21)
		Live Virus nAb ID80		523	112.02	(80.54, 155.81)
		Anti-Spike IgG	D57 vs. Baseline	523	249597.86	(1395967.64, 4461427.68)
		Anti-RBD IgG		523	1289604.60	(770765.88, 2157698.03)
		Pseudo nAb ID50		523	4396.88	(2638.73, 7326.44)
		Pseudo nAb ID80		523	1610.72	(934.67, 2775.76)
		Live Virus nAb ID50		523	3601.66	(2495.30, 5198.57)
		Live Virus nAb ID80		523	1834.44	(1283.12, 2622.66)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age Age < 65		Anti-Spike IgG	D57 vs. D29	523	62.53	(57.33, 68.21)
		Anti-RBD IgG		523	64.22	(63.16, 65.30)
		Pseudo nAb ID50		523	19.95	(15.52, 25.64)
		Pseudo nAb ID80		523	17.44	(16.28, 18.69)
		Live Virus nAb ID50		523	16.57	(15.65, 17.55)
		Live Virus nAb ID80		523	16.38	(15.53, 17.27)
	Negative	Anti-Spike IgG	D29 vs. Baseline	513	244.33	(203.15, 293.87)
		Anti-RBD IgG		513	148.15	(123.95, 177.08)
		Pseudo nAb ID50		513	12.89	(10.22, 16.27)
		Pseudo nAb ID80		513	8.72	(6.85, 11.12)
		Live Virus nAb ID50		513	14.39	(12.44, 16.64)
		Live Virus nAb ID80		513	11.12	(9.85, 12.56)
		Anti-Spike IgG	D57 vs. Baseline	513	1848.62	(1328.14, 2573.05)
		Anti-RBD IgG		513	1168.86	(917.56, 1488.97)
		Pseudo nAb ID50		513	52.97	(45.73, 61.35)
		Pseudo nAb ID80		513	39.73	(32.97, 47.87)
		Live Virus nAb ID50		513	56.76	(52.59, 61.25)
		Live Virus nAb ID80		513	43.62	(39.58, 48.06)
		Anti-Spike IgG	D57 vs. D29	513	7.57	(6.54, 8.76)
		Anti-RBD IgG		513	7.89	(7.40, 8.41)
		Pseudo nAb ID50		513	4.11	(3.77, 4.48)
		Pseudo nAb ID80		513	4.55	(4.31, 4.82)
		Live Virus nAb ID50		513	3.94	(3.68, 4.23)
		Live Virus nAb ID80		513	3.92	(3.83, 4.02)
	Positive	Anti-Spike IgG	D29 vs. Baseline	295	32892.47	(29957.04, 36115.54)
		Anti-RBD IgG		295	16495.05	(15772.89, 17250.29)
		Pseudo nAb ID50		295	181.28	(154.83, 212.24)
		Pseudo nAb ID80		295	76.67	(67.22, 87.46)
		Live Virus nAb ID50		295	190.46	(168.07, 215.83)
		Live Virus nAb ID80		295	98.52	(90.94, 106.74)
		Anti-Spike IgG	D57 vs. Baseline	295	1989987.95	(1711960.14, 2313168.35)
		Anti-RBD IgG		295	1059131.73	(993306.23, 1129319.43)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age ≥ 65	Negative	Pseudo nAb ID50	D57 vs. D29	295	3668.87	(2387.79, 5637.26)
		Pseudo nAb ID80		295	1301.89	(1101.45, 1538.81)
		Live Virus nAb ID50		295	3124.12	(2893.21, 3373.46)
		Live Virus nAb ID80		295	1594.60	(1383.26, 1838.23)
		Anti-Spike IgG		295	60.50	(57.15, 64.05)
		Anti-RBD IgG		295	64.21	(62.98, 65.47)
		Pseudo nAb ID50		295	20.24	(15.42, 26.56)
		Pseudo nAb ID80		295	16.98	(16.39, 17.59)
		Live Virus nAb ID50		295	16.40	(15.63, 17.21)
		Live Virus nAb ID80		295	16.19	(15.21, 17.22)
		Anti-Spike IgG	D29 vs. Baseline	576	423.67	(423.67, 423.67)
		Anti-RBD IgG		576	279.78	(279.78, 279.78)
		Pseudo nAb ID50		576	24.77	(24.77, 24.77)
		Pseudo nAb ID80		576	16.52	(16.52, 16.52)
		Live Virus nAb ID50		576	22.05	(22.05, 22.05)
		Live Virus nAb ID80		576	17.29	(17.29, 17.29)
		Anti-Spike IgG	D57 vs. Baseline	576	2774.43	(2774.43, 2774.43)
		Anti-RBD IgG		576	1773.88	(1773.88, 1773.88)
		Pseudo nAb ID50		576	104.80	(104.80, 104.80)
		Pseudo nAb ID80		576	82.75	(82.75, 82.75)
		Live Virus nAb ID50		576	96.43	(96.43, 96.43)
		Live Virus nAb ID80		576	67.49	(67.49, 67.49)
		Anti-Spike IgG	D57 vs. D29	576	6.55	(6.55, 6.55)
		Anti-RBD IgG		576	6.34	(6.34, 6.34)
		Pseudo nAb ID50		576	4.23	(4.23, 4.23)
		Pseudo nAb ID80		576	5.01	(5.01, 5.01)
		Live Virus nAb ID50		576	4.37	(4.37, 4.37)
		Live Virus nAb ID80		576	3.90	(3.90, 3.90)
	Positive	Anti-Spike IgG	D29 vs. Baseline	228	141806.14	(141806.14, 141806.14)
		Anti-RBD IgG		228	72925.44	(72925.44, 72925.44)
		Pseudo nAb ID50		228	793.55	(793.55, 793.55)
		Pseudo nAb ID80		228	312.43	(312.43, 312.43)
		Live Virus nAb ID50		228	515.90	(515.90, 515.90)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
High Risk At-risk		Live Virus nAb ID80	D57 vs. Baseline	228	259.93	(259.93, 259.93)
		Anti-Spike IgG		228	11011423.72	(11011423.72, 11011423.72)
		Anti-RBD IgG		228	4689064.67	(4689064.67, 4689064.67)
		Pseudo nAb ID50		228	14406.96	(14406.96, 14406.96)
		Pseudo nAb ID80		228	6503.45	(6503.45, 6503.45)
		Live Virus nAb ID50		228	9152.49	(9152.49, 9152.49)
		Live Virus nAb ID80	D57 vs. D29	228	4597.18	(4597.18, 4597.18)
		Anti-Spike IgG		228	77.65	(77.65, 77.65)
		Anti-RBD IgG		228	64.30	(64.30, 64.30)
		Pseudo nAb ID50		228	18.16	(18.16, 18.16)
		Pseudo nAb ID80		228	20.82	(20.82, 20.82)
		Live Virus nAb ID50		228	17.74	(17.74, 17.74)
		Live Virus nAb ID80		228	17.69	(17.69, 17.69)
	Negative	Anti-Spike IgG	D29 vs. Baseline	568	255.84	(125.31, 522.34)
		Anti-RBD IgG		568	161.35	(73.65, 353.51)
		Pseudo nAb ID50		568	13.07	(5.89, 28.98)
		Pseudo nAb ID80		568	8.48	(4.08, 17.64)
		Live Virus nAb ID50		568	14.51	(8.82, 23.87)
		Live Virus nAb ID80		568	11.36	(7.25, 17.79)
		Anti-Spike IgG	D57 vs. Baseline	568	1610.75	(746.59, 3475.16)
		Anti-RBD IgG		568	1102.56	(569.20, 2135.70)
		Pseudo nAb ID50		568	58.34	(28.77, 118.30)
		Pseudo nAb ID80		568	42.02	(19.99, 88.31)
		Live Virus nAb ID50		568	62.35	(39.03, 99.60)
		Live Virus nAb ID80		568	47.30	(28.49, 78.55)
		Anti-Spike IgG	D57 vs. D29	568	6.30	(5.96, 6.65)
		Anti-RBD IgG		568	6.83	(6.04, 7.73)
		Pseudo nAb ID50		568	4.47	(4.08, 4.88)
		Pseudo nAb ID80		568	4.95	(4.90, 5.01)
		Live Virus nAb ID50		568	4.30	(4.17, 4.43)
		Live Virus nAb ID80		568	4.16	(3.93, 4.41)
	Positive	Anti-Spike IgG	D29 vs. Baseline	222	38420.02	(17521.19, 84246.43)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Not at-risk		Anti-RBD IgG	D57 vs. Baseline	222	21955.96	(8442.83, 57097.46)
		Pseudo nAb ID50		222	202.99	(81.18, 507.59)
		Pseudo nAb ID80		222	87.87	(36.45, 211.83)
		Live Virus nAb ID50		222	201.37	(106.84, 379.52)
		Live Virus nAb ID80		222	109.60	(60.14, 199.76)
		Anti-Spike IgG		222	2303219.98	(864956.04, 6133054.21)
		Anti-RBD IgG		222	1381499.13	(521177.35, 3661977.73)
		Pseudo nAb ID50		222	2887.30	(1066.57, 7816.20)
		Pseudo nAb ID80		222	1543.09	(509.15, 4676.65)
		Live Virus nAb ID50		222	3488.15	(1919.42, 6338.99)
		Live Virus nAb ID80		222	1676.37	(845.94, 3321.98)
		Anti-Spike IgG	D57 vs. D29	222	59.95	(49.37, 72.80)
		Anti-RBD IgG		222	62.92	(61.73, 64.14)
		Pseudo nAb ID50		222	14.22	(13.14, 15.40)
		Pseudo nAb ID80		222	17.56	(13.97, 22.08)
		Live Virus nAb ID50		222	17.32	(16.70, 17.96)
		Live Virus nAb ID80		222	15.29	(14.07, 16.63)
	Negative	Anti-Spike IgG	D29 vs. Baseline	521	271.36	(243.19, 302.79)
		Anti-RBD IgG		521	165.41	(144.88, 188.85)
		Pseudo nAb ID50		521	14.81	(12.66, 17.33)
		Pseudo nAb ID80		521	10.13	(8.47, 12.12)
		Live Virus nAb ID50		521	15.75	(14.11, 17.60)
		Live Virus nAb ID80		521	12.16	(10.64, 13.90)
		Anti-Spike IgG	D57 vs. Baseline	521	2117.76	(2035.91, 2202.91)
		Anti-RBD IgG		521	1306.46	(1224.89, 1393.46)
		Pseudo nAb ID50		521	59.52	(49.37, 71.75)
		Pseudo nAb ID80		521	45.78	(36.79, 56.96)
		Live Virus nAb ID50		521	61.73	(52.17, 73.05)
		Live Virus nAb ID80		521	46.68	(42.40, 51.40)
		Anti-Spike IgG	D57 vs. D29	521	7.80	(7.28, 8.37)
		Anti-RBD IgG		521	7.90	(7.38, 8.45)
		Pseudo nAb ID50		521	4.02	(3.90, 4.14)
		Pseudo nAb ID80		521	4.52	(4.35, 4.70)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age, Risk Age < 65 At-risk	Positive	Live Virus nAb ID50	D29 vs. Baseline	521	3.92	(3.70, 4.15)
		Live Virus nAb ID80		521	3.84	(3.70, 3.98)
		Anti-Spike IgG		301	40354.08	(24239.10, 67182.84)
		Anti-RBD IgG		301	19565.30	(12315.95, 31081.73)
		Pseudo nAb ID50		301	225.74	(139.33, 365.75)
		Pseudo nAb ID80		301	93.68	(59.46, 147.60)
		Live Virus nAb ID50		301	222.18	(160.87, 306.85)
		Live Virus nAb ID80		301	112.73	(82.26, 154.50)
		Anti-Spike IgG	D57 vs. Baseline	301	2554593.26	(1427388.68, 4571947.95)
		Anti-RBD IgG		301	1264007.71	(798278.11, 2001452.20)
		Pseudo nAb ID50		301	4969.85	(3229.86, 7647.21)
		Pseudo nAb ID80		301	1630.97	(999.20, 2662.21)
		Live Virus nAb ID50	D57 vs. D29	301	3635.42	(2512.34, 5260.53)
		Live Virus nAb ID80		301	1883.23	(1339.48, 2647.70)
		Anti-Spike IgG		301	63.30	(58.89, 68.05)
		Anti-RBD IgG		301	64.60	(64.39, 64.82)
		Pseudo nAb ID50		301	22.02	(20.91, 23.18)
		Pseudo nAb ID80		301	17.41	(16.81, 18.04)
		Live Virus nAb ID50		301	16.36	(15.62, 17.14)
		Live Virus nAb ID80		301	16.71	(16.28, 17.14)
	Negative	Anti-Spike IgG	D29 vs. Baseline	259	187.95	(187.95, 187.95)
		Anti-RBD IgG		259	114.98	(114.98, 114.98)
		Pseudo nAb ID50		259	9.26	(9.26, 9.26)
		Pseudo nAb ID80		259	6.18	(6.18, 6.18)
		Live Virus nAb ID50		259	11.70	(11.70, 11.70)
		Live Virus nAb ID80		259	9.36	(9.36, 9.36)
		Anti-Spike IgG	D57 vs. Baseline	259	1155.45	(1155.45, 1155.45)
		Anti-RBD IgG		259	828.61	(828.61, 828.61)
		Pseudo nAb ID50		259	42.99	(42.99, 42.99)
		Pseudo nAb ID80		259	30.48	(30.48, 30.48)
		Live Virus nAb ID50		259	50.93	(50.93, 50.93)
		Live Virus nAb ID80		259	38.00	(38.00, 38.00)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age < 65 Not at-risk	Positive	Anti-Spike IgG	D57 vs. D29	259	6.15	(6.15, 6.15)
		Anti-RBD IgG		259	7.21	(7.21, 7.21)
		Pseudo nAb ID50		259	4.64	(4.64, 4.64)
		Pseudo nAb ID80		259	4.93	(4.93, 4.93)
		Live Virus nAb ID50		259	4.35	(4.35, 4.35)
		Live Virus nAb ID80		259	4.06	(4.06, 4.06)
		Anti-Spike IgG	D29 vs. Baseline	147	28846.71	(28846.71, 28846.71)
		Anti-RBD IgG		147	15490.16	(15490.16, 15490.16)
		Pseudo nAb ID50		147	145.27	(145.27, 145.27)
		Pseudo nAb ID80		147	63.73	(63.73, 63.73)
		Live Virus nAb ID50		147	159.78	(159.78, 159.78)
		Live Virus nAb ID80		147	88.04	(88.04, 88.04)
	Negative	Anti-Spike IgG	D57 vs. Baseline	147	1610970.64	(1610970.64, 1610970.64)
		Anti-RBD IgG		147	967885.90	(967885.90, 967885.90)
		Pseudo nAb ID50		147	2007.38	(2007.38, 2007.38)
		Pseudo nAb ID80		147	1029.51	(1029.51, 1029.51)
		Live Virus nAb ID50		147	2804.83	(2804.83, 2804.83)
		Live Virus nAb ID80		147	1306.03	(1306.03, 1306.03)
		Anti-Spike IgG	D57 vs. D29	147	55.85	(55.85, 55.85)
		Anti-RBD IgG		147	62.48	(62.48, 62.48)
		Pseudo nAb ID50		147	13.82	(13.82, 13.82)
		Pseudo nAb ID80		147	16.15	(16.15, 16.15)
		Live Virus nAb ID50		147	17.55	(17.55, 17.55)
		Live Virus nAb ID80		147	14.83	(14.83, 14.83)
		Anti-Spike IgG	D29 vs. Baseline	254	261.68	(261.68, 261.68)
		Anti-RBD IgG		254	158.30	(158.30, 158.30)
		Pseudo nAb ID50		254	14.06	(14.06, 14.06)
		Pseudo nAb ID80		254	9.54	(9.54, 9.54)
		Live Virus nAb ID50		254	15.19	(15.19, 15.19)
		Live Virus nAb ID80		254	11.63	(11.63, 11.63)
		Anti-Spike IgG	D57 vs. Baseline	254	2090.30	(2090.30, 2090.30)
		Anti-RBD IgG		254	1278.86	(1278.86, 1278.86)
		Pseudo nAb ID50		254	55.94	(55.94, 55.94)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age >= 65 At-risk	Positive	Pseudo nAb ID80	D57 vs. D29	254	42.58	(42.58, 42.58)
		Live Virus nAb ID50		254	58.38	(58.38, 58.38)
		Live Virus nAb ID80		254	45.22	(45.22, 45.22)
		Anti-Spike IgG		254	7.99	(7.99, 7.99)
		Anti-RBD IgG		254	8.08	(8.08, 8.08)
		Pseudo nAb ID50		254	3.98	(3.98, 3.98)
		Pseudo nAb ID80		254	4.46	(4.46, 4.46)
		Live Virus nAb ID50		254	3.84	(3.84, 3.84)
		Live Virus nAb ID80		254	3.89	(3.89, 3.89)
		Anti-Spike IgG	D29 vs. Baseline	148	34058.90	(34058.90, 34058.90)
		Anti-RBD IgG		148	16772.65	(16772.65, 16772.65)
		Pseudo nAb ID50		148	192.25	(192.25, 192.25)
		Pseudo nAb ID80		148	80.53	(80.53, 80.53)
		Live Virus nAb ID50		148	199.55	(199.55, 199.55)
		Live Virus nAb ID80		148	101.51	(101.51, 101.51)
		Anti-Spike IgG	D57 vs. Baseline	148	2104817.23	(2104817.23, 2104817.23)
		Anti-RBD IgG		148	1084771.52	(1084771.52, 1084771.52)
		Pseudo nAb ID50		148	4305.96	(4305.96, 4305.96)
		Pseudo nAb ID80		148	1385.62	(1385.62, 1385.62)
		Live Virus nAb ID50		148	3214.84	(3214.84, 3214.84)
		Live Virus nAb ID80		148	1681.40	(1681.40, 1681.40)
		Anti-Spike IgG	D57 vs. D29	148	61.80	(61.80, 61.80)
		Anti-RBD IgG		148	64.68	(64.68, 64.68)
		Pseudo nAb ID50		148	22.40	(22.40, 22.40)
		Pseudo nAb ID80		148	17.21	(17.21, 17.21)
		Live Virus nAb ID50		148	16.11	(16.11, 16.11)
		Live Virus nAb ID80		148	16.56	(16.56, 16.56)
	Negative	Anti-Spike IgG	D29 vs. Baseline	309	495.40	(495.40, 495.40)
		Anti-RBD IgG		309	333.53	(333.53, 333.53)
		Pseudo nAb ID50		309	27.32	(27.32, 27.32)
		Pseudo nAb ID80		309	16.71	(16.71, 16.71)
		Live Virus nAb ID50		309	23.00	(23.00, 23.00)
		Live Virus nAb ID80		309	17.21	(17.21, 17.21)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age >= 65 Not at-risk	Positive	Anti-Spike IgG	D57 vs. Baseline	309	3282.47	(3282.47, 3282.47)
		Anti-RBD IgG		309	2033.48	(2033.48, 2033.48)
		Pseudo nAb ID50		309	112.26	(112.26, 112.26)
		Pseudo nAb ID80		309	83.57	(83.57, 83.57)
		Live Virus nAb ID50		309	96.20	(96.20, 96.20)
		Live Virus nAb ID80		309	75.65	(75.65, 75.65)
		Anti-Spike IgG	D57 vs. D29	309	6.63	(6.63, 6.63)
		Anti-RBD IgG		309	6.10	(6.10, 6.10)
		Pseudo nAb ID50		309	4.11	(4.11, 4.11)
		Pseudo nAb ID80		309	5.00	(5.00, 5.00)
		Live Virus nAb ID50		309	4.18	(4.18, 4.18)
		Live Virus nAb ID80		309	4.40	(4.40, 4.40)
		Anti-Spike IgG	D29 vs. Baseline	75	127397.12	(127397.12, 127397.12)
		Anti-RBD IgG		75	94458.09	(94458.09, 94458.09)
		Pseudo nAb ID50		75	822.57	(822.57, 822.57)
		Pseudo nAb ID80		75	336.72	(336.72, 336.72)
		Live Virus nAb ID50		75	529.92	(529.92, 529.92)
		Live Virus nAb ID80		75	274.04	(274.04, 274.04)
		Anti-Spike IgG	D57 vs. Baseline	75	10273356.42	(10273356.42, 10273356.42)
		Anti-RBD IgG		75	6119420.47	(6119420.47, 6119420.47)
		Pseudo nAb ID50		75	13206.98	(13206.98, 13206.98)
		Pseudo nAb ID80		75	8386.36	(8386.36, 8386.36)
		Live Virus nAb ID50		75	8682.88	(8682.88, 8682.88)
		Live Virus nAb ID80		75	4762.64	(4762.64, 4762.64)
		Anti-Spike IgG	D57 vs. D29	75	80.64	(80.64, 80.64)
		Anti-RBD IgG		75	64.78	(64.78, 64.78)
		Pseudo nAb ID50		75	16.06	(16.06, 16.06)
		Pseudo nAb ID80		75	24.91	(24.91, 24.91)
		Live Virus nAb ID50		75	16.39	(16.39, 16.39)
		Live Virus nAb ID80		75	17.38	(17.38, 17.38)
Age >= 65 Not at-risk	Negative	Anti-Spike IgG	D29 vs. Baseline	267	363.38	(363.38, 363.38)
		Anti-RBD IgG		267	235.45	(235.45, 235.45)
		Pseudo nAb ID50		267	22.51	(22.51, 22.51)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Positive	D57 vs. Baseline	Pseudo nAb ID80		267	16.33	(16.33, 16.33)
		Live Virus nAb ID50		267	21.15	(21.15, 21.15)
		Live Virus nAb ID80		267	17.36	(17.36, 17.36)
		Anti-Spike IgG		267	2352.30	(2352.30, 2352.30)
		Anti-RBD IgG		267	1551.32	(1551.32, 1551.32)
		Pseudo nAb ID50		267	97.95	(97.95, 97.95)
		Pseudo nAb ID80		267	81.94	(81.94, 81.94)
		Live Virus nAb ID50		267	96.67	(96.67, 96.67)
		Live Virus nAb ID80		267	60.34	(60.34, 60.34)
		Anti-Spike IgG	D57 vs. D29	267	6.47	(6.47, 6.47)
		Anti-RBD IgG		267	6.59	(6.59, 6.59)
		Pseudo nAb ID50		267	4.35	(4.35, 4.35)
		Pseudo nAb ID80		267	5.02	(5.02, 5.02)
		Live Virus nAb ID50		267	4.57	(4.57, 4.57)
		Live Virus nAb ID80		267	3.48	(3.48, 3.48)
	D29 vs. Baseline	Anti-Spike IgG		153	149450.79	(149450.79, 149450.79)
		Anti-RBD IgG		153	64242.23	(64242.23, 64242.23)
		Pseudo nAb ID50		153	779.71	(779.71, 779.71)
		Pseudo nAb ID80		153	301.17	(301.17, 301.17)
		Live Virus nAb ID50		153	509.17	(509.17, 509.17)
	D57 vs. Baseline	Live Virus nAb ID80		153	253.29	(253.29, 253.29)
		Anti-Spike IgG		153	11392217.18	(11392217.18, 11392217.18)
		Anti-RBD IgG		153	4115554.74	(4115554.74, 4115554.74)
		Pseudo nAb ID50		153	15034.18	(15034.18, 15034.18)
		Pseudo nAb ID80		153	5741.58	(5741.58, 5741.58)
	D57 vs. D29	Live Virus nAb ID50		153	9391.79	(9391.79, 9391.79)
		Live Virus nAb ID80		153	4518.21	(4518.21, 4518.21)
		Anti-Spike IgG		153	76.23	(76.23, 76.23)
		Anti-RBD IgG		153	64.06	(64.06, 64.06)
		Pseudo nAb ID50		153	19.28	(19.28, 19.28)
		Pseudo nAb ID80		153	19.06	(19.06, 19.06)
		Live Virus nAb ID50		153	18.45	(18.45, 18.45)
		Live Virus nAb ID80		153	17.84	(17.84, 17.84)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Sex						
Female	Negative	Anti-Spike IgG	D29 vs. Baseline	595	263.99	(218.52, 318.91)
		Anti-RBD IgG		595	193.39	(152.79, 244.79)
		Pseudo nAb ID50		595	16.67	(13.43, 20.69)
		Pseudo nAb ID80		595	11.49	(8.53, 15.49)
		Live Virus nAb ID50		595	16.35	(12.66, 21.10)
		Live Virus nAb ID80		595	12.57	(10.71, 14.76)
		Anti-Spike IgG	D57 vs. Baseline	595	2160.21	(1297.56, 3596.38)
		Anti-RBD IgG		595	1472.59	(892.18, 2430.60)
		Pseudo nAb ID50		595	66.47	(53.90, 81.96)
		Pseudo nAb ID80		595	49.05	(40.06, 60.05)
		Live Virus nAb ID50		595	66.62	(55.32, 80.24)
		Live Virus nAb ID80		595	51.22	(40.26, 65.17)
		Anti-Spike IgG	D57 vs. D29	595	8.18	(5.82, 11.50)
		Anti-RBD IgG		595	7.61	(5.61, 10.33)
		Pseudo nAb ID50		595	3.99	(3.82, 4.16)
		Pseudo nAb ID80		595	4.27	(3.86, 4.72)
		Live Virus nAb ID50		595	4.08	(3.80, 4.37)
		Live Virus nAb ID80		595	4.07	(3.66, 4.53)
	Positive	Anti-Spike IgG	D29 vs. Baseline	294	35467.09	(22360.82, 56255.30)
		Anti-RBD IgG		294	19295.59	(12101.34, 30766.82)
		Pseudo nAb ID50		294	191.84	(115.02, 319.97)
		Pseudo nAb ID80		294	78.32	(49.01, 125.16)
		Live Virus nAb ID50		294	214.94	(156.51, 295.18)
		Live Virus nAb ID80		294	110.71	(81.23, 150.87)
		Anti-Spike IgG	D57 vs. Baseline	294	1994970.66	(1097001.56, 3627987.48)
		Anti-RBD IgG		294	1253140.08	(776373.40, 2022686.61)
		Pseudo nAb ID50		294	3773.58	(2052.81, 6936.77)
		Pseudo nAb ID80		294	1738.71	(1001.28, 3019.24)
		Live Virus nAb ID50		294	3459.99	(2435.89, 4914.63)
		Live Virus nAb ID80		294	1805.85	(1280.78, 2546.18)
		Anti-Spike IgG	D57 vs. D29	294	56.25	(48.90, 64.70)
		Anti-RBD IgG		294	64.94	(64.11, 65.79)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Male	Negative	Pseudo nAb ID50		294	19.67	(15.94, 24.27)
		Pseudo nAb ID80		294	22.20	(20.16, 24.45)
		Live Virus nAb ID50		294	16.10	(15.24, 17.00)
		Live Virus nAb ID80		294	16.31	(15.76, 16.88)
		Anti-Spike IgG	D29 vs. Baseline	494	271.27	(168.20, 437.51)
		Anti-RBD IgG		494	135.94	(77.38, 238.81)
		Pseudo nAb ID50		494	12.04	(7.10, 20.40)
		Pseudo nAb ID80		494	7.93	(4.77, 13.17)
		Live Virus nAb ID50		494	14.42	(9.89, 21.04)
		Live Virus nAb ID80		494	11.26	(7.95, 15.96)
		Anti-Spike IgG	D57 vs. Baseline	494	1779.47	(1021.82, 3098.89)
		Anti-RBD IgG		494	1034.58	(543.38, 1969.80)
		Pseudo nAb ID50		494	51.74	(27.67, 96.77)
		Pseudo nAb ID80		494	40.28	(22.50, 72.12)
		Live Virus nAb ID50		494	56.78	(34.79, 92.69)
		Live Virus nAb ID80		494	42.20	(26.49, 67.21)
		Anti-Spike IgG	D57 vs. D29	494	6.56	(6.07, 7.09)
		Anti-RBD IgG		494	7.61	(6.93, 8.36)
		Pseudo nAb ID50		494	4.30	(3.59, 5.14)
		Pseudo nAb ID80		494	5.08	(4.71, 5.48)
		Live Virus nAb ID50		494	3.94	(3.51, 4.42)
		Live Virus nAb ID80		494	3.75	(3.21, 4.37)
	Positive	Anti-Spike IgG	D29 vs. Baseline	229	46575.02	(26195.49, 82809.39)
		Anti-RBD IgG		229	21156.78	(10976.62, 40778.45)
		Pseudo nAb ID50		229	264.28	(156.76, 445.57)
		Pseudo nAb ID80		229	114.55	(67.70, 193.81)
		Live Virus nAb ID50		229	220.44	(146.42, 331.88)
		Live Virus nAb ID80		229	113.76	(73.13, 176.96)
		Anti-Spike IgG	D57 vs. Baseline	229	3345335.86	(1923534.33, 5818077.60)
		Anti-RBD IgG		229	1338937.23	(714968.92, 2507455.74)
		Pseudo nAb ID50		229	5370.77	(3726.55, 7740.46)
		Pseudo nAb ID80		229	1457.34	(782.12, 2715.49)
		Live Virus nAb ID50		229	3795.89	(2434.24, 5919.23)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age, Sex Age < 65 Female		Live Virus nAb ID80	D57 vs. D29	229	1872.55	(1223.50, 2865.91)
		Anti-Spike IgG		229	71.83	(67.14, 76.84)
		Anti-RBD IgG		229	63.29	(61.08, 65.58)
		Pseudo nAb ID50		229	20.32	(14.74, 28.01)
		Pseudo nAb ID80		229	12.72	(11.54, 14.03)
		Live Virus nAb ID50		229	17.22	(15.90, 18.65)
		Live Virus nAb ID80		229	16.46	(15.00, 18.06)
	Negative	Anti-Spike IgG	D29 vs. Baseline	285	263.54	(209.41, 331.66)
		Anti-RBD IgG		285	193.91	(146.24, 257.10)
		Pseudo nAb ID50		285	16.48	(12.59, 21.59)
		Pseudo nAb ID80		285	11.32	(7.80, 16.43)
		Live Virus nAb ID50		285	16.22	(11.84, 22.22)
		Live Virus nAb ID80		285	12.39	(10.11, 15.17)
		Anti-Spike IgG	D57 vs. Baseline	285	2319.91	(1391.42, 3867.98)
		Anti-RBD IgG		285	1615.59	(1027.55, 2540.15)
		Pseudo nAb ID50		285	66.87	(52.25, 85.58)
		Pseudo nAb ID80		285	48.04	(37.18, 62.09)
		Live Virus nAb ID50		285	66.11	(52.48, 83.28)
		Live Virus nAb ID80		285	51.86	(39.32, 68.40)
		Anti-Spike IgG	D57 vs. D29	285	8.80	(6.64, 11.66)
		Anti-RBD IgG		285	8.33	(7.03, 9.88)
		Pseudo nAb ID50		285	4.06	(3.96, 4.15)
		Pseudo nAb ID80		285	4.24	(3.78, 4.76)
		Live Virus nAb ID50		285	4.08	(3.75, 4.43)
		Live Virus nAb ID80		285	4.19	(3.89, 4.51)
	Positive	Anti-Spike IgG	D29 vs. Baseline	177	29682.88	(24679.85, 35700.12)
		Anti-RBD IgG		177	16126.41	(13029.66, 19959.17)
		Pseudo nAb ID50		177	157.95	(119.30, 209.12)
		Pseudo nAb ID80		177	65.51	(51.00, 84.14)
		Live Virus nAb ID50		177	191.40	(153.41, 238.80)
		Live Virus nAb ID80		177	98.95	(79.18, 123.66)
		Anti-Spike IgG	D57 vs. Baseline	177	1583448.00	(1295485.53, 1935419.20)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age < 65 Male	Negative	Anti-RBD IgG	D57 vs. D29	177	1042591.97	(833613.82, 1303958.74)
		Pseudo nAb ID50		177	3075.67	(1816.10, 5208.84)
		Pseudo nAb ID80		177	1415.31	(997.16, 2008.79)
		Live Virus nAb ID50		177	3029.47	(2481.31, 3698.73)
		Live Virus nAb ID80		177	1593.64	(1248.15, 2034.78)
		Anti-Spike IgG		177	53.35	(52.49, 54.21)
		Anti-RBD IgG		177	64.65	(63.98, 65.33)
		Pseudo nAb ID50		177	19.47	(15.22, 24.91)
		Pseudo nAb ID80		177	21.61	(19.55, 23.87)
		Live Virus nAb ID50		177	15.83	(15.49, 16.17)
		Live Virus nAb ID80		177	16.11	(15.76, 16.45)
		Anti-Spike IgG	D29 vs. Baseline	228	224.13	(194.68, 258.02)
		Anti-RBD IgG		228	108.98	(99.78, 119.03)
		Pseudo nAb ID50		228	9.74	(7.85, 12.09)
		Pseudo nAb ID80		228	6.48	(5.74, 7.31)
		Live Virus nAb ID50		228	12.55	(12.12, 13.01)
		Live Virus nAb ID80		228	9.84	(9.45, 10.23)
		Anti-Spike IgG	D57 vs. Baseline	228	1426.63	(1229.84, 1654.91)
		Anti-RBD IgG		228	807.91	(779.48, 837.38)
		Pseudo nAb ID50		228	40.60	(38.34, 43.00)
		Pseudo nAb ID80		228	31.98	(28.19, 36.29)
		Live Virus nAb ID50		228	47.68	(43.83, 51.88)
		Live Virus nAb ID80		228	35.80	(32.72, 39.17)
		Anti-Spike IgG	D57 vs. D29	228	6.37	(6.32, 6.41)
		Anti-RBD IgG		228	7.41	(7.04, 7.81)
		Pseudo nAb ID50		228	4.17	(3.56, 4.89)
		Pseudo nAb ID80		228	4.94	(4.91, 4.96)
		Live Virus nAb ID50		228	3.80	(3.62, 3.99)
		Live Virus nAb ID80		228	3.64	(3.20, 4.14)
	Positive	Anti-Spike IgG	D29 vs. Baseline	118	37799.04	(35746.27, 39969.71)
		Anti-RBD IgG		118	17007.74	(14077.73, 20547.58)
		Pseudo nAb ID50		118	218.46	(209.13, 228.20)
		Pseudo nAb ID80		118	94.88	(88.57, 101.65)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age >= 65 Female	Negative	Live Virus nAb ID50	D57 vs. Baseline	118	189.19	(188.45, 189.94)
		Live Virus nAb ID80		118	97.95	(87.55, 109.57)
		Anti-Spike IgG		118	2711753.41	(2645531.26, 2779633.21)
		Anti-RBD IgG		118	1081948.91	(925814.05, 1264415.28)
		Pseudo nAb ID50		118	4658.57	(3616.64, 6000.67)
		Pseudo nAb ID80		118	1162.66	(1095.48, 1233.96)
		Live Virus nAb ID50	D57 vs. D29	118	3257.02	(2955.03, 3589.88)
		Live Virus nAb ID80		118	1595.89	(1590.07, 1601.74)
		Anti-Spike IgG		118	71.74	(66.19, 77.76)
		Anti-RBD IgG		118	63.62	(61.54, 65.76)
		Pseudo nAb ID50		118	21.32	(15.85, 28.69)
		Pseudo nAb ID80		118	12.25	(12.14, 12.37)
		Live Virus nAb ID50	D29 vs. Baseline	118	17.22	(15.68, 18.90)
		Live Virus nAb ID80		118	16.29	(14.51, 18.29)
		Anti-Spike IgG		310	266.15	(266.15, 266.15)
		Anti-RBD IgG		310	190.96	(190.96, 190.96)
		Pseudo nAb ID50		310	17.57	(17.57, 17.57)
		Pseudo nAb ID80		310	12.34	(12.34, 12.34)
		Live Virus nAb ID50		310	16.98	(16.98, 16.98)
		Live Virus nAb ID80		310	13.53	(13.53, 13.53)
		Anti-Spike IgG	D57 vs. Baseline	310	1533.52	(1533.52, 1533.52)
		Anti-RBD IgG		310	943.46	(943.46, 943.46)
		Pseudo nAb ID50		310	64.56	(64.56, 64.56)
		Pseudo nAb ID80		310	54.16	(54.16, 54.16)
		Live Virus nAb ID50		310	69.13	(69.13, 69.13)
		Live Virus nAb ID80		310	48.27	(48.27, 48.27)
		Anti-Spike IgG	D57 vs. D29	310	5.76	(5.76, 5.76)
		Anti-RBD IgG		310	4.94	(4.94, 4.94)
		Pseudo nAb ID50		310	3.67	(3.67, 3.67)
		Pseudo nAb ID80		310	4.39	(4.39, 4.39)
		Live Virus nAb ID50		310	4.07	(4.07, 4.07)
		Live Virus nAb ID80		310	3.57	(3.57, 3.57)
	Positive	Anti-Spike IgG	D29 vs. Baseline	117	131600.83	(131600.83, 131600.83)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age >= 65 Male	Negative	Anti-RBD IgG	D57 vs. Baseline	117	72329.70	(72329.70, 72329.70)
		Pseudo nAb ID50		117	803.02	(803.02, 803.02)
		Pseudo nAb ID80		117	291.81	(291.81, 291.81)
		Live Virus nAb ID50		117	505.06	(505.06, 505.06)
		Live Virus nAb ID80		117	253.07	(253.07, 253.07)
		Anti-Spike IgG		117	10935892.55	(10935892.55, 10935892.55)
		Anti-RBD IgG		117	4856556.60	(4856556.60, 4856556.60)
		Pseudo nAb ID50		117	17015.11	(17015.11, 17015.11)
		Pseudo nAb ID80		117	7914.98	(7914.98, 7914.98)
		Live Virus nAb ID50		117	9206.05	(9206.05, 9206.05)
		Live Virus nAb ID80	D57 vs. D29	117	4534.39	(4534.39, 4534.39)
		Anti-Spike IgG		117	83.10	(83.10, 83.10)
		Anti-RBD IgG		117	67.14	(67.14, 67.14)
		Pseudo nAb ID50		117	21.19	(21.19, 21.19)
		Pseudo nAb ID80		117	27.12	(27.12, 27.12)
		Live Virus nAb ID50		117	18.23	(18.23, 18.23)
		Live Virus nAb ID80		117	17.92	(17.92, 17.92)
		Anti-Spike IgG	D29 vs. Baseline	266	781.02	(781.02, 781.02)
		Anti-RBD IgG		266	462.43	(462.43, 462.43)
		Pseudo nAb ID50		266	38.92	(38.92, 38.92)
		Pseudo nAb ID80		266	24.23	(24.23, 24.23)
		Live Virus nAb ID50		266	31.10	(31.10, 31.10)
		Live Virus nAb ID80		266	23.87	(23.87, 23.87)
		Anti-Spike IgG		266	6052.49	(6052.49, 6052.49)
		Anti-RBD IgG		266	4070.75	(4070.75, 4070.75)
		Pseudo nAb ID50		266	198.21	(198.21, 198.21)
		Pseudo nAb ID80		266	144.52	(144.52, 144.52)
		Live Virus nAb ID50		266	149.42	(149.42, 149.42)
		Live Virus nAb ID80	D57 vs. D29	266	104.90	(104.90, 104.90)
		Anti-Spike IgG		266	7.75	(7.75, 7.75)
		Anti-RBD IgG		266	8.80	(8.80, 8.80)
		Pseudo nAb ID50		266	5.09	(5.09, 5.09)
		Pseudo nAb ID80		266	5.96	(5.96, 5.96)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI			
	Positive	Live Virus nAb ID50	D29 vs. Baseline	266	4.80	(4.80, 4.80)			
		Live Virus nAb ID80		266	4.40	(4.40, 4.40)			
		Anti-Spike IgG		111	153370.39	(153370.39, 153370.39)			
		Anti-RBD IgG		111	73556.02	(73556.02, 73556.02)			
		Pseudo nAb ID50		111	783.73	(783.73, 783.73)			
		Pseudo nAb ID80		111	335.63	(335.63, 335.63)			
		Live Virus nAb ID50		111	527.54	(527.54, 527.54)			
		Live Virus nAb ID80		111	267.33	(267.33, 267.33)			
		Anti-Spike IgG		D57 vs. Baseline	111	11091265.29	(11091265.29, 11091265.29)		
		Anti-RBD IgG			111	4519468.91	(4519468.91, 4519468.91)		
	Pseudo nAb ID50	111	12098.27		(12098.27, 12098.27)				
	Pseudo nAb ID80	111	5291.80		(5291.80, 5291.80)				
		Live Virus nAb ID50	D57 vs. D29	111	9096.61	(9096.61, 9096.61)			
		Live Virus nAb ID80		111	4664.01	(4664.01, 4664.01)			
		Anti-Spike IgG		111	72.32	(72.32, 72.32)			
		Anti-RBD IgG		111	61.44	(61.44, 61.44)			
		Pseudo nAb ID50		111	15.44	(15.44, 15.44)			
		Pseudo nAb ID80		111	15.77	(15.77, 15.77)			
		Live Virus nAb ID50		111	17.24	(17.24, 17.24)			
		Live Virus nAb ID80		111	17.45	(17.45, 17.45)			
		Ethnicity							
		Hispanic or Latino		Negative	Anti-Spike IgG	D29 vs. Baseline	139	145.17	(30.89, 682.18)
Anti-RBD IgG					139		119.78	(54.57, 262.92)	
Pseudo nAb ID50					139		13.80	(7.62, 25.02)	
Pseudo nAb ID80	139		7.11		(3.12, 16.17)				
Live Virus nAb ID50	139		14.70		(7.40, 29.19)				
Live Virus nAb ID80	139		13.25		(8.45, 20.76)				
Anti-Spike IgG	D57 vs. Baseline		139		1149.37	(218.43, 6048.01)			
Anti-RBD IgG			139		1020.95	(362.03, 2879.10)			
Pseudo nAb ID50			139		58.60	(24.66, 139.26)			
Pseudo nAb ID80			139		35.06	(14.58, 84.32)			
Live Virus nAb ID50			139		42.22	(17.09, 104.27)			
Live Virus nAb ID80			139		38.05	(16.92, 85.60)			

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
	Positive	Anti-Spike IgG	D57 vs. D29	139	7.92	(6.67, 9.39)
		Anti-RBD IgG		139	8.52	(6.58, 11.04)
		Pseudo nAb ID50		139	4.25	(2.86, 6.29)
		Pseudo nAb ID80		139	4.93	(4.65, 5.24)
		Live Virus nAb ID50		139	2.87	(2.30, 3.59)
		Live Virus nAb ID80		139	2.87	(1.85, 4.45)
		Anti-Spike IgG	D29 vs. Baseline	59	44700.05	(28091.46, 71128.18)
		Anti-RBD IgG		59	17901.73	(12241.17, 26179.85)
		Pseudo nAb ID50		59	332.22	(234.54, 470.58)
		Pseudo nAb ID80		59	112.02	(74.61, 168.19)
		Live Virus nAb ID50		59	364.89	(257.17, 517.75)
		Live Virus nAb ID80		59	149.06	(106.27, 209.08)
		Anti-Spike IgG	D57 vs. Baseline	59	2547676.63	(1406116.89, 4616014.66)
		Anti-RBD IgG		59	1845741.14	(970777.55, 3509311.02)
		Pseudo nAb ID50		59	9123.62	(4307.94, 19322.53)
		Pseudo nAb ID80		59	1884.69	(1054.61, 3368.12)
		Live Virus nAb ID50		59	3376.42	(2163.71, 5268.82)
		Live Virus nAb ID80		59	2057.18	(1180.53, 3584.82)
	Negative	Anti-Spike IgG	D57 vs. D29	59	56.99	(49.95, 65.04)
		Anti-RBD IgG		59	103.10	(63.52, 167.36)
		Pseudo nAb ID50		59	27.46	(16.16, 46.67)
		Pseudo nAb ID80		59	16.82	(13.19, 21.45)
		Live Virus nAb ID50		59	9.25	(6.74, 12.71)
		Live Virus nAb ID80		59	13.80	(11.03, 17.27)
		Anti-Spike IgG	D29 vs. Baseline	837	364.70	(223.57, 594.94)
		Anti-RBD IgG		837	202.91	(144.15, 285.64)
		Pseudo nAb ID50		837	16.10	(11.39, 22.75)
		Pseudo nAb ID80		837	10.64	(7.61, 14.89)
		Live Virus nAb ID50		837	16.55	(13.38, 20.47)
		Live Virus nAb ID80		837	12.23	(9.83, 15.23)
		Anti-Spike IgG	D57 vs. Baseline	837	2955.05	(1399.48, 6239.70)
		Anti-RBD IgG		837	1617.33	(1030.83, 2537.53)
		Pseudo nAb ID50		837	68.93	(48.11, 98.78)
Not Hispanic or Latino						

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI		
Race	Positive	Pseudo nAb ID80	D57 vs. D29	837	49.44	(35.06, 69.71)		
		Live Virus nAb ID50		837	74.53	(59.38, 93.54)		
		Live Virus nAb ID80		837	53.74	(42.82, 67.46)		
		Anti-Spike IgG		837	8.10	(6.14, 10.70)		
		Anti-RBD IgG		837	7.97	(6.69, 9.50)		
		Pseudo nAb ID50		837	4.28	(4.22, 4.34)		
		Pseudo nAb ID80		837	4.64	(4.50, 4.80)		
		Live Virus nAb ID50		837	4.50	(4.43, 4.58)		
		Live Virus nAb ID80		837	4.39	(3.99, 4.84)		
		Anti-Spike IgG	D29 vs. Baseline	418	38503.98	(23003.94, 64447.92)		
		Anti-RBD IgG		418	20457.12	(12204.91, 34288.97)		
		Pseudo nAb ID50		418	207.41	(124.61, 345.22)		
		Pseudo nAb ID80		418	89.45	(55.46, 144.27)		
		Live Virus nAb ID50		418	201.26	(139.83, 289.69)		
		Live Virus nAb ID80		418	107.58	(77.66, 149.03)		
		Anti-Spike IgG	D57 vs. Baseline	418	2511471.28	(1434979.87, 4395523.69)		
		Anti-RBD IgG		418	1231405.90	(714036.97, 2123644.23)		
		Pseudo nAb ID50		418	3918.25	(2424.27, 6332.91)		
		Pseudo nAb ID80		418	1600.71	(952.96, 2688.75)		
		Live Virus nAb ID50		418	3695.93	(2645.45, 5163.54)		
		Live Virus nAb ID80		418	1841.14	(1310.27, 2587.11)		
		Anti-Spike IgG	D57 vs. D29	418	65.23	(60.41, 70.43)		
		Anti-RBD IgG		418	60.19	(57.01, 63.55)		
		Pseudo nAb ID50		418	18.89	(15.64, 22.82)		
		Pseudo nAb ID80		418	17.90	(17.15, 18.68)		
		Live Virus nAb ID50		418	18.36	(17.72, 19.03)		
		Live Virus nAb ID80		418	17.11	(16.21, 18.07)		
		American Indian or Alaska Native	Negative	Anti-Spike IgG	D29 vs. Baseline	29	530.22	(4.16, 67554.52)
				Anti-RBD IgG		29	392.93	(1.84, 83727.06)
		Pseudo nAb ID50	29	16.54		(2.28, 119.80)		
		Pseudo nAb ID80	29	9.27		(2.04, 42.23)		
		Live Virus nAb ID50	29	35.65		(2.35, 541.24)		

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Asian	Positive	Live Virus nAb ID80	D57 vs. Baseline	29	26.46	(2.21, 316.92)
		Anti-Spike IgG		29	5142.84	(2.45, 10815120.25)
		Anti-RBD IgG		29	4398.66	(1.45, 13372734.93)
		Pseudo nAb ID50		29	66.03	(0.84, 5195.38)
		Pseudo nAb ID80	D57 vs. D29	29	68.45	(1.86, 2512.96)
		Live Virus nAb ID50		29	135.15	(1.18, 15455.23)
		Live Virus nAb ID80		29	91.29	(1.49, 5599.74)
		Anti-Spike IgG		29	9.70	(0.57, 165.65)
		Anti-RBD IgG		29	11.19	(0.77, 161.97)
		Pseudo nAb ID50	D29 vs. Baseline	29	3.99	(0.37, 43.52)
		Pseudo nAb ID80		29	7.38	(0.89, 61.03)
		Live Virus nAb ID50		29	3.79	(0.48, 29.84)
		Live Virus nAb ID80		29	3.45	(0.67, 17.67)
		Anti-Spike IgG	D57 vs. Baseline	8	39762.94	(27722.99, 57031.78)
		Anti-RBD IgG		8	35237.55	(28430.28, 43674.75)
		Pseudo nAb ID50		8	473.15	(422.21, 530.24)
		Pseudo nAb ID80		8	230.24	(219.79, 241.19)
		Live Virus nAb ID50	D57 vs. D29	8	261.09	(209.30, 325.70)
		Live Virus nAb ID80		8	173.40	(160.16, 187.73)
		Anti-Spike IgG		8	1817565.52	(1283780.82, 2573293.19)
		Anti-RBD IgG		8	1551508.54	(1458861.57, 1650039.18)
	Negative	Pseudo nAb ID50	D29 vs. Baseline	8	9428.83	(7920.94, 11223.78)
		Pseudo nAb ID80		8	7081.47	(6072.59, 8257.95)
		Live Virus nAb ID50		8	4918.05	(3728.77, 6486.65)
		Live Virus nAb ID80		8	1881.88	(1329.98, 2662.80)
		Anti-Spike IgG	D57 vs. D29	8	45.71	(45.10, 46.33)
		Anti-RBD IgG		8	44.03	(36.19, 53.57)
		Pseudo nAb ID50		8	19.93	(15.93, 24.93)
		Pseudo nAb ID80		8	30.76	(27.48, 34.42)
		Live Virus nAb ID50	D29 vs. Baseline	8	18.84	(15.04, 23.59)
		Live Virus nAb ID80		8	10.85	(8.17, 14.42)
		Anti-Spike IgG		73	139.62	(108.18, 180.20)
		Anti-RBD IgG		73	90.79	(84.01, 98.12)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Positive		Pseudo nAb ID50	D57 vs. Baseline	73	7.38	(5.29, 10.30)
		Pseudo nAb ID80		73	5.98	(4.28, 8.35)
		Live Virus nAb ID50		73	9.68	(7.03, 13.31)
		Live Virus nAb ID80		73	7.67	(5.86, 10.04)
		Anti-Spike IgG		73	542.14	(494.50, 594.37)
		Anti-RBD IgG		73	500.61	(428.99, 584.19)
		Pseudo nAb ID50		73	30.88	(22.41, 42.56)
		Pseudo nAb ID80		73	20.55	(14.28, 29.56)
		Live Virus nAb ID50		73	22.91	(19.33, 27.16)
		Live Virus nAb ID80		73	29.58	(23.40, 37.38)
		Anti-Spike IgG	D57 vs. D29	73	3.88	(3.14, 4.80)
		Anti-RBD IgG		73	5.51	(4.96, 6.13)
		Pseudo nAb ID50		73	4.18	(3.24, 5.40)
		Pseudo nAb ID80		73	3.44	(2.37, 4.99)
		Live Virus nAb ID50	D29 vs. Baseline	73	2.37	(1.99, 2.81)
		Live Virus nAb ID80		73	3.86	(3.57, 4.16)
		Anti-Spike IgG		33	44620.28	(22011.74, 90450.34)
		Anti-RBD IgG		33	27559.22	(13534.57, 56116.34)
		Pseudo nAb ID50		33	115.15	(25.20, 526.18)
		Pseudo nAb ID80		33	52.18	(11.76, 231.62)
		Live Virus nAb ID50		33	239.92	(113.79, 505.86)
		Live Virus nAb ID80		33	121.39	(74.31, 198.31)
		Anti-Spike IgG	D57 vs. Baseline	33	2357816.68	(1004834.79, 5532550.75)
		Anti-RBD IgG		33	2348445.30	(1039145.95, 5307430.91)
		Pseudo nAb ID50		33	2920.61	(924.25, 9229.07)
		Pseudo nAb ID80		33	774.36	(158.52, 3782.62)
		Live Virus nAb ID50	D57 vs. D29	33	6161.61	(3207.26, 11837.32)
		Live Virus nAb ID80		33	2030.39	(632.54, 6517.38)
		Anti-Spike IgG		33	52.84	(43.27, 64.54)
		Anti-RBD IgG		33	85.21	(76.05, 95.48)
		Pseudo nAb ID50		33	25.36	(16.97, 37.90)
		Pseudo nAb ID80		33	14.84	(13.48, 16.34)
		Live Virus nAb ID50		33	25.68	(20.67, 31.91)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Black or African American	Negative	Live Virus nAb ID80		33	16.73	(8.51, 32.86)
		Anti-Spike IgG	D29 vs. Baseline	242	657.05	(384.13, 1123.87)
		Anti-RBD IgG		242	321.48	(211.62, 488.37)
		Pseudo nAb ID50		242	22.55	(15.80, 32.19)
		Pseudo nAb ID80		242	12.33	(8.67, 17.53)
		Live Virus nAb ID50		242	22.64	(16.57, 30.94)
		Live Virus nAb ID80		242	15.63	(12.27, 19.92)
		Anti-Spike IgG	D57 vs. Baseline	242	7322.73	(3657.47, 14661.05)
		Anti-RBD IgG		242	3453.45	(2342.17, 5091.98)
		Pseudo nAb ID50		242	122.29	(80.11, 186.69)
		Pseudo nAb ID80		242	88.92	(60.10, 131.54)
		Live Virus nAb ID50		242	105.70	(77.87, 143.46)
		Live Virus nAb ID80		242	70.76	(53.61, 93.40)
		Anti-Spike IgG	D57 vs. D29	242	11.14	(8.92, 13.92)
		Anti-RBD IgG		242	10.74	(9.97, 11.57)
		Pseudo nAb ID50		242	5.42	(5.04, 5.83)
		Pseudo nAb ID80		242	7.21	(6.54, 7.95)
		Live Virus nAb ID50		242	4.67	(3.56, 6.12)
		Live Virus nAb ID80		242	4.53	(3.69, 5.56)
	Positive	Anti-Spike IgG	D29 vs. Baseline	101	35833.01	(25300.17, 50750.83)
		Anti-RBD IgG		101	18518.30	(12073.58, 28403.14)
		Pseudo nAb ID50		101	173.08	(107.03, 279.90)
		Pseudo nAb ID80		101	74.16	(43.29, 127.03)
		Live Virus nAb ID50		101	199.89	(156.06, 256.02)
		Live Virus nAb ID80		101	104.76	(86.43, 126.98)
		Anti-Spike IgG	D57 vs. Baseline	101	2151392.53	(1282694.42, 3608411.90)
		Anti-RBD IgG		101	1258054.53	(858480.59, 1843607.44)
		Pseudo nAb ID50		101	3007.79	(2005.16, 4511.78)
		Pseudo nAb ID80		101	1245.79	(743.28, 2088.02)
		Live Virus nAb ID50		101	3044.34	(2144.00, 4322.78)
		Live Virus nAb ID80		101	1368.67	(1042.92, 1796.18)
		Anti-Spike IgG	D57 vs. D29	101	60.04	(49.12, 73.39)
		Anti-RBD IgG		101	67.94	(59.51, 77.55)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Multiracial	Negative	Pseudo nAb ID50	D29 vs. Baseline	101	17.38	(12.15, 24.86)
		Pseudo nAb ID80		101	16.80	(9.57, 29.49)
		Live Virus nAb ID50		101	15.23	(13.54, 17.13)
		Live Virus nAb ID80		101	13.07	(10.59, 16.13)
		Anti-Spike IgG		64	51.30	(4.89, 537.68)
		Anti-RBD IgG		64	24.30	(2.72, 217.06)
		Pseudo nAb ID50		64	7.87	(2.87, 21.63)
		Pseudo nAb ID80		64	5.45	(2.27, 13.08)
		Live Virus nAb ID50		64	10.02	(4.20, 23.93)
		Live Virus nAb ID80		64	9.99	(5.65, 17.67)
		Anti-Spike IgG	D57 vs. Baseline	64	240.75	(11.38, 5091.36)
		Anti-RBD IgG		64	234.79	(18.40, 2995.19)
		Pseudo nAb ID50		64	24.67	(4.30, 141.60)
		Pseudo nAb ID80		64	20.22	(5.77, 70.87)
		Live Virus nAb ID50		64	10.69	(2.11, 54.07)
		Live Virus nAb ID80		64	13.48	(3.43, 53.02)
		Anti-Spike IgG	D57 vs. D29	64	4.69	(2.30, 9.58)
		Anti-RBD IgG		64	9.66	(6.72, 13.90)
		Pseudo nAb ID50		64	3.13	(1.49, 6.57)
		Pseudo nAb ID80		64	3.71	(2.54, 5.42)
		Live Virus nAb ID50		64	1.07	(0.49, 2.32)
		Live Virus nAb ID80		64	1.35	(0.59, 3.08)
	Positive	Anti-Spike IgG	D29 vs. Baseline	31	51552.48	(26634.20, 99783.69)
		Anti-RBD IgG		31	13896.76	(6318.90, 30562.25)
		Pseudo nAb ID50		31	347.82	(174.72, 692.43)
		Pseudo nAb ID80		31	135.40	(69.81, 262.61)
		Live Virus nAb ID50		31	416.71	(294.73, 589.19)
		Live Virus nAb ID80		31	113.89	(79.13, 163.94)
		Anti-Spike IgG	D57 vs. Baseline	31	3301044.90	(1576729.50, 6911075.99)
		Anti-RBD IgG		31	1088967.59	(573106.50, 2069162.39)
		Pseudo nAb ID50		31	8512.90	(2619.74, 27662.80)
		Pseudo nAb ID80		31	1611.45	(677.57, 3832.50)
		Live Virus nAb ID50		31	2720.43	(1296.32, 5709.00)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Native Hawaiian or Other Pacific Islander	Negative	Live Virus nAb ID80	D57 vs. D29	31	2543.95	(1214.84, 5327.19)
		Anti-Spike IgG		31	64.03	(52.36, 78.31)
		Anti-RBD IgG		31	78.36	(67.70, 90.70)
		Pseudo nAb ID50		31	24.47	(9.03, 66.35)
		Pseudo nAb ID80		31	11.90	(7.51, 18.85)
		Live Virus nAb ID50		31	6.53	(3.75, 11.38)
		Live Virus nAb ID80	D29 vs. Baseline	31	22.34	(9.13, 54.62)
		Anti-Spike IgG		11	138.69	(4.62, 4165.43)
		Anti-RBD IgG		11	62.86	(0.99, 3978.30)
		Pseudo nAb ID50		11	13.92	(2.28, 85.05)
		Pseudo nAb ID80		11	10.93	(1.87, 63.83)
		Live Virus nAb ID50		11	10.87	(3.06, 38.59)
		Live Virus nAb ID80	D57 vs. Baseline	11	11.43	(3.55, 36.82)
		Anti-Spike IgG		11	657.87	(6.03, 71815.85)
		Anti-RBD IgG		11	85.57	(0.23, 32151.90)
		Pseudo nAb ID50		11	8.78	(0.44, 174.52)
		Pseudo nAb ID80		11	13.73	(0.95, 198.48)
		Live Virus nAb ID50		11	31.28	(2.22, 441.24)
		Live Virus nAb ID80	D57 vs. D29	11	21.77	(1.65, 287.94)
		Anti-Spike IgG		11	4.74	(1.30, 17.24)
		Anti-RBD IgG		11	1.36	(0.23, 8.09)
		Pseudo nAb ID50		11	0.63	(0.19, 2.08)
		Pseudo nAb ID80		11	1.26	(0.50, 3.18)
		Live Virus nAb ID50		11	2.88	(0.72, 11.44)
	Positive	Live Virus nAb ID80	D29 vs. Baseline	11	1.90	(0.46, 7.83)
		Anti-Spike IgG		7	27058.25	(10242.87, 71478.88)
		Anti-RBD IgG		7	8902.73	(3126.01, 25354.55)
		Pseudo nAb ID50		7	71.45	(38.84, 131.43)
		Pseudo nAb ID80		7	45.82	(21.23, 98.87)
		Live Virus nAb ID50		7	113.78	(65.57, 197.42)
		Live Virus nAb ID80	D57 vs. Baseline	7	39.66	(14.24, 110.50)
		Anti-Spike IgG		7	2221189.32	(745917.26, 6614248.33)
		Anti-RBD IgG		7	1018984.77	(315444.51, 3291640.63)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Not reported and unknown	Negative	Pseudo nAb ID50	D57 vs. D29	7	783.75	(165.27, 3716.68)
		Pseudo nAb ID80		7	225.30	(91.92, 552.21)
		Live Virus nAb ID50		7	1850.92	(862.16, 3973.66)
		Live Virus nAb ID80		7	566.73	(196.99, 1630.44)
		Anti-Spike IgG		7	82.09	(54.06, 124.65)
		Anti-RBD IgG		7	114.46	(62.35, 210.12)
		Pseudo nAb ID50		7	10.97	(3.31, 36.34)
		Pseudo nAb ID80		7	4.92	(3.87, 6.24)
		Live Virus nAb ID50		7	16.27	(10.33, 25.63)
		Live Virus nAb ID80		7	14.29	(9.06, 22.54)
		Anti-Spike IgG	D29 vs. Baseline	115	148.04	(124.26, 176.37)
		Anti-RBD IgG		115	66.02	(37.25, 117.01)
		Pseudo nAb ID50		115	12.01	(10.11, 14.26)
		Pseudo nAb ID80		115	8.67	(6.91, 10.88)
		Live Virus nAb ID50		115	10.79	(9.57, 12.17)
		Live Virus nAb ID80		115	10.30	(8.93, 11.89)
		Anti-Spike IgG		115	898.80	(666.66, 1211.78)
		Anti-RBD IgG		115	418.47	(255.82, 684.51)
		Pseudo nAb ID50		115	44.02	(29.03, 66.73)
		Pseudo nAb ID80		115	27.55	(19.82, 38.28)
		Live Virus nAb ID50		115	36.98	(24.97, 54.78)
		Live Virus nAb ID80		115	41.53	(30.26, 57.01)
		Anti-Spike IgG	D57 vs. D29	115	6.07	(4.74, 7.78)
		Anti-RBD IgG		115	6.34	(4.94, 8.14)
		Pseudo nAb ID50		115	3.66	(2.65, 5.06)
		Pseudo nAb ID80		115	3.18	(2.65, 3.82)
		Live Virus nAb ID50		115	3.43	(2.57, 4.56)
		Live Virus nAb ID80		115	4.03	(3.37, 4.82)
	Positive	Anti-Spike IgG	D29 vs. Baseline	57	48749.55	(26749.73, 88842.73)
		Anti-RBD IgG		57	23701.00	(13018.25, 43150.00)
		Pseudo nAb ID50		57	180.05	(99.26, 326.62)
		Pseudo nAb ID80		57	74.36	(43.47, 127.20)
		Live Virus nAb ID50		57	239.23	(179.33, 319.12)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Other		Live Virus nAb ID80	D57 vs. Baseline	57	139.60	(109.50, 177.99)
		Anti-Spike IgG		57	3199218.96	(1714305.45, 5970349.08)
		Anti-RBD IgG		57	1637735.79	(1036186.91, 2588508.42)
		Pseudo nAb ID50		57	5031.17	(3197.21, 7917.10)
		Pseudo nAb ID80	D57 vs. D29	57	2181.14	(1777.54, 2676.39)
		Live Virus nAb ID50		57	5182.98	(3919.19, 6854.29)
		Live Virus nAb ID80		57	3107.90	(2493.77, 3873.26)
		Anti-Spike IgG		57	65.63	(57.88, 74.40)
		Anti-RBD IgG	D29 vs. Baseline	57	69.10	(54.76, 87.20)
		Pseudo nAb ID50		57	27.94	(24.10, 32.40)
		Pseudo nAb ID80		57	29.33	(20.80, 41.37)
		Live Virus nAb ID50		57	21.67	(20.39, 23.02)
	Negative	Live Virus nAb ID80	D57 vs. Baseline	57	22.26	(18.96, 26.13)
		Anti-Spike IgG		23	9991.61	(2639.48, 37822.72)
		Anti-RBD IgG		23	5525.63	(1101.46, 27720.22)
		Pseudo nAb ID50		23	184.62	(52.91, 644.22)
		Pseudo nAb ID80	D57 vs. Baseline	23	86.50	(41.20, 181.60)
		Live Virus nAb ID50		23	110.26	(54.39, 223.55)
		Live Virus nAb ID80		23	55.52	(31.38, 98.24)
		Anti-Spike IgG		23	354735.73	(37240.06, 3379087.78)
		Anti-RBD IgG	D57 vs. D29	23	262653.16	(15807.86, 4364075.78)
		Pseudo nAb ID50		23	1609.92	(271.31, 9553.13)
		Pseudo nAb ID80		23	1072.56	(160.30, 7176.54)
		Live Virus nAb ID50		23	951.29	(507.51, 1783.12)
	Positive	Live Virus nAb ID80	D29 vs. Baseline	23	701.25	(325.09, 1512.66)
		Anti-Spike IgG		23	35.50	(14.11, 89.35)
		Anti-RBD IgG		23	47.53	(14.09, 160.31)
		Pseudo nAb ID50		23	8.72	(5.11, 14.89)
		Pseudo nAb ID80	D57 vs. Baseline	23	12.40	(3.89, 39.52)
		Live Virus nAb ID50		23	8.63	(7.17, 10.38)
		Live Virus nAb ID80		23	12.63	(10.35, 15.41)
		Anti-Spike IgG		14	44715.20	(35591.33, 56177.99)
		Anti-RBD IgG		14	12342.73	(10044.31, 15167.09)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
White		Pseudo nAb ID50	D57 vs. Baseline	14	97.33	(67.86, 139.60)
		Pseudo nAb ID80		14	31.06	(17.30, 55.74)
		Live Virus nAb ID50		14	172.84	(151.56, 197.12)
		Live Virus nAb ID80		14	129.91	(123.71, 136.42)
		Anti-Spike IgG		14	2233289.66	(1496368.55, 3333124.52)
		Anti-RBD IgG		14	974096.13	(780949.27, 1215012.69)
		Pseudo nAb ID50		14	2407.37	(1387.66, 4176.41)
		Pseudo nAb ID80		14	291.45	(127.16, 668.00)
		Live Virus nAb ID50		14	1396.73	(892.33, 2186.24)
		Live Virus nAb ID80		14	431.93	(224.79, 829.92)
		Anti-Spike IgG	D57 vs. D29	14	49.94	(41.96, 59.45)
		Anti-RBD IgG		14	78.92	(69.51, 89.61)
		Pseudo nAb ID50		14	24.73	(13.57, 45.08)
		Pseudo nAb ID80		14	9.38	(5.14, 17.15)
		Live Virus nAb ID50	D29 vs. Baseline	14	8.08	(4.99, 13.09)
		Live Virus nAb ID80		14	3.32	(1.75, 6.33)
	Negative	Anti-Spike IgG		55	273.50	(101.43, 737.47)
		Anti-RBD IgG		55	379.41	(216.77, 664.06)
		Pseudo nAb ID50		55	11.64	(4.23, 32.05)
		Pseudo nAb ID80		55	11.74	(6.36, 21.66)
		Live Virus nAb ID50		55	19.60	(16.56, 23.20)
		Live Virus nAb ID80		55	15.86	(10.49, 23.96)
		Anti-Spike IgG	D57 vs. Baseline	55	2706.36	(1252.22, 5849.13)
		Anti-RBD IgG		55	2335.33	(987.03, 5525.44)
		Pseudo nAb ID50		55	72.44	(32.87, 159.66)
		Pseudo nAb ID80		55	85.99	(53.01, 139.47)
		Live Virus nAb ID50	D57 vs. D29	55	96.38	(61.31, 151.53)
		Live Virus nAb ID80		55	74.85	(45.94, 121.95)
		Anti-Spike IgG		55	9.90	(7.35, 13.32)
		Anti-RBD IgG		55	6.16	(4.55, 8.33)
		Pseudo nAb ID50		55	6.23	(3.44, 11.26)
		Pseudo nAb ID80		55	7.32	(4.64, 11.57)
		Live Virus nAb ID50		55	4.92	(3.46, 6.99)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
White Non-Hispanic	Positive	Live Virus nAb ID80	D29 vs. Baseline	55	4.72	(3.85, 5.79)
		Anti-Spike IgG		29	39648.38	(26077.11, 60282.54)
		Anti-RBD IgG		29	16825.64	(4484.72, 63125.95)
		Pseudo nAb ID50		29	279.40	(149.50, 522.16)
		Pseudo nAb ID80		29	128.69	(76.74, 215.79)
		Live Virus nAb ID50	D57 vs. Baseline	29	211.30	(127.62, 349.83)
		Live Virus nAb ID80		29	108.82	(60.67, 195.18)
		Anti-Spike IgG		29	1982338.44	(965814.13, 4068759.80)
		Anti-RBD IgG		29	973345.83	(218039.66, 4345090.85)
		Pseudo nAb ID50		29	6951.37	(4576.07, 10559.63)
		Pseudo nAb ID80	D57 vs. D29	29	1565.33	(545.10, 4495.07)
		Live Virus nAb ID50		29	3322.21	(1835.58, 6012.85)
		Live Virus nAb ID80		29	1328.07	(478.20, 3688.38)
		Anti-Spike IgG		29	50.00	(32.35, 77.28)
		Anti-RBD IgG		29	57.85	(48.56, 68.92)
	Negative	Pseudo nAb ID50	D29 vs. Baseline	29	24.88	(14.41, 42.94)
		Pseudo nAb ID80		29	12.16	(7.00, 21.14)
		Live Virus nAb ID50		29	15.72	(12.16, 20.32)
		Live Virus nAb ID80		29	12.20	(6.15, 24.22)
		Anti-Spike IgG	D57 vs. Baseline	437	296.59	(182.23, 482.72)
		Anti-RBD IgG		437	296.59	(182.23, 482.72)
		Pseudo nAb ID50		437	199.50	(117.59, 338.48)
		Pseudo nAb ID80		437	199.50	(117.59, 338.48)
		Live Virus nAb ID50		437	14.67	(9.59, 22.44)
		Live Virus nAb ID80	D57 vs. Baseline	437	14.67	(9.59, 22.44)
		Anti-Spike IgG		437	10.20	(6.78, 15.34)
		Anti-RBD IgG		437	10.20	(6.78, 15.34)
		Pseudo nAb ID50		437	15.18	(11.50, 20.04)
		Pseudo nAb ID80		437	15.18	(11.50, 20.04)
		Live Virus nAb ID50		437	11.22	(8.53, 14.75)
		Live Virus nAb ID80		437	11.22	(8.53, 14.75)
		Anti-Spike IgG		437	2216.21	(1101.03, 4460.92)
		Anti-RBD IgG		437	2216.21	(1101.03, 4460.92)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
		Anti-RBD IgG	D57 vs. D29	437	1440.93	(709.69, 2925.61)
					1440.93	(709.69, 2925.61)
		Pseudo nAb ID50		437	57.22	(36.62, 89.39)
					57.22	(36.62, 89.39)
		Pseudo nAb ID80		437	43.43	(27.31, 69.05)
					43.43	(27.31, 69.05)
		Live Virus nAb ID50		437	76.39	(57.87, 100.84)
					76.39	(57.87, 100.84)
		Live Virus nAb ID80		437	47.82	(36.40, 62.80)
					47.82	(36.40, 62.80)
		Anti-Spike IgG		437	7.47	(5.85, 9.54)
					7.47	(5.85, 9.54)
		Anti-RBD IgG		437	7.22	(5.83, 8.95)
					7.22	(5.83, 8.95)
		Pseudo nAb ID50		437	3.90	(3.78, 4.03)
					3.90	(3.78, 4.03)
		Pseudo nAb ID80		437	4.26	(3.95, 4.59)
					4.26	(3.95, 4.59)
		Live Virus nAb ID50		437	5.03	(4.69, 5.40)
					5.03	(4.69, 5.40)
		Live Virus nAb ID80		437	4.26	(3.63, 5.00)
					4.26	(3.63, 5.00)
Minority	Positive	Anti-Spike IgG	D29 vs. Baseline	230	37887.22	(21712.13, 66112.40)
					37887.22	(21712.13, 66112.40)
		Anti-RBD IgG		230	20870.00	(12518.76, 34792.35)
					20870.00	(12518.76, 34792.35)
		Pseudo nAb ID50		230	263.15	(154.92, 446.97)
					263.15	(154.92, 446.97)
		Pseudo nAb ID80		230	107.85	(64.36, 180.73)
					107.85	(64.36, 180.73)
		Live Virus nAb ID50		230	204.53	(135.68, 308.30)
					204.53	(135.68, 308.30)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Communities of Color		Live Virus nAb ID80		230	103.06	(66.81, 158.99)
					103.06	(66.81, 158.99)
		Anti-Spike IgG	D57 vs. Baseline	230	2590873.29	(1459247.63, 4600058.46)
					2590873.29	(1459247.63, 4600058.46)
		Anti-RBD IgG		230	1168852.32	(672677.59, 2031011.27)
					1168852.32	(672677.59, 2031011.27)
		Pseudo nAb ID50		230	4622.33	(2507.27, 8521.59)
					4622.33	(2507.27, 8521.59)
		Pseudo nAb ID80		230	2010.66	(1161.26, 3481.35)
					2010.66	(1161.26, 3481.35)
		Live Virus nAb ID50		230	3618.02	(2541.93, 5149.65)
					3618.02	(2541.93, 5149.65)
		Live Virus nAb ID80		230	2126.22	(1411.09, 3203.78)
					2126.22	(1411.09, 3203.78)
		Anti-Spike IgG	D57 vs. D29	230	68.38	(63.69, 73.43)
					68.38	(63.69, 73.43)
		Anti-RBD IgG		230	56.01	(50.63, 61.96)
					56.01	(50.63, 61.96)
		Pseudo nAb ID50		230	17.57	(15.65, 19.71)
					17.57	(15.65, 19.71)
		Pseudo nAb ID80		230	18.64	(15.61, 22.27)
					18.64	(15.61, 22.27)
		Live Virus nAb ID50		230	17.69	(16.50, 18.97)
					17.69	(16.50, 18.97)
		Live Virus nAb ID80		230	20.63	(16.42, 25.93)
					20.63	(16.42, 25.93)
	Negative	Anti-Spike IgG	D29 vs. Baseline	557	277.62	(231.85, 332.42)
		Anti-RBD IgG		557	140.86	(100.71, 197.01)
		Pseudo nAb ID50		557	15.03	(12.78, 17.69)
		Pseudo nAb ID80		557	9.61	(7.82, 11.82)
		Live Virus nAb ID50		557	16.00	(14.38, 17.80)
		Live Virus nAb ID80		557	12.80	(10.97, 14.94)
		Anti-Spike IgG	D57 vs. Baseline	557	2084.36	(1721.51, 2523.68)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age, Minority Age < 65 Communities of Color	Positive	Anti-RBD IgG	D57 vs. D29	557	1194.71	(995.41, 1433.93)
		Pseudo nAb ID50		557	63.48	(51.77, 77.84)
		Pseudo nAb ID80		557	46.12	(35.78, 59.47)
		Live Virus nAb ID50		557	52.26	(41.78, 65.37)
		Live Virus nAb ID80		557	47.20	(41.10, 54.21)
		Anti-Spike IgG		557	7.51	(6.52, 8.65)
		Anti-RBD IgG		557	8.48	(7.28, 9.89)
		Pseudo nAb ID50		557	4.22	(3.71, 4.80)
		Pseudo nAb ID80		557	4.80	(4.39, 5.25)
		Live Virus nAb ID50		557	3.27	(2.69, 3.97)
		Live Virus nAb ID80		557	3.69	(3.26, 4.17)
		Anti-Spike IgG	D29 vs. Baseline	251	41726.89	(26332.53, 66120.99)
		Anti-RBD IgG		251	19643.48	(12050.36, 32021.13)
		Pseudo nAb ID50		251	178.18	(101.10, 314.05)
		Pseudo nAb ID80		251	75.14	(41.96, 134.57)
		Live Virus nAb ID50		251	228.95	(175.65, 298.42)
		Live Virus nAb ID80		251	117.10	(93.18, 147.17)
		Anti-Spike IgG	D57 vs. Baseline	251	2477475.00	(1424883.81, 4307637.12)
		Anti-RBD IgG		251	1400471.60	(894518.32, 2192599.82)
		Pseudo nAb ID50		251	3834.23	(2505.01, 5868.75)
		Pseudo nAb ID80		251	1294.90	(767.49, 2184.76)
		Live Virus nAb ID50		251	3530.68	(2403.67, 5186.10)
		Live Virus nAb ID80		251	1683.46	(1253.02, 2261.77)
		Anti-Spike IgG	D57 vs. D29	251	59.37	(54.08, 65.18)
		Anti-RBD IgG		251	71.29	(64.42, 78.90)
		Pseudo nAb ID50		251	21.52	(14.96, 30.95)
		Pseudo nAb ID80		251	17.23	(13.58, 21.87)
		Live Virus nAb ID50		251	15.42	(13.63, 17.44)
		Live Virus nAb ID80		251	14.38	(13.41, 15.41)
	Negative	Anti-Spike IgG	D29 vs. Baseline	259	258.36	(228.46, 292.17)
		Anti-RBD IgG		259	124.30	(119.07, 129.75)
		Pseudo nAb ID50		259	14.18	(12.17, 16.51)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Positive		Pseudo nAb ID80	D57 vs. Baseline	259	8.83	(7.92, 9.86)
		Live Virus nAb ID50		259	15.51	(13.72, 17.54)
		Live Virus nAb ID80		259	12.48	(10.25, 15.19)
		Anti-Spike IgG		259	1999.47	(1576.60, 2535.75)
		Anti-RBD IgG		259	1117.09	(1084.49, 1150.66)
		Pseudo nAb ID50		259	58.46	(56.30, 60.71)
		Pseudo nAb ID80		259	41.68	(40.41, 42.98)
		Live Virus nAb ID50		259	47.81	(46.82, 48.83)
		Live Virus nAb ID80		259	44.71	(40.32, 49.57)
		Anti-Spike IgG	D57 vs. D29	259	7.74	(6.90, 8.68)
		Anti-RBD IgG		259	8.99	(8.87, 9.11)
		Pseudo nAb ID50		259	4.12	(3.68, 4.63)
		Pseudo nAb ID80		259	4.72	(4.36, 5.10)
		Live Virus nAb ID50	D29 vs. Baseline	259	3.08	(2.78, 3.41)
		Live Virus nAb ID80		259	3.58	(3.26, 3.93)
		Anti-Spike IgG		148	35007.62	(32158.82, 38108.79)
		Anti-RBD IgG		148	16403.46	(16248.37, 16560.03)
		Pseudo nAb ID50		148	147.33	(128.82, 168.50)
		Pseudo nAb ID80		148	62.30	(51.78, 74.96)
		Live Virus nAb ID50		148	207.07	(199.22, 215.23)
		Live Virus nAb ID80		148	107.45	(104.82, 110.14)
		Anti-Spike IgG	D57 vs. Baseline	148	2004934.86	(1787829.40, 2248404.58)
		Anti-RBD IgG		148	1178669.92	(1050887.93, 1321989.47)
		Pseudo nAb ID50	D57 vs. D29	148	3260.25	(2556.15, 4158.31)
		Pseudo nAb ID80		148	1060.76	(964.15, 1167.04)
		Live Virus nAb ID50		148	3062.19	(3022.65, 3102.26)
		Live Virus nAb ID80		148	1509.52	(1498.85, 1520.26)
		Anti-Spike IgG		148	57.27	(55.59, 59.00)
		Anti-RBD IgG		148	71.85	(64.68, 79.83)
		Pseudo nAb ID50		148	22.13	(15.17, 32.28)
		Pseudo nAb ID80		148	17.03	(12.86, 22.54)
		Live Virus nAb ID50		148	14.79	(14.41, 15.17)
		Live Virus nAb ID80		148	14.05	(13.80, 14.30)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age < 65 White Non-Hispanic	Negative	Anti-Spike IgG	D29 vs. Baseline	216	279.91	(153.31, 511.03)
		Anti-RBD IgG		216	187.27	(97.43, 359.93)
		Pseudo nAb ID50		216	13.04	(8.13, 20.92)
		Pseudo nAb ID80		216	9.31	(5.73, 15.12)
		Live Virus nAb ID50		216	13.96	(10.39, 18.74)
		Live Virus nAb ID80		216	10.10	(8.35, 12.21)
		Anti-Spike IgG	D57 vs. Baseline	216	2158.00	(928.42, 5016.01)
		Anti-RBD IgG		216	1396.38	(592.76, 3289.47)
		Pseudo nAb ID50		216	50.93	(30.61, 84.73)
		Pseudo nAb ID80		216	38.49	(22.66, 65.38)
		Live Virus nAb ID50		216	71.74	(51.61, 99.71)
		Live Virus nAb ID80		216	44.58	(32.60, 60.95)
		Anti-Spike IgG	D57 vs. D29	216	7.71	(6.06, 9.82)
		Anti-RBD IgG		216	7.46	(6.08, 9.14)
		Pseudo nAb ID50		216	3.91	(3.77, 4.05)
		Pseudo nAb ID80		216	4.13	(3.95, 4.32)
		Live Virus nAb ID50		216	5.14	(4.97, 5.32)
		Live Virus nAb ID80		216	4.41	(3.90, 4.99)
	Positive	Anti-Spike IgG	D29 vs. Baseline	128	30537.78	(27564.21, 33832.15)
		Anti-RBD IgG		128	17068.62	(14057.67, 20724.48)
		Pseudo nAb ID50		128	218.13	(138.47, 343.62)
		Pseudo nAb ID80		128	90.20	(56.80, 143.24)
		Live Virus nAb ID50		128	174.04	(146.48, 206.78)
		Live Virus nAb ID80		128	87.12	(80.22, 94.62)
		Anti-Spike IgG	D57 vs. Baseline	128	2067749.38	(1711151.50, 2498661.00)
		Anti-RBD IgG		128	943980.04	(857658.53, 1038989.62)
		Pseudo nAb ID50		128	3786.13	(2088.45, 6863.84)
		Pseudo nAb ID80		128	1624.89	(1182.64, 2232.53)
		Live Virus nAb ID50		128	3150.30	(2835.72, 3499.76)
		Live Virus nAb ID80		128	1829.86	(1323.97, 2529.05)
		Anti-Spike IgG	D57 vs. D29	128	67.71	(62.08, 73.85)
		Anti-RBD IgG		128	55.30	(50.13, 61.01)
		Pseudo nAb ID50		128	17.36	(15.08, 19.98)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age >= 65 Communities of Color	Negative	Pseudo nAb ID80	D29 vs. Baseline	128	18.01	(15.59, 20.82)
		Live Virus nAb ID50		128	18.10	(16.93, 19.36)
		Live Virus nAb ID80		128	21.00	(16.50, 26.73)
		Anti-Spike IgG		298	393.27	(393.27, 393.27)
		Anti-RBD IgG		298	258.18	(258.18, 258.18)
		Pseudo nAb ID50		298	19.99	(19.99, 19.99)
		Pseudo nAb ID80		298	14.47	(14.47, 14.47)
		Live Virus nAb ID50		298	18.58	(18.58, 18.58)
		Live Virus nAb ID80		298	14.49	(14.49, 14.49)
		Anti-Spike IgG	D57 vs. Baseline	298	2549.40	(2549.40, 2549.40)
		Anti-RBD IgG		298	1654.18	(1654.18, 1654.18)
		Pseudo nAb ID50		298	94.55	(94.55, 94.55)
		Pseudo nAb ID80	D57 vs. D29	298	75.37	(75.37, 75.37)
		Live Virus nAb ID50		298	80.36	(80.36, 80.36)
		Live Virus nAb ID80		298	61.42	(61.42, 61.42)
		Anti-Spike IgG		298	6.48	(6.48, 6.48)
		Anti-RBD IgG		298	6.41	(6.41, 6.41)
		Pseudo nAb ID50		298	4.73	(4.73, 4.73)
		Pseudo nAb ID80		298	5.21	(5.21, 5.21)
		Live Virus nAb ID50		298	4.33	(4.33, 4.33)
		Live Virus nAb ID80		298	4.24	(4.24, 4.24)
	Positive	Anti-Spike IgG	D29 vs. Baseline	103	149890.68	(149890.68, 149890.68)
		Anti-RBD IgG		103	73005.96	(73005.96, 73005.96)
		Pseudo nAb ID50		103	711.73	(711.73, 711.73)
		Pseudo nAb ID80	D57 vs. Baseline	103	293.96	(293.96, 293.96)
		Live Virus nAb ID50		103	475.89	(475.89, 475.89)
		Live Virus nAb ID80		103	219.14	(219.14, 219.14)
		Anti-Spike IgG		103	11571484.34	(11571484.34, 11571484.34)
		Anti-RBD IgG		103	4916385.58	(4916385.58, 4916385.58)
		Pseudo nAb ID50		103	12491.01	(12491.01, 12491.01)
		Pseudo nAb ID80		103	5534.85	(5534.85, 5534.85)
		Live Virus nAb ID50		103	9957.17	(9957.17, 9957.17)
		Live Virus nAb ID80		103	3725.27	(3725.27, 3725.27)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
Age \geq 65 White Non-Hispanic	Negative	Anti-Spike IgG	D57 vs. D29	103	77.20	(77.20, 77.20)
		Anti-RBD IgG		103	67.34	(67.34, 67.34)
		Pseudo nAb ID50		103	17.55	(17.55, 17.55)
		Pseudo nAb ID80		103	18.83	(18.83, 18.83)
		Live Virus nAb ID50		103	20.92	(20.92, 20.92)
		Live Virus nAb ID80		103	17.00	(17.00, 17.00)
		Anti-Spike IgG	D29 vs. Baseline	221	413.49	(413.49, 413.49)
		Anti-RBD IgG		221	286.85	(286.85, 286.85)
		Pseudo nAb ID50		221	28.86	(28.86, 28.86)
		Pseudo nAb ID80		221	17.22	(17.22, 17.22)
		Live Virus nAb ID50		221	24.55	(24.55, 24.55)
		Live Virus nAb ID80		221	20.51	(20.51, 20.51)
		Anti-Spike IgG	D57 vs. Baseline	221	2581.95	(2581.95, 2581.95)
		Anti-RBD IgG		221	1725.43	(1725.43, 1725.43)
		Pseudo nAb ID50		221	111.63	(111.63, 111.63)
	Positive	Pseudo nAb ID80		221	86.76	(86.76, 86.76)
		Live Virus nAb ID50		221	109.59	(109.59, 109.59)
		Live Virus nAb ID80		221	71.48	(71.48, 71.48)
		Anti-Spike IgG	D57 vs. D29	221	6.24	(6.24, 6.24)
		Anti-RBD IgG		221	6.02	(6.02, 6.02)
		Pseudo nAb ID50		221	3.87	(3.87, 3.87)
		Pseudo nAb ID80		221	5.04	(5.04, 5.04)
		Live Virus nAb ID50		221	4.46	(4.46, 4.46)
		Live Virus nAb ID80		221	3.48	(3.48, 3.48)
		Anti-Spike IgG	D29 vs. Baseline	102	150012.34	(150012.34, 150012.34)
		Anti-RBD IgG		102	75293.22	(75293.22, 75293.22)
		Pseudo nAb ID50		102	871.29	(871.29, 871.29)
		Pseudo nAb ID80		102	337.33	(337.33, 337.33)
		Live Virus nAb ID50		102	572.93	(572.93, 572.93)
		Live Virus nAb ID80		102	301.20	(301.20, 301.20)
		Anti-Spike IgG	D57 vs. Baseline	102	10926361.44	(10926361.44, 10926361.44)
		Anti-RBD IgG		102	4570003.81	(4570003.81, 4570003.81)
		Pseudo nAb ID50		102	16515.39	(16515.39, 16515.39)

Table 3: Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination (*continued*)

Group	Baseline	Endpoint	Visits	N	GMTR/GMCR	95% CI
		Pseudo nAb ID80		102	7828.63	(7828.63, 7828.63)
		Live Virus nAb ID50		102	8751.96	(8751.96, 8751.96)
		Live Virus nAb ID80		102	5541.16	(5541.16, 5541.16)
		Anti-Spike IgG	D57 vs. D29	102	72.84	(72.84, 72.84)
		Anti-RBD IgG		102	60.70	(60.70, 60.70)
		Pseudo nAb ID50		102	18.96	(18.96, 18.96)
		Pseudo nAb ID80		102	23.21	(23.21, 23.21)
		Live Virus nAb ID50		102	15.28	(15.28, 15.28)
		Live Virus nAb ID80		102	18.40	(18.40, 18.40)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 3. Ratios of GMTs/GMCs between the vaccine arm vs. placebo arm, by baseline status

Table 4: Ratios of GMTs/GMCs between the vaccine arm vs. placebo arm, by baseline status

Baseline	Visit	Endpoint	N	Ratios of GMT/GMC	95% CI
Negative	D1	Anti-Spike IgG	1089	1.00	(1.00, 1.00)
		Anti-RBD IgG	1089	1.00	(1.00, 1.00)
		Pseudo nAb ID50	1089	1.00	(1.00, 1.00)
		Pseudo nAb ID80	1089	1.00	(1.00, 1.00)
		Live Virus nAb ID50	1089	1.00	(1.00, 1.00)
		Live Virus nAb ID80	1089	1.00	(1.00, 1.00)
	D29	Anti-Spike IgG	1089	2563.24	(2287.33, 2872.43)
		Anti-RBD IgG	1089	1421.62	(1247.48, 1620.07)
		Pseudo nAb ID50	1089	9.85	(8.53, 11.37)
		Pseudo nAb ID80	1089	5.27	(4.61, 6.01)
		Live Virus nAb ID50	1089	9.58	(8.30, 11.04)
		Live Virus nAb ID80	1089	5.92	(5.18, 6.77)
	D57	Anti-Spike IgG	1089	137501.59	(121548.53, 155548.46)
		Anti-RBD IgG	1089	66646.13	(57467.55, 77290.68)
		Pseudo nAb ID50	1089	155.52	(129.05, 187.44)
		Pseudo nAb ID80	1089	90.39	(74.10, 110.25)
		Live Virus nAb ID50	1089	123.45	(102.80, 148.25)
		Live Virus nAb ID80	1089	79.16	(65.15, 96.19)
Positive	D1	Anti-Spike IgG	523	1.00	(1.00, 1.00)
		Anti-RBD IgG	523	1.00	(1.00, 1.00)
		Pseudo nAb ID50	523	1.00	(1.00, 1.00)
		Pseudo nAb ID80	523	1.00	(1.00, 1.00)
		Live Virus nAb ID50	523	1.00	(1.00, 1.00)
		Live Virus nAb ID80	523	1.00	(1.00, 1.00)
	D29	Anti-Spike IgG	523	3.56	(2.79, 4.56)
		Anti-RBD IgG	523	2.43	(1.85, 3.20)
		Pseudo nAb ID50	523	2.34	(1.74, 3.15)
		Pseudo nAb ID80	523	2.03	(1.54, 2.67)
		Live Virus nAb ID50	523	2.82	(2.11, 3.77)
		Live Virus nAb ID80	523	2.98	(2.26, 3.93)

Table 4: Ratios of GMTs/GMCs between the vaccine arm vs. placebo arm, by baseline status (*continued*)

Baseline	Visit	Endpoint	N	Ratios of GMT/GMC	95% CI
	D57	Anti-Spike IgG	523	6.60	(5.09, 8.55)
		Anti-RBD IgG	523	5.40	(4.03, 7.24)
		Pseudo nAb ID50	523	6.93	(4.72, 10.18)
		Pseudo nAb ID80	523	7.80	(5.31, 11.47)
		Live Virus nAb ID50	523	4.10	(2.82, 5.97)
		Live Virus nAb ID80	523	6.88	(4.77, 9.92)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 4. Ratios of GMTs/GMCs between baseline positive participants vs. negative participants, among the vaccinees

Table 5: Ratios of GMTs/GMCs between baseline positive participants vs. negative participants, among the vaccine recipients

Visit	Endpoint	N	Ratios of GMT/GMC	95% CI
D1	Anti-Spike IgG	1187	1.00	(1.00, 1.00)
	Anti-RBD IgG	1187	1.00	(1.00, 1.00)
	Pseudo nAb ID50	1187	1.00	(1.00, 1.00)
	Pseudo nAb ID80	1187	1.00	(1.00, 1.00)
	Live Virus nAb ID50	1187	1.00	(1.00, 1.00)
	Live Virus nAb ID80	1187	1.00	(1.00, 1.00)
D29	Anti-Spike IgG	1187	1.63	(1.26, 2.11)
	Anti-RBD IgG	1187	1.29	(0.96, 1.74)
	Pseudo nAb ID50	1187	1.54	(1.11, 2.13)
	Pseudo nAb ID80	1187	1.38	(1.02, 1.86)
	Live Virus nAb ID50	1187	1.67	(1.21, 2.31)
	Live Virus nAb ID80	1187	1.88	(1.38, 2.54)
D57	Anti-Spike IgG	1187	2.20	(1.67, 2.90)
	Anti-RBD IgG	1187	2.37	(1.70, 3.30)
	Pseudo nAb ID50	1187	2.87	(1.88, 4.37)
	Pseudo nAb ID80	1187	2.29	(1.46, 3.59)
	Live Virus nAb ID50	1187	2.30	(1.52, 3.49)
	Live Virus nAb ID80	1187	2.89	(1.87, 4.48)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 5. Ratios of GMTs/GMCs between demographic subgroups among the vaccine recipients

Table 6: Ratios of GMTs/GMCs between demographic subgroups among the vaccine recipients

Baseline	Visit	Group	Endpoint	N	Ratios of GMT/GMC	95% CI	
Negative	D1	Age	Anti-Spike IgG	924	1.00	(1.00, 1.00)	
			Anti-RBD IgG	924	1.00	(1.00, 1.00)	
			Pseudo nAb ID50	924	1.00	(1.00, 1.00)	
			Pseudo nAb ID80	924	1.00	(1.00, 1.00)	
			Live Virus nAb ID50	924	1.00	(1.00, 1.00)	
			Live Virus nAb ID80	924	1.00	(1.00, 1.00)	
	D29		Anti-Spike IgG	924	3.71	(2.97, 4.63)	
			Anti-RBD IgG	924	3.83	(2.95, 4.96)	
			Pseudo nAb ID50	924	3.17	(2.37, 4.24)	
			Pseudo nAb ID80	924	2.83	(2.16, 3.70)	
			Live Virus nAb ID50	924	2.13	(1.58, 2.85)	
			Live Virus nAb ID80	924	2.22	(1.69, 2.92)	
	D57		Anti-Spike IgG	924	2.82	(2.20, 3.61)	
			Anti-RBD IgG	924	3.29	(2.44, 4.45)	
			Pseudo nAb ID50	924	3.45	(2.36, 5.06)	
			Pseudo nAb ID80	924	3.40	(2.26, 5.11)	
			Live Virus nAb ID50	924	2.53	(1.73, 3.69)	
			Live Virus nAb ID80	924	2.61	(1.74, 3.90)	
	D1	Sex	Anti-Spike IgG	924	1.00	(1.00, 1.00)	
			Anti-RBD IgG	924	1.00	(1.00, 1.00)	
			Pseudo nAb ID50	924	1.00	(1.00, 1.00)	
			Pseudo nAb ID80	924	1.00	(1.00, 1.00)	
			Live Virus nAb ID50	924	1.00	(1.00, 1.00)	
			Live Virus nAb ID80	924	1.00	(1.00, 1.00)	
	D29		Anti-Spike IgG	924	1.08	(0.91, 1.29)	
			Anti-RBD IgG	924	1.08	(0.89, 1.32)	
			Pseudo nAb ID50	924	0.87	(0.70, 1.08)	
			Pseudo nAb ID80	924	0.98	(0.80, 1.20)	
			Live Virus nAb ID50	924	1.06	(0.85, 1.32)	
			Live Virus nAb ID80	924	1.11	(0.91, 1.36)	
	D57			Anti-Spike IgG	924	1.01	(0.84, 1.22)
				Anti-RBD IgG	924	1.14	(0.91, 1.42)

Table 6: Ratios of GMTs/GMCs between demographic subgroups
among the vaccine recipients (*continued*)

Baseline	Visit	Group	Endpoint	N	Ratios of GMT/GMC	95% CI
			Pseudo nAb ID50	924	1.02	(0.77, 1.36)
			Pseudo nAb ID80	924	1.11	(0.82, 1.50)
			Live Virus nAb ID50	924	1.15	(0.87, 1.52)
			Live Virus nAb ID80	924	1.10	(0.82, 1.48)
	D1	High Risk	Anti-Spike IgG	924	1.00	(1.00, 1.00)
			Anti-RBD IgG	924	1.00	(1.00, 1.00)
			Pseudo nAb ID50	924	1.00	(1.00, 1.00)
			Pseudo nAb ID80	924	1.00	(1.00, 1.00)
			Live Virus nAb ID50	924	1.00	(1.00, 1.00)
			Live Virus nAb ID80	924	1.00	(1.00, 1.00)
	D29		Anti-Spike IgG	924	0.77	(0.63, 0.93)
			Anti-RBD IgG	924	0.85	(0.68, 1.07)
			Pseudo nAb ID50	924	0.78	(0.61, 1.00)
			Pseudo nAb ID80	924	0.76	(0.61, 0.96)
			Live Virus nAb ID50	924	0.98	(0.76, 1.26)
			Live Virus nAb ID80	924	0.85	(0.67, 1.07)
	D57		Anti-Spike IgG	924	0.99	(0.80, 1.23)
			Anti-RBD IgG	924	0.90	(0.70, 1.17)
			Pseudo nAb ID50	924	0.93	(0.67, 1.28)
			Pseudo nAb ID80	924	0.84	(0.59, 1.18)
			Live Virus nAb ID50	924	0.83	(0.60, 1.14)
			Live Virus nAb ID80	924	0.71	(0.50, 0.99)
	D1	Ethnicity	Anti-Spike IgG	833	1.00	(1.00, 1.00)
			Anti-RBD IgG	833	1.00	(1.00, 1.00)
			Pseudo nAb ID50	833	1.00	(1.00, 1.00)
			Pseudo nAb ID80	833	1.00	(1.00, 1.00)
			Live Virus nAb ID50	833	1.00	(1.00, 1.00)
			Live Virus nAb ID80	833	1.00	(1.00, 1.00)
	D29		Anti-Spike IgG	833	0.96	(0.71, 1.28)
			Anti-RBD IgG	833	0.80	(0.57, 1.11)
			Pseudo nAb ID50	833	0.76	(0.53, 1.10)
			Pseudo nAb ID80	833	0.82	(0.59, 1.15)
			Live Virus nAb ID50	833	0.62	(0.43, 0.89)
			Live Virus nAb ID80	833	0.52	(0.37, 0.73)

Table 6: Ratios of GMTs/GMCs between demographic subgroups
among the vaccine recipients (*continued*)

Baseline	Visit	Group	Endpoint	N	Ratios of GMT/GMC	95% CI
	D57	Minority	Anti-Spike IgG	833	0.69	(0.51, 0.95)
			Anti-RBD IgG	833	0.68	(0.47, 0.99)
			Pseudo nAb ID50	833	0.56	(0.34, 0.90)
			Pseudo nAb ID80	833	0.76	(0.46, 1.26)
			Live Virus nAb ID50	833	0.73	(0.46, 1.16)
			Live Virus nAb ID80	833	0.80	(0.49, 1.32)
	D1		Anti-Spike IgG	843	1.00	(1.00, 1.00)
			Anti-RBD IgG	843	1.00	(1.00, 1.00)
			Pseudo nAb ID50	843	1.00	(1.00, 1.00)
			Pseudo nAb ID80	843	1.00	(1.00, 1.00)
			Live Virus nAb ID50	843	1.00	(1.00, 1.00)
			Live Virus nAb ID80	843	1.00	(1.00, 1.00)
	D29		Anti-Spike IgG	843	0.92	(0.77, 1.11)
			Anti-RBD IgG	843	1.02	(0.82, 1.25)
			Pseudo nAb ID50	843	0.96	(0.76, 1.20)
			Pseudo nAb ID80	843	1.06	(0.86, 1.31)
			Live Virus nAb ID50	843	1.19	(0.95, 1.50)
			Live Virus nAb ID80	843	1.26	(1.02, 1.56)
	D57		Anti-Spike IgG	843	1.13	(0.93, 1.38)
			Anti-RBD IgG	843	1.24	(0.98, 1.57)
			Pseudo nAb ID50	843	1.22	(0.91, 1.65)
			Pseudo nAb ID80	843	1.16	(0.84, 1.59)
			Live Virus nAb ID50	843	0.99	(0.74, 1.32)
			Live Virus nAb ID80	843	1.10	(0.80, 1.49)
Positive	D1	Age	Anti-Spike IgG	263	1.00	(1.00, 1.00)
			Anti-RBD IgG	263	1.00	(1.00, 1.00)
			Pseudo nAb ID50	263	1.00	(1.00, 1.00)
			Pseudo nAb ID80	263	1.00	(1.00, 1.00)
			Live Virus nAb ID50	263	1.00	(1.00, 1.00)
			Live Virus nAb ID80	263	1.00	(1.00, 1.00)
	D29		Anti-Spike IgG	263	5.17	(3.20, 8.35)
			Anti-RBD IgG	263	5.53	(3.28, 9.31)
			Pseudo nAb ID50	263	4.47	(2.47, 8.10)
			Pseudo nAb ID80	263	4.52	(2.53, 8.07)

Table 6: Ratios of GMTs/GMCs between demographic subgroups
among the vaccine recipients (*continued*)

Baseline	Visit	Group	Endpoint	N	Ratios of GMT/GMC	95% CI
			Live Virus nAb ID50	263	2.29	(1.26, 4.17)
			Live Virus nAb ID80	263	1.95	(1.04, 3.66)
	D57		Anti-Spike IgG	263	2.85	(1.77, 4.58)
			Anti-RBD IgG	263	2.90	(1.64, 5.13)
			Pseudo nAb ID50	263	3.80	(1.72, 8.39)
			Pseudo nAb ID80	263	5.75	(2.53, 13.07)
			Live Virus nAb ID50	263	4.16	(1.88, 9.24)
			Live Virus nAb ID80	263	2.30	(1.07, 4.96)
	D1	Sex	Anti-Spike IgG	263	1.00	(1.00, 1.00)
			Anti-RBD IgG	263	1.00	(1.00, 1.00)
			Pseudo nAb ID50	263	1.00	(1.00, 1.00)
			Pseudo nAb ID80	263	1.00	(1.00, 1.00)
			Live Virus nAb ID50	263	1.00	(1.00, 1.00)
			Live Virus nAb ID80	263	1.00	(1.00, 1.00)
	D29		Anti-Spike IgG	263	1.05	(0.74, 1.49)
			Anti-RBD IgG	263	1.21	(0.83, 1.76)
			Pseudo nAb ID50	263	1.17	(0.77, 1.78)
			Pseudo nAb ID80	263	1.45	(0.96, 2.17)
			Live Virus nAb ID50	263	1.15	(0.77, 1.73)
			Live Virus nAb ID80	263	1.16	(0.76, 1.78)
	D57		Anti-Spike IgG	263	1.43	(1.03, 1.98)
			Anti-RBD IgG	263	0.91	(0.61, 1.35)
			Pseudo nAb ID50	263	0.92	(0.53, 1.58)
			Pseudo nAb ID80	263	0.62	(0.35, 1.09)
			Live Virus nAb ID50	263	0.91	(0.52, 1.57)
			Live Virus nAb ID80	263	0.86	(0.51, 1.45)
	D1	High Risk	Anti-Spike IgG	263	1.00	(1.00, 1.00)
			Anti-RBD IgG	263	1.00	(1.00, 1.00)
			Pseudo nAb ID50	263	1.00	(1.00, 1.00)
			Pseudo nAb ID80	263	1.00	(1.00, 1.00)
			Live Virus nAb ID50	263	1.00	(1.00, 1.00)
			Live Virus nAb ID80	263	1.00	(1.00, 1.00)
	D29		Anti-Spike IgG	263	1.10	(0.72, 1.67)
			Anti-RBD IgG	263	0.77	(0.49, 1.21)

Table 6: Ratios of GMTs/GMCs between demographic subgroups
among the vaccine recipients (*continued*)

Baseline	Visit	Group	Endpoint	N	Ratios of GMT/GMC	95% CI
			Pseudo nAb ID50	263	0.79	(0.48, 1.30)
			Pseudo nAb ID80	263	0.75	(0.46, 1.23)
			Live Virus nAb ID50	263	1.11	(0.68, 1.80)
			Live Virus nAb ID80	263	1.24	(0.75, 2.07)
	D57		Anti-Spike IgG	263	1.05	(0.71, 1.57)
			Anti-RBD IgG	263	0.86	(0.54, 1.38)
			Pseudo nAb ID50	263	1.59	(0.83, 3.03)
			Pseudo nAb ID80	263	0.81	(0.41, 1.60)
			Live Virus nAb ID50	263	0.95	(0.49, 1.82)
			Live Virus nAb ID80	263	1.21	(0.65, 2.25)
	D1	Ethnicity	Anti-Spike IgG	244	1.00	(1.00, 1.00)
			Anti-RBD IgG	244	1.00	(1.00, 1.00)
			Pseudo nAb ID50	244	1.00	(1.00, 1.00)
			Pseudo nAb ID80	244	1.00	(1.00, 1.00)
			Live Virus nAb ID50	244	1.00	(1.00, 1.00)
			Live Virus nAb ID80	244	1.00	(1.00, 1.00)
	D29		Anti-Spike IgG	244	0.74	(0.43, 1.28)
			Anti-RBD IgG	244	1.35	(0.75, 2.42)
			Pseudo nAb ID50	244	1.06	(0.55, 2.03)
			Pseudo nAb ID80	244	1.20	(0.64, 2.27)
			Live Virus nAb ID50	244	0.85	(0.46, 1.60)
			Live Virus nAb ID80	244	0.83	(0.43, 1.60)
	D57		Anti-Spike IgG	244	0.93	(0.55, 1.55)
			Anti-RBD IgG	244	0.65	(0.35, 1.21)
			Pseudo nAb ID50	244	0.39	(0.17, 0.91)
			Pseudo nAb ID80	244	1.12	(0.46, 2.71)
			Live Virus nAb ID50	244	1.06	(0.45, 2.49)
			Live Virus nAb ID80	244	0.73	(0.32, 1.63)
	D1	Minority	Anti-Spike IgG	244	1.00	(1.00, 1.00)
			Anti-RBD IgG	244	1.00	(1.00, 1.00)
			Pseudo nAb ID50	244	1.00	(1.00, 1.00)
			Pseudo nAb ID80	244	1.00	(1.00, 1.00)

Table 6: Ratios of GMTs/GMCs between demographic subgroups
among the vaccine recipients (*continued*)

Baseline	Visit	Group	Endpoint	N	Ratios of GMT/GMC	95% CI
			Live Virus nAb ID50	244	1.00	(1.00, 1.00)
			Live Virus nAb ID80	244	1.00	(1.00, 1.00)
		D29	Anti-Spike IgG	244	1.13	(0.78, 1.63)
			Anti-RBD IgG	244	1.03	(0.69, 1.54)
			Pseudo nAb ID50	244	0.85	(0.54, 1.32)
			Pseudo nAb ID80	244	0.87	(0.57, 1.35)
			Live Virus nAb ID50	244	1.61	(1.06, 2.45)
			Live Virus nAb ID80	244	1.21	(0.77, 1.90)
		D57	Anti-Spike IgG	244	1.25	(0.88, 1.76)
			Anti-RBD IgG	244	1.87	(1.24, 2.81)
			Pseudo nAb ID50	244	1.42	(0.80, 2.52)
			Pseudo nAb ID80	244	1.42	(0.78, 2.58)
			Live Virus nAb ID50	244	1.34	(0.75, 2.40)
			Live Virus nAb ID80	244	0.99	(0.57, 1.72)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo

Table 6. Differences of responder rates between the vaccine arm and the placebo arm

Table 7: Differences of responder rates between the vaccine arm and the placebo arm

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Total							
Negative	Total	D29	Anti-Spike IgG	1089	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	1089	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	1089	80.9% (77.6%, 84.3%)	80.9% (77.6%, 84.3%)	68.8% (64.9%, 72.8%)
			Pseudo nAb ID80	1089	67.6% (63.6%, 71.6%)	67.6% (63.6%, 71.6%)	54.2% (49.9%, 58.4%)
			Live Virus nAb ID50	1089	81.4% (78.1%, 84.7%)	81.4% (78.1%, 84.7%)	65.8% (61.7%, 69.8%)
			Live Virus nAb ID80	1089	69.9% (66.0%, 73.8%)	69.9% (66.0%, 73.8%)	55.9% (51.6%, 60.1%)
		D57	Anti-Spike IgG	1089	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	1089	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	1089	97.7% (96.5%, 99.0%)	97.7% (96.5%, 99.0%)	95.6% (93.9%, 97.4%)
			Pseudo nAb ID80	1089	94.6% (92.7%, 96.5%)	94.6% (92.7%, 96.5%)	89.8% (87.2%, 92.4%)
			Live Virus nAb ID50	1089	97.4% (96.1%, 98.8%)	97.4% (96.1%, 98.8%)	94.8% (92.9%, 96.7%)
			Live Virus nAb ID80	1089	94.7% (92.8%, 96.6%)	94.7% (92.8%, 96.6%)	89.6% (87.0%, 92.2%)
	Age < 65	D29	Anti-Spike IgG	513	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	513	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	513	78.8% (73.7%, 83.9%)	78.8% (73.7%, 83.9%)	65.5% (59.6%, 71.4%)
			Pseudo nAb ID80	513	64.5% (64.5%, 64.5%)	64.5% (64.5%, 64.5%)	50.7% (50.7%, 50.7%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age		D57	Live Virus nAb ID50	513	(58.5%, 70.4%)	(58.5%, 70.4%)	(44.4%, 56.9%)
					79.7%	79.7%	62.9%
			Live Virus nAb ID80	513	(74.7%, 84.8%)	(74.7%, 84.8%)	(56.9%, 68.9%)
					67.6%	67.6%	52.8%
			Anti-Spike IgG	513	(61.8%, 73.5%)	(61.8%, 73.5%)	(46.6%, 59.1%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	513	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	513	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					97.6%	97.6%	95.4%
			Pseudo nAb ID80	513	(95.7%, 99.5%)	(95.7%, 99.5%)	(92.7%, 98.0%)
					94.1%	94.1%	88.9%
			Live Virus nAb ID50	513	(91.2%, 97.1%)	(91.2%, 97.1%)	(85.0%, 92.8%)
					97.3%	97.3%	94.4%
			Live Virus nAb ID80	513	(95.3%, 99.3%)	(95.3%, 99.3%)	(91.6%, 97.3%)
					94.3%	94.3%	88.8%
					(91.4%, 97.2%)	(91.4%, 97.2%)	(84.9%, 92.8%)
Age	Age >= 65	D29	Anti-Spike IgG	576	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	576	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	576	92.5%	92.5%	86.9%
					(89.5%, 95.5%)	(89.5%, 95.5%)	(83.1%, 90.8%)
		D57	Pseudo nAb ID80	576	84.6%	84.6%	73.2%
					(80.5%, 88.7%)	(80.5%, 88.7%)	(68.1%, 78.2%)
			Live Virus nAb ID50	576	90.6%	90.6%	81.5%
					(87.3%, 94.0%)	(87.3%, 94.0%)	(77.1%, 86.0%)
			Live Virus nAb ID80	576	82.5%	82.5%	72.4%
					(78.2%, 86.9%)	(78.2%, 86.9%)	(67.3%, 77.5%)
		D57	Anti-Spike IgG	576	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	576	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
At-risk		D29	Pseudo nAb ID50	576	98.5% (97.2%, 99.9%)	98.5% (97.2%, 99.9%)	97.2% (95.4%, 99.1%)
			Pseudo nAb ID80	576	97.2% (95.4%, 99.1%)	97.2% (95.4%, 99.1%)	94.7% (92.2%, 97.3%)
			Live Virus nAb ID50	576	98.1% (96.5%, 99.6%)	98.1% (96.5%, 99.6%)	96.6% (94.5%, 98.6%)
			Live Virus nAb ID80	576	96.8% (94.8%, 98.8%)	96.8% (94.8%, 98.8%)	93.6% (90.8%, 96.4%)
			Anti-Spike IgG	568	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	568	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	568	81.6% (77.1%, 86.1%)	81.6% (77.1%, 86.1%)	70.6% (65.2%, 75.9%)
			Pseudo nAb ID80	568	71.3% (66.0%, 76.6%)	71.3% (66.0%, 76.6%)	57.5% (51.7%, 63.3%)
			Live Virus nAb ID50	568	79.1% (74.4%, 83.9%)	79.1% (74.4%, 83.9%)	66.1% (60.5%, 71.6%)
			Live Virus nAb ID80	568	72.3% (67.1%, 77.6%)	72.3% (67.1%, 77.6%)	58.4% (52.6%, 64.2%)
			Anti-Spike IgG	568	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	568	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
		D57	Pseudo nAb ID50	568	96.1% (93.9%, 98.4%)	96.1% (93.9%, 98.4%)	94.1% (91.3%, 96.9%)
			Pseudo nAb ID80	568	95.2% (92.7%, 97.7%)	95.2% (92.7%, 97.7%)	90.4% (87.0%, 93.9%)
			Live Virus nAb ID50	568	97.5% (95.7%, 99.3%)	97.5% (95.7%, 99.3%)	92.1% (88.9%, 95.2%)
			Live Virus nAb ID80	568	94.3% (91.6%, 97.0%)	94.3% (91.6%, 97.0%)	91.2% (87.9%, 94.5%)
			Anti-Spike IgG	521	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	521	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
Not at-risk		D29	Anti-Spike IgG	521	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	521	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age < 65 At-risk	D57		Anti-RBD IgG	521	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	521	80.7% (75.8%, 85.6%)	80.7% (75.8%, 85.6%)	68.2% (62.5%, 74.0%)
			Pseudo nAb ID80	521	66.3% (60.5%, 72.2%)	66.3% (60.5%, 72.2%)	53.1% (46.9%, 59.2%)
			Live Virus nAb ID50	521	82.2% (77.5%, 86.9%)	82.2% (77.5%, 86.9%)	65.7% (59.8%, 71.6%)
			Live Virus nAb ID80	521	69.1% (63.4%, 74.9%)	69.1% (63.4%, 74.9%)	55.0% (48.9%, 61.2%)
			Anti-Spike IgG	521	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	521	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	521	98.3% (96.7%, 99.9%)	98.3% (96.7%, 99.9%)	96.2% (93.8%, 98.5%)
			Pseudo nAb ID80	521	94.4% (91.6%, 97.3%)	94.4% (91.6%, 97.3%)	89.6% (85.8%, 93.4%)
			Live Virus nAb ID50	521	97.4% (95.4%, 99.4%)	97.4% (95.4%, 99.4%)	95.7% (93.1%, 98.2%)
			Live Virus nAb ID80	521	94.9% (92.1%, 97.6%)	94.9% (92.1%, 97.6%)	89.0% (85.2%, 92.9%)
		D29	Anti-Spike IgG	259	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	259	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	259	78.1% (70.9%, 85.3%)	78.1% (70.9%, 85.3%)	63.9% (55.6%, 72.3%)
			Pseudo nAb ID80	259	66.2% (58.0%, 74.4%)	66.2% (58.0%, 74.4%)	51.6% (42.9%, 60.2%)
			Live Virus nAb ID50	259	75.4% (67.9%, 82.8%)	75.4% (67.9%, 82.8%)	60.3% (51.8%, 68.8%)
			Live Virus nAb ID80	259	69.0% (61.0%, 77.0%)	69.0% (61.0%, 77.0%)	53.0% (44.3%, 61.6%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
High Risk	Age < 65 Not at-risk	D57	Anti-Spike IgG	259	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	259	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	259	95.4% (91.8%, 99.0%)	95.4% (91.8%, 99.0%)	93.6% (89.4%, 97.8%)
			Pseudo nAb ID80	259	95.0% (91.2%, 98.8%)	95.0% (91.2%, 98.8%)	89.5% (84.1%, 94.8%)
			Live Virus nAb ID50	259	97.7% (95.1%, 100.3%)	97.7% (95.1%, 100.3%)	90.8% (85.8%, 95.8%)
			Live Virus nAb ID80	259	94.1% (90.0%, 98.2%)	94.1% (90.0%, 98.2%)	90.9% (85.9%, 95.9%)
		D29	Anti-Spike IgG	254	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	254	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	254	79.0% (71.7%, 86.3%)	79.0% (71.7%, 86.3%)	65.9% (57.4%, 74.4%)
			Pseudo nAb ID80	254	64.0% (55.4%, 72.6%)	64.0% (55.4%, 72.6%)	50.5% (41.5%, 59.4%)
			Live Virus nAb ID50	254	80.8% (73.8%, 87.9%)	80.8% (73.8%, 87.9%)	63.6% (54.9%, 72.2%)
			Live Virus nAb ID80	254	67.3% (58.9%, 75.7%)	67.3% (58.9%, 75.7%)	52.8% (43.9%, 61.7%)
		D57	Anti-Spike IgG	254	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	254	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	254	98.1% (95.7%, 100.6%)	98.1% (95.7%, 100.6%)	95.8% (92.2%, 99.4%)
			Pseudo nAb ID80	254	93.9% (89.7%, 98.2%)	93.9% (89.7%, 98.2%)	88.8% (83.1%, 94.4%)
			Live Virus nAb ID50	254	97.2%	97.2%	95.3%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Age >= 65 At-risk	D29	Live Virus nAb ID80	254	(94.2%, 100.1%)	(94.2%, 100.1%)	(91.6%, 99.1%)
					94.4%	94.4%	88.3%
			Anti-Spike IgG	309	(90.3%, 98.5%)	(90.3%, 98.5%)	(82.6%, 94.1%)
					100.0%	100.0%	100.0%
		Anti-RBD IgG	309	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)	
				100.0%	100.0%	100.0%	
		Pseudo nAb ID50	309	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)	
				88.9%	88.9%	84.3%	
		Pseudo nAb ID80	309	(83.8%, 94.0%)	(83.8%, 94.0%)	(78.5%, 90.2%)	
				81.8%	81.8%	69.7%	
		Live Virus nAb ID50	309	(75.6%, 88.1%)	(75.6%, 88.1%)	(62.3%, 77.1%)	
				87.0%	87.0%	78.1%	
		Live Virus nAb ID80	309	(81.6%, 92.4%)	(81.6%, 92.4%)	(71.4%, 84.7%)	
				79.3%	79.3%	69.6%	
	D57	Anti-Spike IgG	309	(72.7%, 85.8%)	(72.7%, 85.8%)	(62.2%, 77.0%)	
				100.0%	100.0%	100.0%	
		Anti-RBD IgG	309	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)	
				100.0%	100.0%	100.0%	
	Age >= 65 Not at-risk	D57	Pseudo nAb ID50	309	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					97.6%	97.6%	95.1%
		Pseudo nAb ID80	309	(95.2%, 100.1%)	(95.2%, 100.1%)	(91.7%, 98.6%)	
				95.6%	95.6%	92.5%	
		Live Virus nAb ID50	309	(92.4%, 98.9%)	(92.4%, 98.9%)	(88.2%, 96.7%)	
				97.1%	97.1%	94.6%	
		Live Virus nAb ID80	309	(94.4%, 99.8%)	(94.4%, 99.8%)	(91.0%, 98.3%)	
				94.7%	94.7%	91.9%	
		D29	Anti-Spike IgG	267	(91.1%, 98.3%)	(91.1%, 98.3%)	(87.5%, 96.3%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	267	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	267	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					96.5%	96.5%	89.8%
		Pseudo nAb ID80	267	(93.4%, 99.5%)	(93.4%, 99.5%)	(84.9%, 94.8%)	
				87.6%	87.6%	77.0%	

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
					(82.2%, 93.0%)	(82.2%, 93.0%)	(70.1%, 83.9%)
			Live Virus nAb ID50	267	94.7%	94.7%	85.4%
					(91.0%, 98.4%)	(91.0%, 98.4%)	(79.6%, 91.2%)
			Live Virus nAb ID80	267	86.2%	86.2%	75.6%
					(80.6%, 91.8%)	(80.6%, 91.8%)	(68.6%, 82.6%)
		D57	Anti-Spike IgG	267	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	267	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	267	99.6%	99.6%	99.6%
					(98.5%, 100.6%)	(98.5%, 100.6%)	(98.5%, 100.6%)
			Pseudo nAb ID80	267	99.0%	99.0%	97.2%
					(97.4%, 100.6%)	(97.4%, 100.6%)	(94.6%, 99.9%)
			Live Virus nAb ID50	267	99.1%	99.1%	98.7%
					(97.6%, 100.6%)	(97.6%, 100.6%)	(96.8%, 100.5%)
			Live Virus nAb ID80	267	99.1%	99.1%	95.6%
					(97.6%, 100.6%)	(97.6%, 100.6%)	(92.2%, 98.9%)
		D29	Anti-Spike IgG	595	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	595	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	595	82.0%	82.0%	69.9%
					(77.5%, 86.4%)	(77.5%, 86.4%)	(64.5%, 75.2%)
			Pseudo nAb ID80	595	68.5%	68.5%	53.9%
					(63.1%, 73.9%)	(63.1%, 73.9%)	(48.1%, 59.7%)
			Live Virus nAb ID50	595	79.8%	79.8%	63.2%
					(75.1%, 84.5%)	(75.1%, 84.5%)	(57.6%, 68.9%)
			Live Virus nAb ID80	595	68.1%	68.1%	54.5%
					(62.7%, 73.5%)	(62.7%, 73.5%)	(48.7%, 60.3%)
		D57	Anti-Spike IgG	595	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	595	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	595	98.0%	98.0%	96.4%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age, Risk	Male		Pseudo nAb ID80	595	(96.4%, 99.6%)	(96.4%, 99.6%)	(94.2%, 98.6%)
					93.0%	93.0%	88.6%
			Live Virus nAb ID50	595	(90.0%, 96.0%)	(90.0%, 96.0%)	(84.9%, 92.3%)
					96.4%	96.4%	94.2%
			Live Virus nAb ID80	595	(94.2%, 98.5%)	(94.2%, 98.5%)	(91.5%, 97.0%)
					94.0%	94.0%	87.6%
					(91.2%, 96.7%)	(91.2%, 96.7%)	(83.8%, 91.5%)
		D29	Anti-Spike IgG	494	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	494	100.0%	100.0%	100.0%
	Age < 65 Female		Pseudo nAb ID50	494	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					79.7%	79.7%	67.5%
			Pseudo nAb ID80	494	(74.6%, 84.7%)	(74.6%, 84.7%)	(61.7%, 73.4%)
					66.4%	66.4%	54.5%
			Live Virus nAb ID50	494	(60.5%, 72.4%)	(60.5%, 72.4%)	(48.2%, 60.7%)
					83.4%	83.4%	68.9%
			Live Virus nAb ID80	494	(78.8%, 88.1%)	(78.8%, 88.1%)	(63.1%, 74.7%)
					72.2%	72.2%	57.5%
		D57	Anti-Spike IgG	494	(66.6%, 77.8%)	(66.6%, 77.8%)	(51.3%, 63.7%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	494	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	494	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					97.4%	97.4%	94.8%
			Pseudo nAb ID80	494	(95.4%, 99.4%)	(95.4%, 99.4%)	(92.0%, 97.5%)
					96.6%	96.6%	91.3%
			Live Virus nAb ID50	494	(94.3%, 98.9%)	(94.3%, 98.9%)	(87.8%, 94.9%)
					98.7%	98.7%	95.4%
			Live Virus nAb ID80	494	(97.3%, 100.1%)	(97.3%, 100.1%)	(92.7%, 98.0%)
					95.6%	95.6%	91.9%
		D29	Anti-Spike IgG	285	(93.0%, 98.2%)	(93.0%, 98.2%)	(88.5%, 95.3%)
					100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age < 65 Male	D57		Anti-RBD IgG	285	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	285	80.3% (73.5%, 87.1%)	80.3% (73.5%, 87.1%)	67.0% (59.0%, 75.1%)
			Pseudo nAb ID80	285	65.8% (57.7%, 73.9%)	65.8% (57.7%, 73.9%)	51.0% (42.4%, 59.6%)
			Live Virus nAb ID50	285	77.6% (70.5%, 84.8%)	77.6% (70.5%, 84.8%)	60.0% (51.6%, 68.3%)
			Live Virus nAb ID80	285	65.3% (57.2%, 73.5%)	65.3% (57.2%, 73.5%)	51.0% (42.5%, 59.6%)
			Anti-Spike IgG	285	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	285	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	285	98.0% (95.6%, 100.4%)	98.0% (95.6%, 100.4%)	96.3% (93.1%, 99.5%)
			Pseudo nAb ID80	285	92.2% (87.7%, 96.8%)	92.2% (87.7%, 96.8%)	87.7% (82.1%, 93.3%)
			Live Virus nAb ID50	285	96.3% (93.0%, 99.5%)	96.3% (93.0%, 99.5%)	94.1% (90.1%, 98.1%)
			Live Virus nAb ID80	285	93.4% (89.2%, 97.7%)	93.4% (89.2%, 97.7%)	86.7% (80.9%, 92.5%)
			Anti-Spike IgG	228	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
	D29		Anti-RBD IgG	228	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	228	76.9% (69.2%, 84.7%)	76.9% (69.2%, 84.7%)	63.6% (54.8%, 72.5%)
			Pseudo nAb ID80	228	62.8% (53.9%, 71.7%)	62.8% (53.9%, 71.7%)	50.3% (41.1%, 59.5%)
			Live Virus nAb ID50	228	82.3% (75.3%, 89.4%)	82.3% (75.3%, 89.4%)	66.5% (57.9%, 75.2%)
			Live Virus nAb ID80	228	70.5% (62.1%, 78.9%)	70.5% (62.1%, 78.9%)	55.1% (45.9%, 64.2%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Age >= 65 Female	D57	Anti-Spike IgG	228	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	228	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	228	97.1% (94.0%, 100.2%)	97.1% (94.0%, 100.2%)	94.2% (89.9%, 98.5%)
			Pseudo nAb ID80	228	96.5% (93.1%, 99.9%)	96.5% (93.1%, 99.9%)	90.4% (85.0%, 95.8%)
			Live Virus nAb ID50	228	98.6% (96.4%, 100.7%)	98.6% (96.4%, 100.7%)	94.8% (90.7%, 98.9%)
			Live Virus nAb ID80	228	95.4% (91.6%, 99.3%)	95.4% (91.6%, 99.3%)	91.5% (86.3%, 96.6%)
		D29	Anti-Spike IgG	310	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	310	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	310	91.4% (87.2%, 95.6%)	91.4% (87.2%, 95.6%)	86.5% (81.3%, 91.6%)
			Pseudo nAb ID80	310	84.1% (78.6%, 89.6%)	84.1% (78.6%, 89.6%)	70.7% (63.9%, 77.6%)
			Live Virus nAb ID50	310	92.3% (88.3%, 96.3%)	92.3% (88.3%, 96.3%)	82.2% (76.5%, 88.0%)
			Live Virus nAb ID80	310	84.1% (78.6%, 89.6%)	84.1% (78.6%, 89.6%)	74.7% (68.2%, 81.3%)
		D57	Anti-Spike IgG	310	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	310	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	310	98.0% (95.9%, 100.1%)	98.0% (95.9%, 100.1%)	96.8% (94.1%, 99.4%)
			Pseudo nAb ID80	310	97.2% (94.7%, 99.7%)	97.2% (94.7%, 99.7%)	93.6% (89.9%, 97.3%)
			Live Virus nAb ID50	310	96.8% (94.1%, 99.4%)	96.8% (94.1%, 99.4%)	95.1% (91.8%, 98.3%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Age \geq 65 Male	D29	Live Virus nAb ID80	310	97.1% (94.6%, 99.6%)	97.1% (94.6%, 99.6%)	93.1% (89.3%, 96.9%)
			Anti-Spike IgG	266	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	266	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	266	93.7% (89.3%, 98.0%)	93.7% (89.3%, 98.0%)	87.4% (81.5%, 93.3%)
			Pseudo nAb ID80	266	85.1% (78.8%, 91.5%)	85.1% (78.8%, 91.5%)	75.9% (68.2%, 83.5%)
		D57	Live Virus nAb ID50	266	88.9% (83.3%, 94.5%)	88.9% (83.3%, 94.5%)	80.8% (73.8%, 87.8%)
			Live Virus nAb ID80	266	80.9% (73.9%, 87.9%)	80.9% (73.9%, 87.9%)	69.9% (61.8%, 78.1%)
			Anti-Spike IgG	266	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	266	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	266	99.1% (97.5%, 100.8%)	99.1% (97.5%, 100.8%)	97.7% (95.0%, 100.4%)
	Hispanic or Latino	D29	Pseudo nAb ID80	266	97.3% (94.4%, 100.2%)	97.3% (94.4%, 100.2%)	96.0% (92.5%, 99.5%)
			Live Virus nAb ID50	266	99.5% (98.1%, 100.8%)	99.5% (98.1%, 100.8%)	98.1% (95.7%, 100.5%)
			Live Virus nAb ID80	266	96.5% (93.2%, 99.8%)	96.5% (93.2%, 99.8%)	94.2% (90.1%, 98.4%)
			Anti-Spike IgG	139	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	139	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
		D57	Pseudo nAb ID50	139	82.4% (73.5%, 91.3%)	82.4% (73.5%, 91.3%)	78.9% (69.3%, 88.4%)
			Pseudo nAb ID80	139	78.2% (68.5%, 87.8%)	78.2% (68.5%, 87.8%)	59.9% (48.5%, 71.4%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
			Live Virus nAb ID50	139	89.7% (82.5%, 96.8%)	89.7% (82.5%, 96.8%)	71.9% (61.4%, 82.4%)
			Live Virus nAb ID80	139	80.4% (71.1%, 89.7%)	80.4% (71.1%, 89.7%)	70.3% (59.6%, 81.0%)
		D57	Anti-Spike IgG	139	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	139	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	139	96.4% (92.1%, 100.8%)	96.4% (92.1%, 100.8%)	96.4% (92.1%, 100.8%)
			Pseudo nAb ID80	139	96.0% (91.4%, 100.6%)	96.0% (91.4%, 100.6%)	92.6% (86.5%, 98.7%)
			Live Virus nAb ID50	139	98.7% (96.0%, 101.3%)	98.7% (96.0%, 101.3%)	97.1% (93.1%, 101.0%)
			Live Virus nAb ID80	139	93.7% (88.0%, 99.4%)	93.7% (88.0%, 99.4%)	89.0% (81.7%, 96.3%)
	Not Hispanic or Latino	D29	Anti-Spike IgG	837	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	837	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	837	81.7% (77.8%, 85.5%)	81.7% (77.8%, 85.5%)	67.6% (62.9%, 72.3%)
			Pseudo nAb ID80	837	67.6% (63.0%, 72.3%)	67.6% (63.0%, 72.3%)	54.5% (49.6%, 59.5%)
			Live Virus nAb ID50	837	80.8% (76.9%, 84.7%)	80.8% (76.9%, 84.7%)	64.9% (60.1%, 69.6%)
			Live Virus nAb ID80	837	67.8% (63.2%, 72.5%)	67.8% (63.2%, 72.5%)	53.6% (48.7%, 58.6%)
		D57	Anti-Spike IgG	837	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	837	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	837	97.7% (96.3%, 99.2%)	97.7% (96.3%, 99.2%)	95.5% (93.4%, 97.6%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Sex	American Indian or Alaska Native	D29	Pseudo nAb ID80	837	94.6% (92.3%, 96.8%)	94.6% (92.3%, 96.8%)	89.8% (86.8%, 92.8%)
			Live Virus nAb ID50	837	97.3% (95.7%, 98.9%)	97.3% (95.7%, 98.9%)	94.7% (92.5%, 96.9%)
			Live Virus nAb ID80	837	95.1% (93.0%, 97.3%)	95.1% (93.0%, 97.3%)	89.7% (86.7%, 92.8%)
			Anti-Spike IgG	29	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	29	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	29	72.9% (47.3%, 98.5%)	72.9% (47.3%, 98.5%)	59.1% (30.8%, 87.4%)
			Pseudo nAb ID80	29	56.4% (27.8%, 84.9%)	56.4% (27.8%, 84.9%)	55.0% (26.3%, 83.6%)
			Live Virus nAb ID50	29	93.4% (79.2%, 107.7%)	93.4% (79.2%, 107.7%)	67.5% (40.5%, 94.4%)
			Live Virus nAb ID80	29	78.5% (54.9%, 102.2%)	78.5% (54.9%, 102.2%)	78.5% (54.9%, 102.2%)
		D57	Anti-Spike IgG	29	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	29	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	29	94.6% (81.5%, 107.6%)	94.6% (81.5%, 107.6%)	93.4% (79.2%, 107.7%)
			Pseudo nAb ID80	29	87.8% (68.9%, 106.7%)	87.8% (68.9%, 106.7%)	86.7% (67.1%, 106.2%)
			Live Virus nAb ID50	29	97.3% (87.9%, 106.6%)	97.3% (87.9%, 106.6%)	93.4% (79.2%, 107.7%)
			Live Virus nAb ID80	29	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	88.9% (70.8%, 107.0%)
		D29	Anti-Spike IgG	73	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	73	100.0%	100.0%	100.0%
	Asian	D29	Anti-Spike IgG	73	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	73	100.0%	100.0%	100.0%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	73	76.2%	76.2%	48.6%
					(63.0%, 89.4%)	(63.0%, 89.4%)	(33.0%, 64.1%)
			Pseudo nAb ID80	73	46.7%	46.7%	35.8%
					(31.2%, 62.3%)	(31.2%, 62.3%)	(20.9%, 50.7%)
			Live Virus nAb ID50	73	71.2%	71.2%	62.2%
					(57.1%, 85.3%)	(57.1%, 85.3%)	(47.1%, 77.2%)
			Live Virus nAb ID80	73	69.9%	69.9%	55.9%
					(55.7%, 84.2%)	(55.7%, 84.2%)	(40.4%, 71.3%)
		D57	Anti-Spike IgG	73	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	73	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	73	99.5%	99.5%	91.2%
					(97.2%, 101.7%)	(97.2%, 101.7%)	(82.4%, 100.0%)
			Pseudo nAb ID80	73	93.0%	93.0%	87.2%
					(85.0%, 100.9%)	(85.0%, 100.9%)	(76.9%, 97.6%)
			Live Virus nAb ID50	73	89.0%	89.0%	80.8%
					(79.3%, 98.8%)	(79.3%, 98.8%)	(68.5%, 93.0%)
			Live Virus nAb ID80	73	91.2%	91.2%	86.0%
					(82.4%, 100.0%)	(82.4%, 100.0%)	(75.2%, 96.8%)
	Black or African American	D29	Anti-Spike IgG	242	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	242	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	242	78.5%	78.5%	67.0%
					(70.2%, 86.8%)	(70.2%, 86.8%)	(57.4%, 76.5%)
			Pseudo nAb ID80	242	67.1%	67.1%	48.9%
					(57.6%, 76.6%)	(57.6%, 76.6%)	(38.8%, 59.0%)
			Live Virus nAb ID50	242	82.8%	82.8%	60.6%
					(75.1%, 90.4%)	(75.1%, 90.4%)	(50.7%, 70.5%)
			Live Virus nAb ID80	242	68.7%	68.7%	55.3%
					(59.3%, 78.1%)	(59.3%, 78.1%)	(45.2%, 65.4%)
		D57	Anti-Spike IgG	242	100.0%	100.0%	100.0%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	242	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	242	97.2%	97.2%	94.2%
					(93.9%, 100.6%)	(93.9%, 100.6%)	(89.4%, 98.9%)
			Pseudo nAb ID80	242	95.3%	95.3%	89.3%
					(91.0%, 99.6%)	(91.0%, 99.6%)	(83.0%, 95.6%)
			Live Virus nAb ID50	242	99.9%	99.9%	94.2%
					(99.1%, 100.6%)	(99.1%, 100.6%)	(89.4%, 98.9%)
			Live Virus nAb ID80	242	93.2%	93.2%	88.1%
					(88.1%, 98.3%)	(88.1%, 98.3%)	(81.5%, 94.7%)
		D29	Anti-Spike IgG	64	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	64	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	64	75.8%	75.8%	74.2%
					(62.3%, 89.3%)	(62.3%, 89.3%)	(60.3%, 88.0%)
			Pseudo nAb ID80	64	78.9%	78.9%	67.6%
					(66.0%, 91.8%)	(66.0%, 91.8%)	(52.8%, 82.3%)
			Live Virus nAb ID50	64	92.6%	92.6%	78.6%
					(84.3%, 100.9%)	(84.3%, 100.9%)	(65.7%, 91.6%)
			Live Virus nAb ID80	64	83.6%	83.6%	59.7%
					(72.0%, 95.3%)	(72.0%, 95.3%)	(44.3%, 75.2%)
		D57	Anti-Spike IgG	64	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	64	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	64	97.6%	97.6%	95.9%
					(92.8%, 102.4%)	(92.8%, 102.4%)	(89.7%, 102.2%)
			Pseudo nAb ID80	64	97.6%	97.6%	92.9%
					(92.8%, 102.4%)	(92.8%, 102.4%)	(84.7%, 101.0%)
			Live Virus nAb ID50	64	93.8%	93.8%	93.8%
					(86.2%, 101.4%)	(86.2%, 101.4%)	(86.2%, 101.4%)
			Live Virus nAb ID80	64	96.9%	96.9%	95.2%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age, Sex	Native Hawaiian or Other Pacific Islander	D29	Anti-Spike IgG	11	(91.5%, 102.4%)	(91.5%, 102.4%)	(88.5%, 102.0%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	11	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	11	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
		D57	Pseudo nAb ID80	11	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	89.1%
			Live Virus nAb ID50	11	(100.0%, 100.0%)	(100.0%, 100.0%)	(64.5%, 113.7%)
					78.2%	78.2%	73.7%
			Live Virus nAb ID80	11	(45.7%, 110.8%)	(45.7%, 110.8%)	(38.9%, 108.4%)
					84.5%	84.5%	80.0%
	Not reported and unknown	D29	Anti-Spike IgG	11	(56.0%, 113.1%)	(56.0%, 113.1%)	(48.4%, 111.6%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	11	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	11	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
		D57	Pseudo nAb ID80	11	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Live Virus nAb ID50	11	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Live Virus nAb ID80	11	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
Age, Sex	Not reported and unknown	D29	Anti-Spike IgG	115	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	115	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	115	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					87.8%	87.8%	71.4%
			Pseudo nAb ID80	115	(79.8%, 95.9%)	(79.8%, 95.9%)	(60.3%, 82.5%)
					81.3%	81.3%	66.6%
					(71.7%, 90.9%)	(71.7%, 90.9%)	(55.0%, 78.2%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
			Live Virus nAb ID50	115	76.8% (66.4%, 87.1%)	76.8% (66.4%, 87.1%)	70.0% (58.8%, 81.3%)
			Live Virus nAb ID80	115	79.1% (69.1%, 89.1%)	79.1% (69.1%, 89.1%)	65.8% (54.1%, 77.5%)
		D57	Anti-Spike IgG	115	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	115	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	115	97.0% (92.7%, 101.2%)	97.0% (92.7%, 101.2%)	96.6% (92.2%, 101.1%)
			Pseudo nAb ID80	115	99.9% (99.2%, 100.6%)	99.9% (99.2%, 100.6%)	90.7% (83.5%, 97.8%)
			Live Virus nAb ID50	115	99.7% (98.3%, 101.1%)	99.7% (98.3%, 101.1%)	98.2% (94.9%, 101.5%)
			Live Virus nAb ID80	115	99.3% (97.1%, 101.4%)	99.3% (97.1%, 101.4%)	89.2% (81.5%, 96.8%)
	Other	D29	Anti-Spike IgG	23	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	23	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	23	87.8% (39.9%, 135.8%)	87.8% (39.9%, 135.8%)	84.8% (32.3%, 137.4%)
			Pseudo nAb ID80	23	82.3% (26.4%, 138.3%)	82.3% (26.4%, 138.3%)	67.2% (-1.7%, 136.0%)
			Live Virus nAb ID50	23	84.8% (32.3%, 137.4%)	84.8% (32.3%, 137.4%)	84.8% (32.3%, 137.4%)
			Live Virus nAb ID80	23	83.6% (29.3%, 137.9%)	83.6% (29.3%, 137.9%)	78.1% (17.5%, 138.7%)
		D57	Anti-Spike IgG	23	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	23	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	23	87.8% (39.9%, 135.8%)	87.8% (39.9%, 135.8%)	87.8% (39.9%, 135.8%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	White		Pseudo nAb ID80	23	86.6% (36.6%, 136.6%)	86.6% (36.6%, 136.6%)	85.3% (33.4%, 137.2%)
			Live Virus nAb ID50	23	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Live Virus nAb ID80	23	84.8% (32.3%, 137.4%)	84.8% (32.3%, 137.4%)	84.8% (32.3%, 137.4%)
		D29	Anti-Spike IgG	55	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
					100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
					100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	55	78.1% (62.1%, 94.1%)	78.1% (62.1%, 94.1%)	75.2% (58.4%, 91.9%)
			Pseudo nAb ID80	55	57.1% (38.0%, 76.3%)	57.1% (38.0%, 76.3%)	41.5% (22.4%, 60.6%)
			Live Virus nAb ID50	55	76.8% (60.4%, 93.1%)	76.8% (60.4%, 93.1%)	66.4% (48.2%, 84.7%)
			Live Virus nAb ID80	55	79.8% (64.2%, 95.3%)	79.8% (64.2%, 95.3%)	65.1% (46.6%, 83.5%)
		D57	Anti-Spike IgG	55	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
					100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
					100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	55	99.3% (96.2%, 102.5%)	99.3% (96.2%, 102.5%)	99.3% (96.2%, 102.5%)
			Pseudo nAb ID80	55	92.8% (82.8%, 102.8%)	92.8% (82.8%, 102.8%)	85.6% (72.0%, 99.2%)
			Live Virus nAb ID50	55	93.5% (83.9%, 103.0%)	93.5% (83.9%, 103.0%)	92.8% (82.8%, 102.8%)
			Live Virus nAb ID80	55	91.4% (80.6%, 102.3%)	91.4% (80.6%, 102.3%)	90.8% (79.6%, 102.0%)
	White Non-Hispanic	D29	Anti-Spike IgG	437	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
					100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
					100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
			Anti-RBD IgG	437	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	437	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
					82.2% (77.0%, 87.4%)	82.2% (77.0%, 87.4%)	69.8% (63.6%, 76.1%)
					82.2% (77.0%, 87.4%)	82.2% (77.0%, 87.4%)	69.8% (63.6%, 76.1%)
			Pseudo nAb ID80	437	66.5% (60.1%, 72.9%)	66.5% (60.1%, 72.9%)	55.5% (48.7%, 62.2%)
					66.5% (60.1%, 72.9%)	66.5% (60.1%, 72.9%)	55.5% (48.7%, 62.2%)
			Live Virus nAb ID50	437	80.9% (75.6%, 86.3%)	80.9% (75.6%, 86.3%)	65.3% (58.9%, 71.8%)
					80.9% (75.6%, 86.3%)	80.9% (75.6%, 86.3%)	65.3% (58.9%, 71.8%)
			Live Virus nAb ID80	437	63.7% (57.2%, 70.2%)	63.7% (57.2%, 70.2%)	49.0% (42.2%, 55.8%)
					63.7% (57.2%, 70.2%)	63.7% (57.2%, 70.2%)	49.0% (42.2%, 55.8%)
			Anti-Spike IgG	437	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
					100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	437	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
					100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	437	98.5% (96.8%, 100.1%)	98.5% (96.8%, 100.1%)	96.7% (94.3%, 99.1%)
					98.5% (96.8%, 100.1%)	98.5% (96.8%, 100.1%)	96.7% (94.3%, 99.1%)
			Pseudo nAb ID80	437	93.7% (90.4%, 97.0%)	93.7% (90.4%, 97.0%)	90.5% (86.5%, 94.5%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
					93.7%	93.7%	90.5%
					(90.4%, 97.0%)	(90.4%, 97.0%)	(86.5%, 94.5%)
			Live Virus nAb ID50	437	97.2%	97.2%	96.0%
					(95.0%, 99.5%)	(95.0%, 99.5%)	(93.3%, 98.6%)
					97.2%	97.2%	96.0%
					(95.0%, 99.5%)	(95.0%, 99.5%)	(93.3%, 98.6%)
			Live Virus nAb ID80	437	95.0%	95.0%	90.0%
					(92.0%, 97.9%)	(92.0%, 97.9%)	(85.9%, 94.1%)
					95.0%	95.0%	90.0%
					(92.0%, 97.9%)	(92.0%, 97.9%)	(85.9%, 94.1%)
	Communities of Color	D29	Anti-Spike IgG	557	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	557	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	557	80.4%	80.4%	67.3%
					(75.6%, 85.1%)	(75.6%, 85.1%)	(61.6%, 72.9%)
			Pseudo nAb ID80	557	69.3%	69.3%	54.5%
					(63.8%, 74.8%)	(63.8%, 74.8%)	(48.5%, 60.4%)
			Live Virus nAb ID50	557	81.7%	81.7%	66.1%
					(77.1%, 86.3%)	(77.1%, 86.3%)	(60.5%, 71.8%)
			Live Virus nAb ID80	557	73.9%	73.9%	60.7%
					(68.6%, 79.1%)	(68.6%, 79.1%)	(54.9%, 66.6%)
		D57	Anti-Spike IgG	557	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Anti-RBD IgG	557	100.0%	100.0%	100.0%
					(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
			Pseudo nAb ID50	557	96.9%	96.9%	94.2%
					(94.8%, 99.0%)	(94.8%, 99.0%)	(91.4%, 97.0%)
			Pseudo nAb ID80	557	95.4%	95.4%	89.4%
					(92.9%, 97.9%)	(92.9%, 97.9%)	(85.8%, 93.1%)
			Live Virus nAb ID50	557	97.9%	97.9%	93.7%
					(96.1%, 99.6%)	(96.1%, 99.6%)	(90.8%, 96.6%)
			Live Virus nAb ID80	557	94.6%	94.6%	88.8%
					(91.9%, 97.3%)	(91.9%, 97.3%)	(85.0%, 92.5%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Age < 65 Communities of Color	D29	Anti-Spike IgG	259	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	259	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	259	78.3% (71.0%, 85.6%)	78.3% (71.0%, 85.6%)	63.5% (55.0%, 72.1%)
			Pseudo nAb ID80	259	66.3% (57.9%, 74.7%)	66.3% (57.9%, 74.7%)	50.8% (42.0%, 59.7%)
			Live Virus nAb ID50	259	79.8% (72.7%, 86.9%)	79.8% (72.7%, 86.9%)	62.8% (54.3%, 71.4%)
			Live Virus nAb ID80	259	72.4% (64.5%, 80.3%)	72.4% (64.5%, 80.3%)	58.9% (50.2%, 67.7%)
		D57	Anti-Spike IgG	259	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	259	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	259	96.5% (93.3%, 99.8%)	96.5% (93.3%, 99.8%)	93.6% (89.2%, 97.9%)
			Pseudo nAb ID80	259	95.0% (91.2%, 98.9%)	95.0% (91.2%, 98.9%)	88.6% (82.9%, 94.2%)
			Live Virus nAb ID50	259	98.0% (95.5%, 100.5%)	98.0% (95.5%, 100.5%)	93.2% (88.7%, 97.7%)
			Live Virus nAb ID80	259	94.1% (89.9%, 98.3%)	94.1% (89.9%, 98.3%)	87.7% (81.8%, 93.5%)
	Age < 65 White Non-Hispanic	D29	Anti-Spike IgG	216	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	216	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	216	80.3% (72.5%, 88.0%)	80.3% (72.5%, 88.0%)	67.1% (57.9%, 76.2%)
			Pseudo nAb ID80	216	63.8% (54.4%, 73.1%)	63.8% (54.4%, 73.1%)	52.7% (43.0%, 62.4%)
			Live Virus nAb ID50	216	79.6% (71.8%, 87.5%)	79.6% (71.8%, 87.5%)	63.2% (53.8%, 72.6%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Ethnicity	Age >= 65	D57	Live Virus nAb ID80	216	60.1% (50.5%, 69.6%)	60.1% (50.5%, 69.6%)	44.5% (34.8%, 54.2%)
			Anti-Spike IgG	216	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	216	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	216	98.5% (96.1%, 100.9%)	98.5% (96.1%, 100.9%)	96.7% (93.3%, 100.2%)
		D57	Pseudo nAb ID80	216	93.1% (88.1%, 98.0%)	93.1% (88.1%, 98.0%)	89.6% (83.6%, 95.5%)
			Live Virus nAb ID50	216	97.0% (93.6%, 100.3%)	97.0% (93.6%, 100.3%)	95.9% (92.0%, 99.7%)
			Live Virus nAb ID80	216	94.6% (90.2%, 99.0%)	94.6% (90.2%, 99.0%)	89.4% (83.4%, 95.4%)
	Communities of Color	D29	Anti-Spike IgG	298	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	298	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Pseudo nAb ID50	298	91.4% (87.0%, 95.9%)	91.4% (87.0%, 95.9%)	87.0% (81.7%, 92.3%)
			Pseudo nAb ID80	298	85.0% (79.4%, 90.6%)	85.0% (79.4%, 90.6%)	73.9% (67.0%, 80.9%)
		D57	Live Virus nAb ID50	298	91.8% (87.5%, 96.2%)	91.8% (87.5%, 96.2%)	83.8% (78.0%, 89.6%)
			Live Virus nAb ID80	298	81.7% (75.6%, 87.8%)	81.7% (75.6%, 87.8%)	70.3% (63.1%, 77.5%)
			Anti-Spike IgG	298	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
			Anti-RBD IgG	298	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)	100.0% (100.0%, 100.0%)
		D57	Pseudo nAb ID50	298	98.8% (97.1%, 100.5%)	98.8% (97.1%, 100.5%)	97.6% (95.2%, 100.0%)
			Pseudo nAb ID80	298	97.3% (94.1%, 99.5%)	97.3% (94.1%, 99.5%)	94.1% (90.9%, 97.3%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Age >= 65 White Non-Hispanic	D29	Live Virus nAb ID50	298	(94.7%, 99.9%)	(94.7%, 99.9%)	(90.3%, 97.8%)
					97.2%	97.2%	96.3%
			Live Virus nAb ID80	298	(94.6%, 99.8%)	(94.6%, 99.8%)	(93.3%, 99.3%)
					97.1%	97.1%	94.7%
			Anti-Spike IgG	221	(94.4%, 99.7%)	(94.4%, 99.7%)	(91.1%, 98.2%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	221	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	221	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					94.1%	94.1%	86.7%
			Pseudo nAb ID80	221	(89.7%, 98.5%)	(89.7%, 98.5%)	(80.4%, 93.0%)
					83.3%	83.3%	72.3%
		D57	Live Virus nAb ID50	221	(76.3%, 90.2%)	(76.3%, 90.2%)	(64.0%, 80.6%)
					88.8%	88.8%	78.7%
			Live Virus nAb ID80	221	(82.9%, 94.6%)	(82.9%, 94.6%)	(71.1%, 86.4%)
					86.0%	86.0%	76.7%
			Anti-Spike IgG	221	(79.6%, 92.5%)	(79.6%, 92.5%)	(68.8%, 84.5%)
					100.0%	100.0%	100.0%
			Anti-RBD IgG	221	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					100.0%	100.0%	100.0%
			Pseudo nAb ID50	221	(100.0%, 100.0%)	(100.0%, 100.0%)	(100.0%, 100.0%)
					98.4%	98.4%	96.6%
			Pseudo nAb ID80	221	(96.0%, 100.7%)	(96.0%, 100.7%)	(93.2%, 100.0%)
					97.7%	97.7%	96.0%
Positive	Total	D29	Live Virus nAb ID50	221	(94.9%, 100.5%)	(94.9%, 100.5%)	(92.4%, 99.7%)
					98.8%	98.8%	96.6%
			Live Virus nAb ID80	221	(96.7%, 100.8%)	(96.7%, 100.8%)	(93.2%, 100.0%)
					97.3%	97.3%	93.8%
			Anti-Spike IgG	523	(94.2%, 100.3%)	(94.2%, 100.3%)	(89.4%, 98.3%)
					0.0%	0.0%	0.0%
			Anti-RBD IgG	523	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					0.0%	0.0%	0.0%
			Pseudo nAb ID50	523	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					19.5%	19.5%	25.0%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age < 65	D57		Pseudo nAb ID80	523	(12.7%, 26.4%)	(12.7%, 26.4%)	(17.2%, 32.7%)
					19.1%	19.1%	19.7%
			Live Virus nAb ID50	523	(11.0%, 27.1%)	(11.0%, 27.1%)	(11.2%, 28.1%)
					26.3%	26.3%	26.1%
			Live Virus nAb ID80	523	(19.4%, 33.2%)	(19.4%, 33.2%)	(18.2%, 33.9%)
					22.4%	22.4%	33.8%
			Anti-Spike IgG	523	(14.7%, 30.0%)	(14.7%, 30.0%)	(25.8%, 41.9%)
					0.0%	0.0%	0.0%
			Anti-RBD IgG	523	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					0.0%	0.0%	0.0%
			Pseudo nAb ID50	523	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					4.9%	4.9%	7.1%
			Pseudo nAb ID80	523	(1.3%, 8.4%)	(1.3%, 8.4%)	(3.1%, 11.2%)
					11.3%	11.3%	16.3%
			Live Virus nAb ID50	523	(6.9%, 15.8%)	(6.9%, 15.8%)	(10.7%, 21.9%)
					2.5%	2.5%	6.2%
			Live Virus nAb ID80	523	(-0.6%, 5.6%)	(-0.6%, 5.6%)	(2.0%, 10.3%)
					7.9%	7.9%	14.0%
	D29		Anti-Spike IgG	295	(4.5%, 11.3%)	(4.5%, 11.3%)	(9.6%, 18.4%)
					-0.0%	-0.0%	-0.0%
			Anti-RBD IgG	295	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					-0.0%	-0.0%	-0.0%
			Pseudo nAb ID50	295	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					21.8%	21.8%	27.4%
			Pseudo nAb ID80	295	(12.4%, 31.2%)	(12.4%, 31.2%)	(16.9%, 37.9%)
					19.9%	19.9%	19.1%
			Live Virus nAb ID50	295	(9.0%, 30.8%)	(9.0%, 30.8%)	(7.9%, 30.3%)
					29.8%	29.8%	27.7%
			Live Virus nAb ID80	295	(20.4%, 39.1%)	(20.4%, 39.1%)	(17.1%, 38.2%)
					24.1%	24.1%	36.2%
	D57		Anti-Spike IgG	295	(13.8%, 34.4%)	(13.8%, 34.4%)	(25.5%, 46.9%)
					-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
			Anti-RBD IgG	295	-0.0%	-0.0%	-0.0%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Race	Age >= 65		Pseudo nAb ID50	295	(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					5.5%	5.5%	7.6%
			Pseudo nAb ID80	295	(0.5%, 10.5%)	(0.5%, 10.5%)	(1.9%, 13.3%)
					12.5%	12.5%	17.5%
			Live Virus nAb ID50	295	(6.2%, 18.7%)	(6.2%, 18.7%)	(9.8%, 25.2%)
					2.6%	2.6%	6.6%
		Live Virus nAb ID80	295	(-1.8%, 6.9%)	(-1.8%, 6.9%)	(0.8%, 12.5%)	
				8.7%	8.7%	15.4%	
				(4.1%, 13.4%)	(4.1%, 13.4%)	(9.4%, 21.4%)	
		D29	Anti-Spike IgG	228	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
			Anti-RBD IgG	228	0.0%	0.0%	0.0%
				(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)	
	Pseudo nAb ID50		228	5.5%	5.5%	10.1%	
				(-1.0%, 12.0%)	(-1.0%, 12.0%)	(1.6%, 18.6%)	
	D57	Pseudo nAb ID80	228	14.9%	14.9%	24.2%	
				(5.7%, 24.1%)	(5.7%, 24.1%)	(12.6%, 35.8%)	
		Live Virus nAb ID50	228	4.4%	4.4%	16.2%	
				(-3.4%, 12.2%)	(-3.4%, 12.2%)	(6.1%, 26.2%)	
		Live Virus nAb ID80	228	11.7%	11.7%	19.1%	
				(2.0%, 21.4%)	(2.0%, 21.4%)	(7.6%, 30.6%)	
		Anti-Spike IgG	228	0.0%	0.0%	0.0%	
				(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)	
		Anti-RBD IgG	228	0.0%	0.0%	0.0%	
			(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)		
Pseudo nAb ID50		228	0.9%	0.9%	4.2%		
			(-0.8%, 2.6%)	(-0.8%, 2.6%)	(0.5%, 7.8%)		
Pseudo nAb ID80	228	4.2%	4.2%	8.6%			
		(0.5%, 7.8%)	(0.5%, 7.8%)	(3.5%, 13.8%)			
Live Virus nAb ID50	228	2.4%	2.4%	3.3%			
		(-0.4%, 5.2%)	(-0.4%, 5.2%)	(-0.0%, 6.5%)			
Live Virus nAb ID80	228	2.7%	2.7%	5.1%			
		(-1.1%, 6.5%)	(-1.1%, 6.5%)	(-0.6%, 10.9%)			

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
At-risk	D29	Anti-Spike IgG	222	-0.0%	(-0.0%, 0.0%)	-0.0%	(-0.0%, 0.0%)
		Anti-RBD IgG	222	-0.0%	(-0.0%, 0.0%)	-0.0%	(-0.0%, 0.0%)
		Pseudo nAb ID50	222	27.7%	(17.5%, 38.0%)	27.7%	23.2%
		Pseudo nAb ID80	222	23.0%	(10.8%, 35.2%)	23.0%	29.1%
		Live Virus nAb ID50	222	30.5%	(20.1%, 40.8%)	30.5%	34.3%
		Live Virus nAb ID80	222	23.7%	(11.8%, 35.5%)	23.7%	28.7%
	D57	Anti-Spike IgG	222	-0.0%	(-0.0%, 0.0%)	-0.0%	(-0.0%, 0.0%)
		Anti-RBD IgG	222	-0.0%	(-0.0%, 0.0%)	-0.0%	(-0.0%, 0.0%)
		Pseudo nAb ID50	222	5.6%	(0.6%, 10.7%)	5.6%	6.3%
		Pseudo nAb ID80	222	12.9%	(6.2%, 19.6%)	12.9%	21.9%
		Live Virus nAb ID50	222	2.8%	(-1.3%, 6.9%)	2.8%	11.2%
		Live Virus nAb ID80	222	14.6%	(7.6%, 21.5%)	14.6%	20.2%
Not at-risk	D29	Anti-Spike IgG	301	-0.0%	(-0.0%, 0.0%)	-0.0%	(-0.0%, 0.0%)
		Anti-RBD IgG	301	-0.0%	(-0.0%, 0.0%)	-0.0%	(-0.0%, 0.0%)
		Pseudo nAb ID50	301	17.2%	(8.1%, 26.2%)	17.2%	25.5%
		Pseudo nAb ID80	301	17.9%	(7.3%, 28.6%)	17.9%	16.9%
		Live Virus nAb ID50	301	25.1%	(16.0%, 34.3%)	25.1%	23.6%
		Live Virus nAb ID80	301	25.1%	(16.0%, 34.3%)	25.1%	23.6%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age < 65 At-risk	D57		Live Virus nAb ID80	301	22.0% (12.0%, 32.0%)	22.0% (12.0%, 32.0%)	35.3% (24.8%, 45.9%)
			Anti-Spike IgG	301	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	301	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	301	4.6% (-0.1%, 9.4%)	4.6% (-0.1%, 9.4%)	7.4% (2.0%, 12.7%)
			Pseudo nAb ID80	301	10.9% (4.9%, 16.8%)	10.9% (4.9%, 16.8%)	14.7% (7.5%, 21.9%)
			Live Virus nAb ID50	301	2.4% (-1.8%, 6.7%)	2.4% (-1.8%, 6.7%)	4.7% (-0.7%, 10.0%)
		D29	Live Virus nAb ID80	301	6.0% (2.1%, 9.8%)	6.0% (2.1%, 9.8%)	12.2% (6.9%, 17.5%)
			Anti-Spike IgG	147	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	147	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	147	32.3% (19.2%, 45.4%)	32.3% (19.2%, 45.4%)	25.9% (11.0%, 40.9%)
			Pseudo nAb ID80	147	26.1% (10.8%, 41.4%)	26.1% (10.8%, 41.4%)	30.8% (15.4%, 46.2%)
			Live Virus nAb ID50	147	35.1% (21.9%, 48.3%)	35.1% (21.9%, 48.3%)	37.2% (22.2%, 52.1%)
	D57	Live Virus nAb ID80	147	24.6% (9.6%, 39.5%)	24.6% (9.6%, 39.5%)	29.3% (13.8%, 44.9%)	
		Anti-Spike IgG	147	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	
		Anti-RBD IgG	147	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	
		Pseudo nAb ID50	147	7.0% (0.2%, 13.8%)	7.0% (0.2%, 13.8%)	7.1% (-1.4%, 15.6%)	
		Pseudo nAb ID80	147	15.3% (6.5%, 24.2%)	15.3% (6.5%, 24.2%)	25.2% (13.5%, 36.9%)	

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Age < 65 Not at-risk		Live Virus nAb ID50	147	2.8% (-2.4%, 8.1%)	2.8% (-2.4%, 8.1%)	12.6% (3.6%, 21.6%)
			Live Virus nAb ID80	147	16.7% (7.6%, 25.9%)	16.7% (7.6%, 25.9%)	23.7% (13.0%, 34.4%)
		D29	Anti-Spike IgG	148	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	148	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	148	19.0% (5.7%, 32.3%)	19.0% (5.7%, 32.3%)	27.8% (12.9%, 42.7%)
			Pseudo nAb ID80	148	18.2% (2.7%, 33.7%)	18.2% (2.7%, 33.7%)	16.0% (0.0%, 32.0%)
			Live Virus nAb ID50	148	28.4% (15.1%, 41.6%)	28.4% (15.1%, 41.6%)	25.1% (10.3%, 40.0%)
			Live Virus nAb ID80	148	24.0% (9.5%, 38.5%)	24.0% (9.5%, 38.5%)	38.0% (23.1%, 53.0%)
		D57	Anti-Spike IgG	148	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	148	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	148	5.1% (-2.1%, 12.3%)	5.1% (-2.1%, 12.3%)	7.7% (-0.2%, 15.7%)
			Pseudo nAb ID80	148	11.7% (2.9%, 20.5%)	11.7% (2.9%, 20.5%)	15.5% (4.8%, 26.1%)
			Live Virus nAb ID50	148	2.5% (-3.8%, 8.8%)	2.5% (-3.8%, 8.8%)	5.0% (-3.0%, 13.1%)
			Live Virus nAb ID80	148	6.6% (1.0%, 12.2%)	6.6% (1.0%, 12.2%)	13.2% (5.5%, 20.8%)
	Age >= 65 At-risk	D29	Anti-Spike IgG	75	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	75	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	75	8.5% (-2.8%, 19.9%)	8.5% (-2.8%, 19.9%)	11.7% (-3.8%, 27.1%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age \geq 65 Not at-risk		D57	Pseudo nAb ID80	75	10.0% (-5.9%, 25.9%)	10.0% (-5.9%, 25.9%)	21.9% (1.4%, 42.4%)
			Live Virus nAb ID50	75	11.3% (-1.0%, 23.6%)	11.3% (-1.0%, 23.6%)	22.6% (6.5%, 38.7%)
			Live Virus nAb ID80	75	20.0% (3.2%, 36.9%)	20.0% (3.2%, 36.9%)	26.0% (6.8%, 45.1%)
			Anti-Spike IgG	75	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	75	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	75	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	2.8% (-2.5%, 8.1%)
			Pseudo nAb ID80	75	2.8% (-2.5%, 8.1%)	2.8% (-2.5%, 8.1%)	8.3% (-0.5%, 17.2%)
			Live Virus nAb ID50	75	2.8% (-2.5%, 8.1%)	2.8% (-2.5%, 8.1%)	5.6% (-1.8%, 12.9%)
			Live Virus nAb ID80	75	5.6% (-1.8%, 12.9%)	5.6% (-1.8%, 12.9%)	5.7% (-4.5%, 16.0%)
		D29	Anti-Spike IgG	153	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	153	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	153	4.0% (-4.0%, 12.0%)	4.0% (-4.0%, 12.0%)	9.3% (-1.0%, 19.6%)
			Pseudo nAb ID80	153	17.3% (5.9%, 28.6%)	17.3% (5.9%, 28.6%)	25.3% (11.2%, 39.5%)
			Live Virus nAb ID50	153	1.0% (-9.0%, 10.9%)	1.0% (-9.0%, 10.9%)	12.9% (0.1%, 25.7%)
			Live Virus nAb ID80	153	7.6% (-4.3%, 19.5%)	7.6% (-4.3%, 19.5%)	15.7% (1.3%, 30.1%)
		D57	Anti-Spike IgG	153	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	153	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Female	D29	Pseudo nAb ID50	153	1.3%	(-1.3%, 3.9%)	1.3%	4.8%
		Pseudo nAb ID80	153	4.8%	(-0.0%, 9.6%)	4.8%	8.8%
		Live Virus nAb ID50	153	2.2%	(-1.1%, 5.4%)	2.2%	2.2%
		Live Virus nAb ID80	153	1.3%	(-3.1%, 5.8%)	1.3%	4.8%
		Anti-Spike IgG	294	-0.0%	(-0.0%, 0.0%)	-0.0%	-0.0%
		Anti-RBD IgG	294	-0.0%	(-0.0%, 0.0%)	-0.0%	-0.0%
	D57	Pseudo nAb ID50	294	16.6%	(7.3%, 26.0%)	16.6%	27.0%
		Pseudo nAb ID80	294	19.6%	(8.6%, 30.6%)	19.6%	23.7%
		Live Virus nAb ID50	294	25.3%	(16.4%, 34.3%)	25.3%	21.4%
		Live Virus nAb ID80	294	18.3%	(8.1%, 28.5%)	18.3%	29.0%
		Anti-Spike IgG	294	-0.0%	(-0.0%, 0.0%)	-0.0%	-0.0%
		Anti-RBD IgG	294	-0.0%	(-0.0%, 0.0%)	-0.0%	-0.0%
	Male	D29	Anti-Spike IgG	229	0.0%	(-0.0%, 0.0%)	0.0%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age < 65 Female	D57		Anti-RBD IgG	229	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	229	23.2% (13.2%, 33.2%)	23.2% (13.2%, 33.2%)	21.2% (9.8%, 32.6%)
			Pseudo nAb ID80	229	16.9% (5.2%, 28.7%)	16.9% (5.2%, 28.7%)	13.3% (0.3%, 26.2%)
			Live Virus nAb ID50	229	28.6% (17.8%, 39.4%)	28.6% (17.8%, 39.4%)	31.8% (20.3%, 43.2%)
			Live Virus nAb ID80	229	28.4% (16.9%, 40.0%)	28.4% (16.9%, 40.0%)	40.1% (28.3%, 52.0%)
			Anti-Spike IgG	229	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	229	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	229	9.7% (3.2%, 16.2%)	9.7% (3.2%, 16.2%)	10.2% (3.6%, 16.8%)
			Pseudo nAb ID80	229	14.6% (7.5%, 21.6%)	14.6% (7.5%, 21.6%)	20.4% (11.3%, 29.4%)
			Live Virus nAb ID50	229	7.3% (1.2%, 13.3%)	7.3% (1.2%, 13.3%)	8.4% (1.3%, 15.6%)
			Live Virus nAb ID80	229	6.3% (1.5%, 11.1%)	6.3% (1.5%, 11.1%)	15.7% (9.0%, 22.5%)
		D29	Anti-Spike IgG	177	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	177	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	177	18.0% (5.6%, 30.5%)	18.0% (5.6%, 30.5%)	28.5% (14.6%, 42.4%)
			Pseudo nAb ID80	177	20.0% (5.6%, 34.4%)	20.0% (5.6%, 34.4%)	23.0% (8.7%, 37.3%)
			Live Virus nAb ID50	177	27.1% (15.4%, 38.9%)	27.1% (15.4%, 38.9%)	21.6% (7.5%, 35.6%)
			Live Virus nAb ID80	177	18.3% (5.0%, 31.6%)	18.3% (5.0%, 31.6%)	28.9% (14.7%, 43.1%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Age < 65 Male	D57	Anti-Spike IgG	177	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	177	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	177	2.0% (-3.2%, 7.1%)	2.0% (-3.2%, 7.1%)	5.2% (-1.7%, 12.1%)
			Pseudo nAb ID80	177	9.5% (1.8%, 17.3%)	9.5% (1.8%, 17.3%)	14.6% (5.3%, 23.9%)
			Live Virus nAb ID50	177	-0.7% (-4.5%, 3.2%)	-0.7% (-4.5%, 3.2%)	5.5% (-1.2%, 12.1%)
			Live Virus nAb ID80	177	9.7% (3.4%, 16.1%)	9.7% (3.4%, 16.1%)	14.4% (6.6%, 22.2%)
		D29	Anti-Spike IgG	118	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	118	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	118	27.0% (12.5%, 41.4%)	27.0% (12.5%, 41.4%)	24.6% (8.2%, 40.9%)
			Pseudo nAb ID80	118	17.9% (1.0%, 34.8%)	17.9% (1.0%, 34.8%)	12.8% (-5.5%, 31.0%)
			Live Virus nAb ID50	118	35.3% (20.0%, 50.7%)	35.3% (20.0%, 50.7%)	35.6% (19.5%, 51.8%)
			Live Virus nAb ID80	118	33.6% (17.2%, 49.9%)	33.6% (17.2%, 49.9%)	46.4% (30.2%, 62.7%)
		D57	Anti-Spike IgG	118	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	118	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	118	11.5% (1.8%, 21.2%)	11.5% (1.8%, 21.2%)	11.5% (1.8%, 21.2%)
			Pseudo nAb ID80	118	17.2% (6.7%, 27.6%)	17.2% (6.7%, 27.6%)	23.0% (9.9%, 36.2%)
			Live Virus nAb ID50	118	8.0% (-0.9%, 16.9%)	8.0% (-0.9%, 16.9%)	9.2% (-1.3%, 19.7%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Age \geq 65 Female		Live Virus nAb ID80	118	7.2% (0.4%, 14.0%)	7.2% (0.4%, 14.0%)	17.0% (7.5%, 26.4%)
		D29	Anti-Spike IgG	117	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	117	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	117	3.4% (-6.2%, 13.0%)	3.4% (-6.2%, 13.0%)	11.3% (-1.4%, 24.0%)
			Pseudo nAb ID80	117	12.4% (-1.4%, 26.1%)	12.4% (-1.4%, 26.1%)	25.2% (8.4%, 42.0%)
			Live Virus nAb ID50	117	10.5% (-1.7%, 22.6%)	10.5% (-1.7%, 22.6%)	16.8% (2.3%, 31.3%)
		D57	Live Virus nAb ID80	117	16.8% (2.3%, 31.3%)	16.8% (2.3%, 31.3%)	26.5% (10.7%, 42.4%)
			Anti-Spike IgG	117	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	117	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	117	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	3.7% (-1.0%, 8.4%)
			Pseudo nAb ID80	117	5.6% (-0.2%, 11.3%)	5.6% (-0.2%, 11.3%)	7.4% (0.8%, 14.0%)
			Live Virus nAb ID50	117	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Live Virus nAb ID80	117	3.7% (-1.0%, 8.4%)	3.7% (-1.0%, 8.4%)	0.5% (-6.2%, 7.2%)
	Age \geq 65 Male	D29	Anti-Spike IgG	111	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	111	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	111	7.9% (-1.0%, 16.7%)	7.9% (-1.0%, 16.7%)	9.3% (-2.1%, 20.8%)
			Pseudo nAb ID80	111	18.1% (5.8%, 30.5%)	18.1% (5.8%, 30.5%)	24.3% (8.5%, 40.2%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Hispanic or Latino	D57	Live Virus nAb ID50	111	-1.2% (-10.8%, 8.3%)	-1.2% (-10.8%, 8.3%)	16.0% (1.9%, 30.0%)
			Live Virus nAb ID80	111	7.3% (-5.4%, 20.0%)	7.3% (-5.4%, 20.0%)	11.4% (-5.4%, 28.3%)
			Anti-Spike IgG	111	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	111	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	111	1.7% (-1.8%, 5.3%)	1.7% (-1.8%, 5.3%)	4.6% (-1.1%, 10.3%)
			Pseudo nAb ID80	111	2.8% (-1.7%, 7.4%)	2.8% (-1.7%, 7.4%)	9.8% (1.7%, 17.9%)
			Live Virus nAb ID50	111	4.6% (-1.1%, 10.3%)	4.6% (-1.1%, 10.3%)	6.3% (-0.3%, 12.9%)
			Live Virus nAb ID80	111	1.6% (-4.5%, 7.7%)	1.6% (-4.5%, 7.7%)	9.6% (0.2%, 19.0%)
		D29	Anti-Spike IgG	59	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	59	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	59	18.4% (-0.8%, 37.6%)	18.4% (-0.8%, 37.6%)	19.2% (-3.6%, 41.9%)
			Pseudo nAb ID80	59	20.1% (-2.1%, 42.4%)	20.1% (-2.1%, 42.4%)	1.0% (-24.7%, 26.8%)
			Live Virus nAb ID50	59	13.5% (0.3%, 26.7%)	13.5% (0.3%, 26.7%)	7.9% (-11.3%, 27.1%)
			Live Virus nAb ID80	59	12.1% (-7.4%, 31.6%)	12.1% (-7.4%, 31.6%)	26.6% (2.9%, 50.3%)
		D57	Anti-Spike IgG	59	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	59	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	59	7.5% (-2.0%, 17.0%)	7.5% (-2.0%, 17.0%)	8.1% (-1.7%, 18.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Not Hispanic or Latino		Pseudo nAb ID80	59	2.7% (-3.2%, 8.6%)	2.7% (-3.2%, 8.6%)	5.9% (-2.6%, 14.3%)
			Live Virus nAb ID50	59	1.6% (-2.9%, 6.2%)	1.6% (-2.9%, 6.2%)	1.8% (-6.8%, 10.4%)
			Live Virus nAb ID80	59	4.2% (-3.0%, 11.4%)	4.2% (-3.0%, 11.4%)	14.4% (1.7%, 27.1%)
		D29	Anti-Spike IgG	418	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	418	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	418	19.6% (11.8%, 27.3%)	19.6% (11.8%, 27.3%)	27.0% (18.3%, 35.8%)
			Pseudo nAb ID80	418	18.2% (9.1%, 27.3%)	18.2% (9.1%, 27.3%)	21.9% (12.5%, 31.3%)
			Live Virus nAb ID50	418	29.4% (21.6%, 37.2%)	29.4% (21.6%, 37.2%)	29.5% (20.7%, 38.3%)
			Live Virus nAb ID80	418	24.9% (16.2%, 33.6%)	24.9% (16.2%, 33.6%)	36.9% (27.9%, 45.8%)
		D57	Anti-Spike IgG	418	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	418	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	418	3.7% (-0.2%, 7.6%)	3.7% (-0.2%, 7.6%)	6.5% (1.8%, 11.1%)
			Pseudo nAb ID80	418	10.8% (5.7%, 15.8%)	10.8% (5.7%, 15.8%)	16.4% (10.0%, 22.9%)
			Live Virus nAb ID50	418	1.9% (-1.6%, 5.5%)	1.9% (-1.6%, 5.5%)	6.6% (1.7%, 11.4%)
			Live Virus nAb ID80	418	6.8% (3.2%, 10.4%)	6.8% (3.2%, 10.4%)	11.9% (7.2%, 16.5%)
	American Indian or Alaska Native	D29	Anti-Spike IgG	8	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	8	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Asian		D57	Pseudo nAb ID50	8	-30.7% (-85.0%, 23.6%)	-30.7% (-85.0%, 23.6%)	-61.5% (-118.7%, -4.2%)
			Pseudo nAb ID80	8	-61.5% (-118.7%, -4.2%)	-61.5% (-118.7%, -4.2%)	-61.5% (-118.7%, -4.2%)
			Live Virus nAb ID50	8	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Live Virus nAb ID80	8	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	-6.6% (-83.2%, 70.0%)
			Anti-Spike IgG	8	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	8	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	8	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID80	8	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Live Virus nAb ID50	8	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Live Virus nAb ID80	8	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-Spike IgG	33	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	33	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
		D29	Pseudo nAb ID50	33	43.1% (18.7%, 67.5%)	43.1% (18.7%, 67.5%)	71.8% (48.6%, 95.1%)
			Pseudo nAb ID80	33	60.1% (32.1%, 88.0%)	60.1% (32.1%, 88.0%)	31.3% (-0.3%, 62.8%)
			Live Virus nAb ID50	33	53.0% (28.4%, 77.6%)	53.0% (28.4%, 77.6%)	59.5% (32.8%, 86.3%)
			Live Virus nAb ID80	33	26.9% (-2.1%, 55.8%)	26.9% (-2.1%, 55.8%)	64.1% (37.1%, 91.1%)
			Anti-Spike IgG	33	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
			Anti-RBD IgG	33	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	33	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	14.4% (-2.9%, 31.7%)
			Pseudo nAb ID80	33	30.7% (8.0%, 53.4%)	30.7% (8.0%, 53.4%)	26.8% (2.0%, 51.5%)
			Live Virus nAb ID50	33	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	4.0% (-5.7%, 13.8%)
			Live Virus nAb ID80	33	14.4% (-2.9%, 31.7%)	14.4% (-2.9%, 31.7%)	14.4% (-2.9%, 31.7%)
	Black or African American	D29	Anti-Spike IgG	101	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	101	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	101	29.1% (11.9%, 46.4%)	29.1% (11.9%, 46.4%)	34.3% (16.9%, 51.7%)
			Pseudo nAb ID80	101	22.5% (3.7%, 41.3%)	22.5% (3.7%, 41.3%)	30.0% (11.2%, 48.8%)
			Live Virus nAb ID50	101	29.2% (13.3%, 45.0%)	29.2% (13.3%, 45.0%)	27.8% (10.0%, 45.6%)
			Live Virus nAb ID80	101	29.9% (12.2%, 47.6%)	29.9% (12.2%, 47.6%)	37.4% (19.6%, 55.2%)
		D57	Anti-Spike IgG	101	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	101	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	101	11.6% (2.5%, 20.7%)	11.6% (2.5%, 20.7%)	17.4% (6.7%, 28.2%)
			Pseudo nAb ID80	101	18.1% (7.1%, 29.0%)	18.1% (7.1%, 29.0%)	32.7% (18.9%, 46.6%)
			Live Virus nAb ID50	101	3.1% (-3.6%, 9.9%)	3.1% (-3.6%, 9.9%)	8.8% (-1.3%, 19.0%)
			Live Virus nAb ID80	101	5.1% (-3.2%, 13.3%)	5.1% (-3.2%, 13.3%)	14.7% (3.5%, 26.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Minority	Multiracial	D29	Anti-Spike IgG	31	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
			Anti-RBD IgG	31	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
			Pseudo nAb ID50	31	9.8% (-21.1%, 40.7%)	9.8% (-21.1%, 40.7%)	14.2% (-17.4%, 45.8%)
			Pseudo nAb ID80	31	18.6% (-13.5%, 50.7%)	18.6% (-13.5%, 50.7%)	25.0% (-7.6%, 57.6%)
			Live Virus nAb ID50	31	16.1% (-6.8%, 39.0%)	16.1% (-6.8%, 39.0%)	22.6% (-2.2%, 47.5%)
			Live Virus nAb ID80	31	-10.3% (-36.8%, 16.3%)	-10.3% (-36.8%, 16.3%)	7.6% (-25.4%, 40.7%)
		D57	Anti-Spike IgG	31	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
			Anti-RBD IgG	31	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
			Pseudo nAb ID50	31	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	2.1% (-5.3%, 9.5%)
			Pseudo nAb ID80	31	15.7% (-2.9%, 34.3%)	15.7% (-2.9%, 34.3%)	15.7% (-2.9%, 34.3%)
			Live Virus nAb ID50	31	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	4.4% (-6.1%, 14.9%)
			Live Virus nAb ID80	31	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	4.4% (-6.1%, 14.9%)
	Native Hawaiian or Other Pacific Islander	D29	Anti-Spike IgG	7	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	7	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	7	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	-67.2% (-127.9%, -6.4%)
			Pseudo nAb ID80	7	-67.2% (-127.9%, -6.4%)	-67.2% (-127.9%, -6.4%)	-55.2% (-128.6%, 18.2%)
			Live Virus nAb ID50	7	-75.1%	-75.1%	-92.1%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Not reported and unknown	D57	Live Virus nAb ID80	7		(-131.0%, -19.1%)	(-131.0%, -19.1%)	(-127.0%, -57.3%)
					-67.2%	-67.2%	6.2%
					(-127.9%, -6.4%)	(-127.9%, -6.4%)	(-52.5%, 65.0%)
					0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
		Pseudo nAb ID50	7		-67.2%	-67.2%	-67.2%
					(-127.9%, -6.4%)	(-127.9%, -6.4%)	(-127.9%, -6.4%)
					0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					0.0%	0.0%	0.0%
	D29	Live Virus nAb ID80	7		(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					0.0%	0.0%	0.0%
		Anti-Spike IgG	57		(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					18.0%	18.0%	39.4%
					(-1.7%, 37.6%)	(-1.7%, 37.6%)	(17.5%, 61.3%)
	D57	Pseudo nAb ID80	57		32.5%	32.5%	21.1%
					(8.6%, 56.4%)	(8.6%, 56.4%)	(-4.5%, 46.8%)
					49.2%	49.2%	55.4%
					(30.4%, 68.0%)	(30.4%, 68.0%)	(34.6%, 76.2%)
					38.4%	38.4%	45.2%
					(15.0%, 61.9%)	(15.0%, 61.9%)	(21.9%, 68.6%)
		Anti-Spike IgG	57		-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					-0.0%	-0.0%	-0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					11.2%	11.2%	12.4%
					(-0.1%, 22.6%)	(-0.1%, 22.6%)	(0.5%, 24.3%)
					2.8%	2.8%	6.5%

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
					(-12.8%, 18.5%)	(-12.8%, 18.5%)	(-10.3%, 23.2%)
			Live Virus nAb ID50	57	2.5%	2.5%	-5.9%
			Live Virus nAb ID80	57	(-3.1%, 8.0%) 11.2%	(-3.1%, 8.0%) 11.2%	(-18.1%, 6.2%) 13.7%
					(-0.1%, 22.6%)	(-0.1%, 22.6%)	(1.3%, 26.1%)
	Other	D29	Anti-Spike IgG	14	-0.0%	-0.0%	-0.0%
			Anti-RBD IgG	14	(-0.0%, 0.0%) -0.0%	(-0.0%, 0.0%) -0.0%	(-0.0%, 0.0%) -0.0%
			Pseudo nAb ID50	14	(-0.0%, 0.0%) 34.9%	(-0.0%, 0.0%) 34.9%	(-0.0%, 0.0%) 36.8%
			Pseudo nAb ID80	14	(-1.6%, 71.3%) 6.0%	(-1.6%, 71.3%) 6.0%	(-14.9%, 88.5%) 0.2%
			Live Virus nAb ID50	14	(-50.7%, 62.7%) 42.1%	(-50.7%, 62.7%) 42.1%	(-51.4%, 51.8%) 45.5%
			Live Virus nAb ID80	14	(4.3%, 79.8%) 34.9%	(4.3%, 79.8%) 34.9%	(7.4%, 83.6%) 40.2%
					(-1.6%, 71.3%)	(-1.6%, 71.3%)	(-11.0%, 91.5%)
		D57	Anti-Spike IgG	14	-0.0%	-0.0%	-0.0%
			Anti-RBD IgG	14	(-0.0%, 0.0%) -0.0%	(-0.0%, 0.0%) -0.0%	(-0.0%, 0.0%) -0.0%
			Pseudo nAb ID50	14	(-0.0%, 0.0%) -0.0%	(-0.0%, 0.0%) -0.0%	(-0.0%, 0.0%) 2.2%
			Pseudo nAb ID80	14	(-0.0%, 0.0%) 42.1%	(-0.0%, 0.0%) 42.1%	(-9.0%, 13.3%) 42.1%
			Live Virus nAb ID50	14	(4.3%, 79.8%) 2.2%	(4.3%, 79.8%) 2.2%	(4.3%, 79.8%) 27.7%
			Live Virus nAb ID80	14	(-9.0%, 13.3%) 32.7%	(-9.0%, 13.3%) 32.7%	(-6.5%, 61.9%) 60.4%
					(-3.2%, 68.6%)	(-3.2%, 68.6%)	(23.0%, 97.8%)
Age, Minority							
	White	D29	Anti-Spike IgG	29	0.0%	0.0%	0.0%
			Anti-RBD IgG	29	(-0.0%, 0.0%) 0.0%	(-0.0%, 0.0%) 0.0%	(-0.0%, 0.0%) 0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
			Pseudo nAb ID50	29	11.8% (-14.8%, 38.4%)	11.8% (-14.8%, 38.4%)	11.8% (-14.8%, 38.4%)
			Pseudo nAb ID80	29	26.2% (-5.9%, 58.3%)	26.2% (-5.9%, 58.3%)	5.3% (-33.5%, 44.1%)
			Live Virus nAb ID50	29	-14.7% (-47.4%, 18.0%)	-14.7% (-47.4%, 18.0%)	-4.6% (-40.2%, 31.0%)
			Live Virus nAb ID80	29	1.9% (-27.7%, 31.5%)	1.9% (-27.7%, 31.5%)	-6.6% (-45.2%, 32.0%)
		D57	Anti-Spike IgG	29	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	29	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	29	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID80	29	14.4% (-7.1%, 35.9%)	14.4% (-7.1%, 35.9%)	14.4% (-7.1%, 35.9%)
			Live Virus nAb ID50	29	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Live Virus nAb ID80	29	14.4% (-7.1%, 35.9%)	14.4% (-7.1%, 35.9%)	28.9% (1.2%, 56.6%)
	White Non-Hispanic	D29	Anti-Spike IgG	230	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
					0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	230	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
					0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	230	16.4% (6.1%, 26.7%)	16.4% (6.1%, 26.7%)	22.3% (10.3%, 34.3%)
					16.4% (6.1%, 26.7%)	16.4% (6.1%, 26.7%)	22.3% (10.3%, 34.3%)
			Pseudo nAb ID80	230	16.5% (4.4%, 28.6%)	16.5% (4.4%, 28.6%)	24.5% (11.9%, 37.1%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
					16.5%	16.5%	24.5%
					(4.4%, 28.6%)	(4.4%, 28.6%)	(11.9%, 37.1%)
			Live Virus nAb ID50	230	24.9%	24.9%	23.1%
					(14.0%, 35.7%)	(14.0%, 35.7%)	(10.8%, 35.4%)
					24.9%	24.9%	23.1%
					(14.0%, 35.7%)	(14.0%, 35.7%)	(10.8%, 35.4%)
			Live Virus nAb ID80	230	23.7%	23.7%	34.6%
					(11.8%, 35.6%)	(11.8%, 35.6%)	(22.5%, 46.8%)
					23.7%	23.7%	34.6%
					(11.8%, 35.6%)	(11.8%, 35.6%)	(22.5%, 46.8%)
		D57	Anti-Spike IgG	230	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
			Anti-RBD IgG	230	0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
					0.0%	0.0%	0.0%
					(-0.0%, 0.0%)	(-0.0%, 0.0%)	(-0.0%, 0.0%)
			Pseudo nAb ID50	230	5.6%	5.6%	5.4%
					(-0.2%, 11.4%)	(-0.2%, 11.4%)	(-0.9%, 11.7%)
					5.6%	5.6%	5.4%
					(-0.2%, 11.4%)	(-0.2%, 11.4%)	(-0.9%, 11.7%)
			Pseudo nAb ID80	230	5.6%	5.6%	9.3%
					(-0.2%, 11.4%)	(-0.2%, 11.4%)	(1.0%, 17.7%)
					5.6%	5.6%	9.3%
					(-0.2%, 11.4%)	(-0.2%, 11.4%)	(1.0%, 17.7%)
			Live Virus nAb ID50	230	3.4%	3.4%	8.2%
					(-2.7%, 9.6%)	(-2.7%, 9.6%)	(1.1%, 15.2%)
					3.4%	3.4%	8.2%
					(-2.7%, 9.6%)	(-2.7%, 9.6%)	(1.1%, 15.2%)
			Live Virus nAb ID80	230	5.8%	5.8%	10.1%
					(1.6%, 10.0%)	(1.6%, 10.0%)	(4.1%, 16.0%)
					5.8%	5.8%	10.1%
					(1.6%, 10.0%)	(1.6%, 10.0%)	(4.1%, 16.0%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Communities of Color	D29	Anti-Spike IgG	251	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
			Anti-RBD IgG	251	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
			Pseudo nAb ID50	251	22.9% (12.9%, 33.0%)	22.9% (12.9%, 33.0%)	29.5% (18.3%, 40.6%)
			Pseudo nAb ID80	251	20.2% (8.4%, 32.1%)	20.2% (8.4%, 32.1%)	17.1% (4.8%, 29.3%)
			Live Virus nAb ID50	251	31.5% (22.0%, 40.9%)	31.5% (22.0%, 40.9%)	33.8% (23.2%, 44.4%)
			Live Virus nAb ID80	251	23.0% (12.2%, 33.8%)	23.0% (12.2%, 33.8%)	35.4% (24.0%, 46.9%)
		D57	Anti-Spike IgG	251	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
			Anti-RBD IgG	251	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)	-0.0% (-0.0%, -0.0%)
			Pseudo nAb ID50	251	5.0% (-0.0%, 10.1%)	5.0% (-0.0%, 10.1%)	9.8% (3.7%, 15.9%)
			Pseudo nAb ID80	251	16.2% (9.1%, 23.4%)	16.2% (9.1%, 23.4%)	22.4% (14.3%, 30.5%)
			Live Virus nAb ID50	251	2.0% (-1.0%, 5.0%)	2.0% (-1.0%, 5.0%)	5.2% (-0.4%, 10.8%)
			Live Virus nAb ID80	251	8.6% (3.3%, 13.8%)	8.6% (3.3%, 13.8%)	15.4% (8.8%, 22.0%)
	Age < 65 Communities of Color	D29	Anti-Spike IgG	148	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	148	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	148	27.0% (13.6%, 40.4%)	27.0% (13.6%, 40.4%)	32.8% (18.2%, 47.4%)
			Pseudo nAb ID80	148	22.4% (6.8%, 37.9%)	22.4% (6.8%, 37.9%)	16.8% (0.8%, 32.8%)
			Live Virus nAb ID50	148	36.2% (23.9%, 48.6%)	36.2% (23.9%, 48.6%)	36.7% (22.9%, 50.5%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
Age < 65 White Non-Hispanic	D57		Live Virus nAb ID80	148	25.2% (11.0%, 39.4%)	25.2% (11.0%, 39.4%)	37.5% (22.6%, 52.3%)
			Anti-Spike IgG	148	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	148	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	148	5.7% (-1.3%, 12.8%)	5.7% (-1.3%, 12.8%)	10.5% (2.2%, 18.7%)
			Pseudo nAb ID80	148	17.8% (8.1%, 27.5%)	17.8% (8.1%, 27.5%)	24.3% (13.4%, 35.3%)
			Live Virus nAb ID50	148	2.1% (-1.9%, 6.1%)	2.1% (-1.9%, 6.1%)	5.8% (-2.0%, 13.5%)
		D29	Live Virus nAb ID80	148	10.0% (2.8%, 17.2%)	10.0% (2.8%, 17.2%)	17.4% (8.5%, 26.3%)
			Anti-Spike IgG	128	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	128	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	128	16.3% (2.0%, 30.7%)	16.3% (2.0%, 30.7%)	23.4% (7.0%, 39.9%)
			Pseudo nAb ID80	128	15.1% (-1.5%, 31.7%)	15.1% (-1.5%, 31.7%)	23.5% (6.5%, 40.4%)
			Live Virus nAb ID50	128	27.3% (12.4%, 42.3%)	27.3% (12.4%, 42.3%)	24.2% (7.4%, 40.9%)
	D57	Live Virus nAb ID80	128	24.6% (8.3%, 40.9%)	24.6% (8.3%, 40.9%)	38.1% (21.9%, 54.2%)	
		Anti-Spike IgG	128	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	
		Anti-RBD IgG	128	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	
		Pseudo nAb ID50	128	6.2% (-2.1%, 14.4%)	6.2% (-2.1%, 14.4%)	5.6% (-3.3%, 14.5%)	
		Pseudo nAb ID80	128	5.8% (-2.4%, 14.0%)	5.8% (-2.4%, 14.0%)	9.5% (-2.2%, 21.2%)	

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
	Age >= 65 Communities of Color		Live Virus nAb ID50	128	3.6% (-5.1%, 12.4%)	3.6% (-5.1%, 12.4%)	8.8% (-1.2%, 18.7%)
			Live Virus nAb ID80	128	5.4% (-0.0%, 10.9%)	5.4% (-0.0%, 10.9%)	9.9% (2.2%, 17.6%)
		D29	Anti-Spike IgG	103	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	103	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	103	-5.8% (-15.0%, 3.5%)	-5.8% (-15.0%, 3.5%)	6.1% (-7.4%, 19.6%)
			Pseudo nAb ID80	103	6.1% (-8.1%, 20.4%)	6.1% (-8.1%, 20.4%)	20.2% (2.3%, 38.0%)
			Live Virus nAb ID50	103	-2.5% (-14.4%, 9.4%)	-2.5% (-14.4%, 9.4%)	13.4% (-2.1%, 28.8%)
			Live Virus nAb ID80	103	7.4% (-7.2%, 22.1%)	7.4% (-7.2%, 22.1%)	21.4% (4.0%, 38.8%)
		D57	Anti-Spike IgG	103	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	103	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	103	-0.0% (-0.0%, 0.0%)	-0.0% (-0.0%, 0.0%)	5.2% (-0.9%, 11.3%)
			Pseudo nAb ID80	103	5.2% (-0.9%, 11.3%)	5.2% (-0.9%, 11.3%)	9.1% (1.2%, 17.1%)
			Live Virus nAb ID50	103	1.2% (-1.8%, 4.3%)	1.2% (-1.8%, 4.3%)	1.2% (-1.8%, 4.3%)
			Live Virus nAb ID80	103	-1.9% (-5.7%, 1.9%)	-1.9% (-5.7%, 1.9%)	1.3% (-4.9%, 7.5%)
	Age >= 65 White Non-Hispanic	D29	Anti-Spike IgG	102	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	102	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	102	16.7% (6.6%, 26.8%)	16.7% (6.6%, 26.8%)	15.3% (2.5%, 28.1%)

Table 7: Differences of responder rates between the vaccine arm and the placebo arm (*continued*)

Baseline	Group	Visit	Endpoint	N	Responder	2-Fold Rise	4-Fold Rise
			Pseudo nAb ID80	102	25.5% (12.0%, 38.9%)	25.5% (12.0%, 38.9%)	30.8% (14.3%, 47.3%)
			Live Virus nAb ID50	102	9.0% (-2.5%, 20.6%)	9.0% (-2.5%, 20.6%)	16.0% (1.0%, 31.0%)
			Live Virus nAb ID80	102	17.6% (3.7%, 31.5%)	17.6% (3.7%, 31.5%)	12.7% (-4.0%, 29.4%)
		D57	Anti-Spike IgG	102	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Anti-RBD IgG	102	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)	0.0% (-0.0%, 0.0%)
			Pseudo nAb ID50	102	2.1% (-1.8%, 6.0%)	2.1% (-1.8%, 6.0%)	4.2% (-1.3%, 9.6%)
			Pseudo nAb ID80	102	4.2% (-1.3%, 9.6%)	4.2% (-1.3%, 9.6%)	8.3% (0.8%, 15.8%)
			Live Virus nAb ID50	102	2.1% (-1.8%, 6.0%)	2.1% (-1.8%, 6.0%)	4.2% (-1.3%, 9.6%)
			Live Virus nAb ID80	102	8.3% (0.8%, 15.8%)	8.3% (0.8%, 15.8%)	10.9% (-0.1%, 21.8%)

All calculations were weighted by the inverse probability sampling (IPS), defined based on the subcohort sampling strata.

T1: Vaccination

P2: Placebo